



Government of the Republic of Trinidad and Tobago
Ministry of Health

CANCER IN TRINIDAD AND TOBAGO

**2003
-2020**

Dr. Elizabeth Quamina Cancer Registry,
The National Cancer Registry of
Trinidad and Tobago

Published 2025

CANCER IN TRINIDAD AND TOBAGO


**2003
-2020**

**Dr. Elizabeth Quamina Cancer Registry,
The National Cancer Registry of
Trinidad and Tobago**

2025

2003
–2020

Photo: U.S. National Cancer Institute
(ovarian tumour microenvironment)



PREPARED BY:

Author

Mr. Akini James

Senior Monitoring and Evaluation Specialist, HSSP-PIU, MOH

Co-Author

Ms. Samantha Llanos

Project Officer – Monitoring and Evaluation, HSSP-PIU, MOH

REVIEWED BY:

Technical Advisors

Mr. Asif Ali

Permanent Secretary, MOH

Dr. Roshan Parasram

Chief Medical Officer, MOH

Dr. Stewart Smith

Senior Health Systems Advisor, MOH

Ms. Renee Franklin

Technical Director, HSSP-PIU, MOH

Dr. Avery Hinds

Technical Director, Epidemiology, MOH

Dr. Maria Clapperton

Director, Non-Communicable Diseases Unit, MOH

Mr. Lawrence Jaisingh

Director, Health Policy Research and Planning, MOH

Ms. Syan Mohammed

Monitoring and Evaluation Officer, Health Policy Research and Planning

Ms. Oneika Pacheco

Monitoring and Evaluation Officer, Health Policy Research and Planning

PROJECT LEAD

Ms. Nkese Felix

Registrar (Ag.), National Cancer Registry

PROJECT TEAM

Ms. Emily Prince-Joseph

Registry Officer, National Cancer Registry

Mrs. Avion Quava-Jones

Registry Officer, National Cancer Registry

NORTH CENTRAL REGIONAL HEALTH AUTHORITY OVERSIGHT

Dr. Chavin Gopaul

Head, Public Health Observatory

REGISTRY MEMBERS OF STAFF

Management

Ms. Nkese Felix

Research Officer I / Registrar (E.D.)

Data Collection, Collation, and Entry

Ms. Emily Prince-Joseph

Registry Officer

Ms. Avion Quava-Jones

Registry Officer

Ms. Jessica Pena

Data Entry Clerk

Ms. Latifah Holder

On-the-Job Trainee (OJT) Research Assistant

Administrative Staff

Ms. Abbi Philip

Administrative Assistant (Ag.)

Ms. Tishana Sutherland

Secretary I (Ag.)

TOBAGO FOCAL POINT FOR DATA COLLECTION

Nr. Karen Frank

Head Nurse, Tobago Oncology Unit

Executive Summary	1	06 Overview of Statistics 2009–2014	44
Message from The Minister of Health	2	Top 5 Leading Cancers, 2009–2014	46
Foreword	3	Top 5 Cancers Overall	46
		Top 5 Cancers By Age Group	46
01 Background of Trinidad and Tobago	4	Top 10 Leading Cancers, 2009–2014	47
Demographics of T&T	5	Age-Sex-Specific Incidence Rates of Top 5 Leading Cancers, 2009–2014	49
Geographical Location	5	Top 8 Leading Cancers by Ethnicity, 2009–2014	51
Trinidad & Tobago Population	6	Basis of Diagnosis of Top 8 Leading Cancers, 2009–2014	52
Cultural Diversity	9	Grades of Top 8 Leading Cancers, 2009–2014	54
Cancer Diagnosis Reported by Location	9	Stages of Top 8 Leading Cancers, 2009–2014	55
Dr. Elizabeth Quamina Cancer Registry			
History of the Cancer Registry	10	07 Overview of Statistics 2015–2020	56
Trinidad And Tobago Cancer Registry Staff	10	Top 5 Leading Cancers, 2015–2020	58
		Top 5 Cancers Overall	58
02 Data Management	11	Top 5 Cancers By Age Group	58
Data Collection	12	Top 10 Leading Cancers, 2015–2020	59
Data Collection Summary	13	Age-Sex-Specific Incidence Rates of Top 5 Leading Cancers, 2015–2020	61
Data Quality	13	Top 8 Leading Cancers by Ethnicity, 2015–2020	63
Comparability	13	Basis of Diagnosis of Top 8 Leading Cancers, 2015–2020	64
Completeness	14	Grades of Top 8 Leading Cancers, 2015–2020	66
Validity	14	Stages of Top 8 Leading Cancers, 2015–2020	67
Timeliness	14		
Coding	15	References	68
Data Processing and Storage	15		
Data Processing Flowchart	16	Appendix A	69
		Summary of Cancer Incidence, 2003–2008	70
03 Terms and Definitions	17	Cancer Incidence Rates by Age, Sex, and Site, 2003–2008	73
Pathological Definitions	18	Cancer Incidence Rates in Males by Age And Site, 2003–2008	73
Behavior Of The Tumour	18	Cancer Incidence Rates in Females by Age And Site, 2003–2008	79
Basis Of Diagnosis	18	Cancer Mortality, 2003–2008	85
Grade Of Cancer	19		
Stage Of Cancer	19	Appendix B	88
Treatment Of Cancer	20	Summary of Cancer Incidence, 2009–2014	89
Epidemiological Definitions	20	Cancer Incidence Rates by Age, Sex, and Site, 2009–2014	92
Crude Incidence Rates	20	Cancer Incidence Rates in Males by Age And Site, 2009–2014	92
Age-Specific Rates	20	Cancer Incidence Rates in Females by Age And Site, 2009–2014	98
Age-Standardised Rates	21	Cancer Mortality, 2009–2014	104
Crude Mortality Rates	22		
Lifetime Risk	22	Appendix C	107
		Summary of Cancer Incidence, 2015–2020	108
04 Cancer Overview 2003–2020	23	Cancer Incidence Rates by Age, Sex, and Site, 2015–2020	111
Demographics	24	Cancer Incidence Rates in Males by Age And Site, 2015–2020	111
Cancer Incidence and Mortality	25	Cancer Incidence Rates in Females by Age And Site, 2015–2020	117
Cancer Incidence	25	Cancer Mortality, 2015–2020	123
Cancer Mortality	26		
Time Trend of Leading Cancers	28	Appendix D - Data Entry Form	126
Top 10 Leading Cancers In Males	28		
Top 10 Leading Cancers In Females	30		
05 Overview of Statistics 2003–2008	32		
Top 5 Leading Cancers, 2003–2008	34		
Top 5 Cancers Overall	34		
Top 5 Cancers By Age Group	34		
Top 10 Leading Cancers, 2003–2008	35		
Age-Sex-Specific Incidence Rates of Top 5 Leading Cancers, 2003–2008	37		
Top 8 Leading Cancers by Ethnicity, 2003–2008	39		
Basis of Diagnosis of Top 8 Leading Cancers, 2003–2008	40		
Grades of Top 8 Leading Cancers, 2003–2008	42		
Stages of Top 8 Leading Cancers, 2003–2008	43		

Executive Summary

The **Dr. Elizabeth Quamina Cancer Registry**, the National Cancer Registry of Trinidad and Tobago, was established in 1994 to monitor cancer trends and provide essential data for public health planning and research. Named after its founder, the Registry adheres to international standards set by the International Agency for Research on Cancer (IARC) and is managed through a collaboration between the Ministry of Health, the North Central Regional Health Authority (NCRHA), and the Trinidad and Tobago Cancer Society.

This epidemiological report offers key stakeholders, healthcare professionals, policymakers, and researchers a comprehensive overview of **cancer incidence, mortality, and trends in Trinidad and Tobago from 2003 to 2020**. The report aims to inform cancer prevention strategies, optimise resource allocation, and support evidence-based health policy development, ultimately reducing the cancer burden and enhancing treatment approaches.

The Registry employs rigorous data collection, coding, and verification standards. Cancer cases are documented and validated according to the International Classification of Diseases for Oncology (ICD-O-3). Data is sourced from both public and private healthcare institutions, ensuring broad and accurate representation.

From 2003 to 2020, a total of 43,380 individuals were diagnosed with cancer, with a nearly even split of 49% male and 51% female patients. Most cases (97.9%) were in individuals over 25 years of age, and 39% fell within the 60-74 age range. Among those diagnosed, 36.2% were Afro-Trinidadians, and 23% were Indo-Trinidadians. The leading cancers in men were prostate, colon and rectum, and bronchus and lung. Breast cancer was most common among women, followed by cancers of the uterus, and colon and rectum.

Overall, the report notes an upward trend in both cancer incidence and mortality over the years, with the highest number of cases recorded in 2020. This data is essential for developing national health strategies, advancing research, and refining cancer prevention and treatment efforts.



Message from The Minister of Health

It is with profound pride that I present to you the National Cancer Registry Report of Trinidad and Tobago for the period 2003 to 2020. This report is a direct product of the Dr. Elizabeth Quamina Cancer Registry, which was established in September 1994. As we acknowledge the Registry's 30th anniversary in September 2024, we celebrate its enduring impact on our healthcare system and its unwavering commitment to advancing cancer care.

Spanning an 18-year period, this report meticulously details cancer trends, incidence rates, mortality statistics, and lifetime risks for cancers diagnosed among the residents of Trinidad and Tobago. It stands as a beacon of insight and hope, guiding our efforts to improve patient outcomes through the analysis of trends, informed public health policies, and strengthened early detection and treatment strategies. This data forms the cornerstone of our oncological treatment, driving progress and fostering resilience in our fight against cancer.

I extend my heartfelt congratulations to the dedicated staff of the Dr. Elizabeth Quamina Cancer Registry. Their unwavering dedication has laid a robust foundation upon which our healthcare initiatives continue to build. I urge all healthcare professionals to embrace this report as a key tool in their ongoing mission to prevent, treat, and care for cancer patients in Trinidad and Tobago.

I am deeply thankful to our esteemed international partners, including the **International Agency for Research on Cancer (IARC)** and the **Caribbean Public Health Agency (CARPHA)**, for their steadfast support and technical guidance provided to the Dr. Elizabeth Quamina Cancer Registry.

Additionally, I express my sincere appreciation to the **Inter-American Development Bank (IDB)** for their generous financial support, which helped us to complete this invaluable project, which will positively impact the delivery of cancer-related healthcare services throughout our nation. As we immerse ourselves in the findings of this report, let us renew our unwavering commitment to the health and well-being of our population.

The Honourable Terrence Deyalsingh
MINISTER OF HEALTH

Foreword

The publication of “**Cancer in Trinidad and Tobago, 2003-2020**” follows the previous report, “Cancer in Trinidad and Tobago, 2000-2002”. The National Cancer Registry of Trinidad and Tobago is one of the longest-running cancer registries in the Caribbean region. It collects, collates, and reports on all cancers diagnosed in residents of Trinidad and Tobago. Currently, the Registry has over 65,000 registered cancer cases managed by dedicated staff with continued support from the Ministry of Health and the North Central Regional Health Authority (NCRHA).

In 2023, the Registry's data was accepted into the prestigious "Cancer in Five Continents" publication, marking the first time Trinidad and Tobago's data has been included. This publication highlights data from cancer registries worldwide, and the acceptance of our country's data is a benchmark, attesting to its high quality.

The information in this report is critical for assisting administrators in policy planning for cancer control programs and implementing measures that can lead to better health, economic, and social outcomes for cancer patients and their families. It also provides evidence for healthcare professionals, researchers, and the public on the current cancer burden in Trinidad and Tobago.

We wish to thank the Registry's stakeholders within public and private institutions that routinely provide access to data. These crucial stakeholders recognise the importance of cancer surveillance work conducted by the Registry, ensuring it can fulfil its duty. I also extend gratitude to the staff of the National Cancer Registry, without whom the data contained in this report would not be available. Credit must also be given to the team at the **Ministry of Health's Health Services Support Programme (HSSP), Project Implementation Unit (PIU)**, for bringing this report to fruition.

Finally, recognition is due to the International Agency for Research on Cancer (IARC) Caribbean Cancer Registry Hub at the Caribbean Public Health Agency (CARPHA), which has provided technical support, capacity building, and network strengthening to the Registry since its establishment in 2016.

The Ministry of Health looks forward to even more engagement and cooperation with all stakeholders in the Registry's operations in the future. We hope that this report provides healthcare workers and the public at large with a greater understanding and appreciation of the national cancer burden and the important work of the National Cancer Registry of Trinidad and Tobago.

Dr. Roshan Parasram
CHIEF MEDICAL OFFICER (CMO)



Background of Trinidad and Tobago

CANCER IN
TRINIDAD AND TOBAGO
2003
-2020

Demographics of Trinidad and Tobago

GEOGRAPHICAL LOCATION

The Republic of Trinidad and Tobago is situated northwest of Venezuela, approximately 10-11 degrees north of the equator and 60-61 degrees west longitude. The country lies between the Caribbean Sea and the Atlantic Ocean. It consists of two islands separated by a channel approximately 31 kilometres wide. Trinidad covers an area of 4,828 square kilometres, while Tobago spans 300 square kilometres. The terrain is mostly flat, but Trinidad has three mountain ranges: the Northern, Central, and Southern ranges. The highest point in Trinidad is Mount El Tucuche, which rises to 940 meters. Tobago has a central mountain range.¹



¹ Trinidad – **Geography**. Accessed July 11, 2024. <https://trinidad.us/geography>

TRINIDAD & TOBAGO POPULATION

This report covers new cancers diagnosed in residents of Trinidad and Tobago between 1st January 2003 and 31st December 2020 as of 1st March 2024. The report is divided into three 6-year categories: **2003–2008**, **2009–2014**, and **2015–2020**. Cancers diagnosed after this date will be included in subsequent reports. Calculations requiring Trinidad and Tobago population data used the estimated mid-year population data for 2005 and 2017 for the periods 2003–2008 and 2015–2020, respectively, whereas the 2011 population census was used for the period 2009–2014. All data was obtained from the Central Statistical Office (CSO) of Trinidad and Tobago.^{2,3}

Population Estimate 2005

Population estimates from June 2005 indicated a total population of **1,294,494**, with **50.2% male and 49.8% female**. Of the total population, 57.4% were under 35 years old. The dependent population comprised 28.9% of the total population estimate, including 21.3% under 15 years and 7.6% over 65 years of age.²




Figure 1.2: 2005 Mid-year Population Estimates of Trinidad and Tobago

Age Group	Male	Female
0-4	43,281	41,710
5-9	43,768	41,820
10-14	53,577	51,388
15-19	65,943	63,668
20-24	69,209	67,593
25-29	54,889	53,307
30-34	46,820	46,058
35-39	44,147	45,042
40-44	49,669	50,472
45-49	44,085	44,037
50-54	36,719	35,808
55-59	30,376	29,221
60-64	21,348	21,813
65-69	16,120	17,323
70-74	12,154	14,056
75+	17,084	21,989
TOTAL	649,189	645,305

Table 1.1: 2005 Mid-year Population Estimates of Trinidad and Tobago

² **Population Statistics.** Central Statistical Office, Ministry of Planning and Development. Accessed July 11, 2024. <https://cso.gov.tt/subjects/population-and-vital-statistics/population/>

³ **2011 Census Data.** (2011). Accessed July 11, 2024. <https://cso.gov.tt/census/2011-census-data/>

Population Estimate 2011

The 2011 census indicated that the population was **1,328,019**, with **50.1% male and 49.9% female**. Of the total population, 54% were under 35 years old. The dependent population comprised 30% of the total population, including 21% under 15 years and 9% over 65 years of age.³




Figure 1.3: 2011 Population Census of Trinidad and Tobago

Age Group	Male	Female
0-4	47,847	46,274
5-9	46,379	44,952
10-14	44,953	43,010
15-19	49,709	48,670
20-24	57,407	56,833
25-29	62,268	61,250
30-34	53,897	51,683
35-39	46,862	45,677
40-44	43,491	42,672
45-49	48,685	47,429
50-54	43,981	43,203
55-59	36,719	36,496
60-64	29,645	29,002
65-69	21,583	23,055
70-74	14,209	16,079
75+	18,670	25,429
TOTAL	666,305	661,714

Table 1.2: 2011 Population Census of Trinidad and Tobago

Population Estimate 2017

Population estimates from June 2017 indicated a total population of **1,356,633**, with **50.2% male and 49.8% female**. Of the total population, 53.8% were under 35 years old. The dependent population comprised 29.6% of the total population, including 20.6% under 15 years of age and 9% over 65 years of age.²




Figure 1.4: 2017 Mid-year Population Estimates of Trinidad and Tobago

Age Group	Male	Female
0-4	48,878	47,271
5-9	47,378	45,921
10-14	45,922	43,937
15-19	50,780	49,719
20-24	58,644	58,058
25-29	63,610	62,570
30-34	55,058	52,797
35-39	47,872	46,661
40-44	44,428	43,591
45-49	49,734	48,451
50-54	44,929	44,134
55-59	37,510	37,282
60-64	30,284	29,627
65-69	22,048	23,552
70-74	14,515	16,425
75+	19,072	25,977
TOTAL	680,662	675,973

Table 1.3: 2017 Mid-year Population Estimates of Trinidad and Tobago

CULTURAL DIVERSITY IN TRINIDAD AND TOBAGO

The official language of Trinidad and Tobago is English. The population is ethnically diverse. The 2011 population census indicated the following ethnic composition:

• East Indian	35.4%
• African Descent	34.2%
• Mixed – Other	15.3%
• Mixed – African/East Indian	7.7%
• Other	1.3%
• Unspecified	6.2%

CANCER DIAGNOSIS REPORTED BY LOCATION

Cancer cases were diagnosed by both public and private institutions. The cancer cases in the Registry were recorded from the following sources: CSO (36.1%), NWRHA (23.8%), NCRHA (12.2%), SWRHA (11.5%), Private Institutions (11.2%), ERHA (2.9%), TRHA (2.3%), and unspecified locations (0.1%).




Figure 1.1: Illustration of the Regional Health Authorities in Trinidad and Tobago

Dr. Elizabeth Quamina Cancer Registry

HISTORY OF THE CANCER REGISTRY

The Dr. Elizabeth Quamina Cancer Registry, the National Cancer Registry of Trinidad and Tobago, was named after its pioneer and founder. Dr. Elizabeth Quamina, the nation's first female Chief Medical Officer. She was an active member of the National Cancer Society and played a pivotal role in establishing cancer screening clinics.⁴ A cancer patient herself, Dr. Quamina continued her impactful work until her passing in 1997. This population-based registry was established in September 1994 as a project of the Trinidad and Tobago Cancer Society. Cancer registry procedures were established according to internationally accepted guidelines set by the International Agency for Research on Cancer (IARC). Initially, Advisory and Management Committees were formed to advise and guide the Director and Registrar, formulate policies and procedures, and assist in mobilising resources.

In November 1998, recognising the need for cancer incidence data, the Registry became institutionalised within the Ministry of Health and has since been provided with office accommodation and regular funding. The Registry is now managed and administered through a tri-partite agreement among the Ministry of Health, the North Central Regional Health Authority (NCRHA), and the Trinidad and Tobago Cancer Society. IARC has a regional Cancer Registry Hub at the Caribbean Public Health Agency (CARPHA), which is a part of the Global Initiative for Cancer Registry Development (GICR). The IARC has played a substantial role in supporting international, regional, and local training.

TRINIDAD AND TOBAGO CANCER REGISTRY STAFF

The Dr. Elizabeth Quamina Cancer Registry, the National Cancer Registry, is operated by a dedicated team and managed in accordance with the National Health Service Plan and Policy established by the Ministry of Health and international standards. Details regarding the staff are provided in the *Acknowledgements* section of the report. All staff members of the Dr. Elizabeth Quamina Cancer Registry sign an oath of confidentiality, which is upheld even after their employment at the Registry.

⁴ Khan, N. (2022, August). **Profiles: Heroes, Role Models and Pioneers of Trinidad and Tobago**. First Citizens Bank. <https://epub.safaripublications.com/firstcitizenstt/profiles/130/>



Data Management

CANCER IN
TRINIDAD AND TOBAGO
2003
-2020



Data Collection

All cancer cases are recorded on a data entry form. The data from each form undergoes a verification process against the database to prevent duplication of recorded cases. Subsequently, the forms are reviewed for consistency and completeness. A copy of the cancer registry form can be found in *Appendix D*.

Cancer notification is not mandatory by law in Trinidad and Tobago; however, Registry Officers actively collect data from most public and some private institutions that permit visitation from Registry staff. In these institutions, cases are identified by the medical records staff and Registry Officers who search patient admission and discharge books. Although individuals from other countries receive treatment in Trinidad and Tobago, the Registry only includes residents of Trinidad and Tobago in their database.

A Registry Officer abstracts the hospital record for each certificate related to an in-hospital death. For deaths occurring outside hospitals, medical information is requested from the certifying physician. Additionally, Registry Officers collect cancer death information from the CSO – which compiles all deaths reported for a particular year listing cancer as the cause of death on the death certificate – integrating clinical information from medical records where possible. The CSO Cancer Death Form can be found in *Appendix D*.

Death information is cross-checked with the Registry's database. If the patient is already in the database, their vital status is updated as 'dead'. Patients not found in the database are entered as new records. In cases where no recorded data indicates a patient's vital status as deceased, the patient is assumed to be alive. Any identified issues are resolved by consulting the source document, the treating physician, or the reporting pathologist.

DATA COLLECTION SUMMARY



Cancer notification is not mandatory by law in Trinidad and Tobago.



The Registry utilises active surveillance and passive follow-up to collect the information on cancer patients in Trinidad and Tobago.



Active Surveillance: Registry Officers visit public and some private hospitals/clinics, cancer treatment centres, laboratories, and hospices to abstract cancer data.



Passive Follow-Up: Cancer data is updated in the database if the same patient is encountered at another institution or Central Statistical Office (CSO) for cancer deaths.

Data Quality

The four main indicators of data quality in a cancer registry are comparability, completeness, validity and timeliness.⁵

COMPARABILITY

Comparability refers to the ability of one registry to compare its data with another.⁵ In this regard, the National Cancer Registry of Trinidad and Tobago follows the recommendation of the World Health Organization (WHO) and utilises the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) as the standard to code all cancers registered.

⁵ Bray F, Parkin M. (2009). **Evaluation of Data Quality in the Cancer Registry: Principles and Methods. Part I: Comparability, Validity and Timeliness.** EJC 45(5): 747-755

COMPLETENESS

Completeness is the ability of the Registry to include all new cases that occur in Trinidad and Tobago during a specified period. High case-finding levels would ensure that the rates calculated from the data are near their actual value.⁶ Cancer notification is not mandatory by law in Trinidad and Tobago; thus, the registry utilises active data collection at all major public hospitals and cancer treatment centres, as well as public hospital pathology labs and some private hospitals and treatment centres, in the aim to collect the majority of new cancers cases diagnosed each year.

VALIDITY

Validity deals with the accuracy and quality control methods utilised in data collection and collation. Validity is measured by the percentage of cases with information missing or unknown, the percentage of cases with morphological verification (MV%) (i.e. diagnosed via histology or cytology), and the percentage of cases identified by death certificate only (DCO%).⁵ While collecting cancers diagnosed via histology is seen as ideal, an MV% that is higher than might reasonably be expected (based on local standards) may indicate the registry is missing cases being diagnosed by other means, such as via clinical investigations. Similarly, a DCO% that is very high may indicate the registry may be missing cases of persons who died before the cancer was registered.⁵

TIMELINESS

Timeliness refers to the speed with which a registry can collect, process, code, and report on data collected with a high level of completeness, validity, and accuracy, in accordance with previously established timeframes.⁵ Although there are no international guidelines for timeliness at present, the registry tries to report on cancers within two to four years behind the current year as is standard internationally. This ensures a high level of completeness and accuracy of the data in the database.

⁶ Bray F, Parkin M. (2009). **Evaluation of Data Quality in the Cancer Registry: Principles and Methods. Part II: Completeness.** EJC 45(5): 759-764

Coding

The Dr. Elizabeth Quamina Cancer Registry codes cancers according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). The Registry adopted the ICD-O-3 First Revision for cancers diagnosed after January 2012 and the ICD-O-3 Second Revision for those diagnosed after January 2020. The definition of incidence data and the coding of diagnoses follow the guidelines outlined in the Caribbean Registry Manual – Data Collection and Operating Procedures Module.⁷

LIMITATIONS

During the calendar years 2013 to 2015, staff shortages affected data collection, potentially impacting data for 2010 to 2014. For new cancers registered from the CSO, where no further information was available, the date of incidence was recorded as the date of death.

Data Processing and Storage


After coding, the case is entered into a password-protected CanReg⁸ database and statistical software. In January 2016, the Registry upgraded from CanReg4 to CanReg5. This software performs checks for internal consistency and completeness. Paper records are stored in locked, fireproof cabinets. The data collected are based on new cancers diagnosed in Trinidad and Tobago residents since the Cancer Registry's commencement date.

Future reports from the registry covering the period from 2003 to 2020 may reveal new data as the database is continually updated. The data in this report were exported from the database on 1st March 2024. Cancer deaths mentioned in this report are those that occurred during the period 2003-2020, regardless of the date of diagnosis.

⁷ Caribbean Public Health Agency. (2018, April). **Caribbean Registry Manual: Data Collection and Operating Procedures Module** – Version 1.0.

⁸ IACR - **CanReg (Version 5)**. (2023). [Computer software].

Data Processing Flowchart





Terms and Definitions

CANCER IN
TRINIDAD AND TOBAGO

2003
-2020

Pathological Definitions

BEHAVIOR OF THE TUMOUR

The type of behaviour of the tumour describes whether the tumour is benign, in situ or malignant.⁷ For this reporting period, all tumours were classified as **malignant tumours**.

BASIS OF DIAGNOSIS

The basis of diagnosis is the most conclusive method used to distinguish how the diagnosis of the reportable tumour was made. *Table 3.1* shows the codes used in this report.⁷

CODE	DESCRIPTION
0	Death Certificate only
1	Clinical; Diagnosis made before death, but without any of the following (codes 2-7)
2	Clinical investigation; All diagnostic techniques, including x-ray, endoscopy, imaging, ultrasound, exploratory surgery (e.g. laparotomy), and autopsy, without a tissue diagnosis
3	Autopsy without microscopic confirmation
4	Specific tumour markers; including biochemical and/or immunological markers that are specific to a tumour site
5	Cytology; Examination of cells from a primary or secondary site, including fluids aspirated by endoscopy or needle; Also includes the microscopic examination of peripheral blood and bone marrow aspirates
6	Histology of a metastasis; Histologic examination of tissue from a metastasis, including autopsy specimens
7	Histology of primary tumour; Histologic examination of tissue from primary tumour, however obtained, including all cutting techniques and bone marrow biopsies; also includes autopsy specimens of primary tumour
8	Autopsy with microscopic confirmation
9	Unknown

Table 3.1: Basis of Diagnosis

GRADE OF CANCER

The grade describes how differentiated the cancer cells are from the normal tissues and can also describe how quickly the cancer cells are likely to grow and spread.⁹ Poorly differentiated tumours tend to be more aggressive and have a poor prognosis for patient survival. See *Table 3.2*.

CODE	GRADE	DESCRIPTION
0	Grade I	Well differentiated; Differentiated; Not otherwise specified (NOS)
1	Grade II	Moderately differentiated: Moderately well differentiated; Intermediate differentiation.
2	Grade III	Poorly differentiated
3	Grade IV	Undifferentiated: Anaplastic
4	T-cell	T-precursor
5	B-cell, Pre-B	B-precursor
6	NK cell	Natural killer cell
9		Grade differentiation not determined, not stated, or not applicable

Table 3.2: *Grades of Cancer*

STAGE OF CANCER

The stage of the cancer categorises how far the cancer has spread from the primary site.⁷ The staging in this report is classified according to the Summary Stage Method for cancer registries in *Table 3.3*.

STAGE	DESCRIPTION
Localised	The cancer is confined to the organ or tissue of origin.
Regional	The cancer has extended beyond the organ or tissue of organ.
Distant	The cancer has spread to areas of the body that are distant from the primary tumour.
Unknown	The stage of the cancer is unknown, untagged, unspecified; or death certificate only.

Table 3.3: *Stages of Cancer*

⁹ National Cancer Institute. (2022, August 1). **Tumor Grade.** <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-grade>

TREATMENT OF CANCER

The treatment concerning diagnoses covered in this reporting period describes treatment that began within the first year of diagnosis. The treatment provided during this reporting period refers to surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, and other treatments. It should be noted that some treatments can be administered concurrently.

Epidemiological Definitions

CRUDE INCIDENCE RATES

Incidence refers to the occurrence of **new** cancer cases among residents of Trinidad and Tobago over a specific period, rather than the total number of people living with cancer. Multiple cancers can occur in one person, but only one tumour is recognised as arising from a specific origin, pair of organs, or tissue, unless the others are of “different” histology, as defined in ICD-O-3.

Crude Incidence Rates (CR) for a cancer site represent the total number of new cases diagnosed over a period – as a proportion of the total population – expressed per 100,000 individuals annually.

$$\text{Crude Incidence Rate} = \frac{\text{New Cancer Cases}}{\text{At Risk population}} \times 100,000$$

AGE-SPECIFIC RATES

Age-specific rates describe the number of cancer cases in a specific age group and sex category divided by the number of persons within that specific age group and sex. It is expressed as the number of cases per 100,000 individuals annually within that age group and sex.

$$\text{Age Specific Rate} = \frac{\text{Number of cancer cases per age – sex category}}{\text{Population per age – sex category}} \times 100,000$$

AGE-STANDARDISED RATES

While crude incidence rates are important for providing baseline information about the burden of a disease, they are not suitable for comparisons between groups. The Age Standardised Rate (ASR) is an adjusted rate that accounts for differences in population structure between populations, allowing for comparisons of health data across multiple populations and countries. The ASR is calculated using the direct method and the WHO World Standard Population. *Table 3.4* shows the WHO World Standard weights.

AGE GROUP	WHO WORLD STANDARD	AGE GROUP	WHO WORLD STANDARD
0-4	8.86	40-44	6.59
5-9	8.69	45-49	6.04
10-14	8.60	50-54	5.37
15-19	8.47	55-59	4.55
20-24	8.22	60-64	3.72
25-29	7.93	65-69	2.96
30-34	7.61	70-74	2.21
35-39	7.15	75+	3.06

Table 3.4: WHO World Standard¹⁰

The ASR represents the number of new cases of cancer or cancer deaths per 100,000 annually that would have occurred in the World Standard Population if the actual age-specific rates observed in Trinidad and Tobago had prevailed in that population.

$$ASR = \text{Age Specific Rate} \times \text{Weight in standard population}$$

¹⁰ Pan American Health Organization. (2009, April). **Age Standardized Mortality Rates per 100,000 Population for Deaths < 70 years**. <https://www3.paho.org/hq/dmdocuments/2012/PAHO-Age-standardized-mortality-rates-2009.pdf>

CRUDE MORTALITY RATES

Crude Mortality Rates (MR) represent the total number of new cancer deaths over a period – as a proportion of the total population – expressed per 100,000 individuals annually.

$$\text{Mortality Rate} = \frac{\text{New Cancer Deaths}}{\text{At Risk population}} \times 100,000$$

LIFETIME RISK

Lifetime Risk (LR) is a measure of the risk of contracting a particular cancer in a lifetime if the risk at the time of calculation continued throughout life. In this report, lifetime risk is calculated as the risk of contracting a particular leading cancer before the age of 75 years using the following formula:

$$\text{Lifetime Risk} = \frac{1}{\text{cumulative risk}}$$

where

$$\text{Cumulative Risk} = 1 - e^{-\left(\frac{\text{cumulative rate}}{100}\right)}$$

where *cumulative rate* = five-year age-sex specific rate per person multiplied by five and summed over age groups from 0-4 to 70-74.



Cancer Overview 2003–2020

CANCER IN
TRINIDAD AND TOBAGO
2003
–2020

Demographics

Between 2003 and 2020, 49% of the 43,380 individuals diagnosed with cancer were male, and 51% were female, as reported in the Cancer Registry.

? *One case of cancer (in 2008) – with an unknown sex, within the age category of 0 to 14 years, having an unknown ethnicity – was excluded from the analysis.*

The majority (97.9%) of the persons diagnosed with cancer were over 25 years of age, with most persons (39%) falling within the age category of 60 to 74 years old. Most cases were among Africans (36.2%), followed by East Indians (23%). Additionally, 24.2% of cases were of unknown ethnicity. See *Table 4.1* and *Figure 4.1*.

DEMOGRAPHICS	n	%
Sex		
Male	21,247	49.0
Female	22,132	51.0
Unknown	1	0.0
Age Group		
0 – 14	446	1.0
15 – 24	464	1.1
25 – 59	15,189	35.0
60 – 74	16,898	39.0
75+	10,383	23.9
Ethnicity		
African	15,692	36.2
East Indian	9,992	23.0
Chinese	240	0.6
Mixed	5,641	13.0
White/Caucasian	434	1.0
Syrian/Lebanese	56	0.1
Other	840	1.9
Unknown	10,485	24.2

Table 4.1: Summary Statistics for the Period 2003-2020




Figure 4.1: Distributions of Cancer by Sex, Age, and Ethnicity, 2003-2020

Cancer Incidence and Mortality

CANCER INCIDENCE

The year 2013 showed the lowest cancer incidence ($n = 1,887$; $CR = 142.1$), while 2020 had the highest ($n = 3,225$; $CR = 237.7$).

During the period 2003 to 2008:

2004 had the lowest incidence rate of 157.9 cases per 100,000 persons, while 2007 had the highest incidence rate of 176.6 cases per 100,000 persons, with a moderate upward trend in cancer cases.

During the period 2009 to 2014:

2013 had the lowest incidence rate, while 2009 had the highest incidence rate of 172.3 cases per 100,000, showing a general downward trend in cancer cases.

During the period 2015 to 2020:

2015 had the lowest incidence rate of 189.7 persons per 100,000, while 2020 had the highest, with a steep upward trend in cancer cases. See *Figure 4.2A* and *Table 4.2*.




Figure 4.2A: Crude Incidence Rate for the Period 2003 to 2020

CANCER MORTALITY

There is a general upward trend in cancer mortality, with the year 2003 having the lowest mortality rate ($n = 910$; $MR = 70.3$), while 2019 had the highest ($n = 2,175$; $MR = 160.3$).

During the period 2003 to 2008:

2003 had the lowest mortality rate of 70.3 deaths per 100,000 persons, while 2008 had the highest mortality rate of 108.5 deaths per 100,000 persons, with a steady upward trend in mortality.

During the period 2009 to 2014:

2013 had the lowest mortality rate of 101.2 deaths per 100,000 persons, while 2011 had the highest mortality rate of 121 deaths per 100,000 persons, with a general upward trend from 2009 to 2011. However, in 2013, there was a decline and then a gradual upward trend in 2014.

During the period 2015 to 2020:

2016 had the lowest mortality rate of 126.6 deaths per 100,000 persons, while 2019 had the highest mortality rate of 160.3 deaths per 100,000. There was an upward trend from 2016 to 2019, followed by a decline in 2020. See *Figure 4.2B* and *Table 4.2*.




Figure 4.2B: Crude Mortality Rate for the Period 2003 to 2020

YEAR OF DIAGNOSIS	CANCER INCIDENCE	CRUDE INCIDENCE RATE	CANCER MORTALITY	CRUDE MORTALITY RATE
2003	2,142	165.5	910	70.3
2004	2,044	157.9	991	76.6
2005	2,154	166.4	1,082	83.6
2006	2,146	165.8	1,144	88.4
2007	2,286	176.6	1,320	102.0
2008	2,276	175.8	1,404	108.5
2009	2,288	172.3	1,446	108.9
2010	2,175	163.8	1,537	115.7
2011	2,263	170.4	1,607	121.0
2012	2,031	152.9	1,578	118.8
2013	1,887	142.1	1,344	101.2
2014	2,146	161.6	1,495	112.6
2015	2,573	189.7	1,810	133.4
2016	2,605	192.0	1,718	126.6
2017	2,877	212.1	1,805	133.0
2018	3,104	228.8	1,910	140.8
2019	3,157	232.7	2,175	160.3
2020	3,225	237.7	2,035	150.0
TOTAL	43,379		27,311	

Table 4.2: *Number of Cancers, Distribution, Crude Incidence Rate, and Mortality Rate by Year of Diagnosis*

Time Trend of Leading Cancers

TOP 10 LEADING CANCERS IN MALES

Table 4.3 and *Figure 4.3* below show the top ten leading cancers in males for the period 2003 to 2020, with **prostate cancer having the highest incidence** throughout those years. There were 609 cancer cases with an unknown primary site among men during the period 2003 to 2020. This may mean that the cancer was diagnosed after it had spread to another organ and the primary organ could not be determined.

Topography Category	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total
Prostate	474	405	439	471	476	423	418	447	391	389	348	368	451	458	526	595	532	510	8,121
Colon & Rectum	127	138	130	115	152	144	121	128	133	111	90	134	150	164	139	192	197	218	2,583
Bronchus & Lung	96	96	107	106	108	122	136	109	120	107	124	136	153	129	164	180	152	152	2,297
Leukemia	56	50	48	44	36	56	47	51	49	73	60	79	92	71	100	77	100	92	1,181
Pancreas	34	39	44	41	38	46	53	35	35	42	42	31	57	45	51	56	69	45	803
Stomach	37	36	47	42	30	38	35	37	31	33	29	21	33	37	30	39	38	37	630
Lymphoma	22	28	26	36	36	44	28	32	34	33	34	37	39	29	30	40	34	42	604
Bladder	21	25	16	17	20	17	26	38	40	27	17	25	34	25	43	34	43	47	515
Larynx	16	27	24	16	29	27	31	30	26	16	17	18	21	32	30	31	32	27	450
Oral Cavity & Salivary Gland	20	17	25	21	18	31	19	16	21	12	11	13	23	24	19	23	23	28	364

Table 4.3: Time Trends of the Top 10 Leading Cancers in Males for the Period 2003 to 2020




Figure 4.3: Time Trends of the Top 10 Leading Cancers in Males for the Period 2003 to 2020

TOP 10 LEADING CANCERS IN FEMALES

Table 4.4 and *Figure 4.4* below show the top ten leading cancers in females for the period 2003 to 2020, with **breast cancer having the highest incidence** throughout the years. There were 584 cancer cases with an unknown primary site among women during the period 2003 to 2020. This may mean that the cancer was diagnosed after it had spread to another organ and the primary organ could not be determined.

Topography Category	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total
Breast	333	327	344	365	406	407	397	363	389	309	308	354	415	443	505	544	567	574	7,350
Uterus	93	90	103	94	109	95	126	123	91	95	79	98	131	164	171	199	240	245	2,346
Colon & Rectum	115	98	85	103	109	116	107	107	135	100	105	100	133	134	157	156	177	180	2,217
Cervix Uteri	124	134	118	134	114	112	118	110	95	99	89	99	100	111	150	112	101	132	2,052
Ovary	63	60	81	64	75	68	60	73	76	61	61	74	85	83	98	93	99	89	1,363
Leukemia	47	42	33	48	46	39	46	40	51	57	57	50	78	76	71	73	63	103	1,020
Bronchus & Lung	24	19	27	26	40	35	46	40	50	41	35	51	53	53	53	59	68	65	785
Pancreas	25	24	41	24	40	38	34	36	35	26	31	37	47	43	44	42	42	37	646
Lymphoma	29	12	29	30	28	23	29	26	35	16	29	34	24	22	32	27	30	39	494
Stomach	18	29	34	19	23	25	31	13	26	27	23	20	25	30	23	25	19	36	446

Table 4.4: Time Trends of the Top 10 Leading Cancers in Females for the Period 2003 to 2020




Figure 4.4: Time Trends of the Top 10 Leading Cancers in Females for the Period 2003 to 2020

Photo: U.S. National Cancer Institute
(acute myelocytic leukemia (AML))

Overview of Cancer Statistics

TRINIDAD AND TOBAGO

2003-2008

Top 5 Leading Cancers, 2003–2008

TOP 5 CANCERS OVERALL

Prostate cancer was the top cancer by percentage of total ($n=2,688$, 20.6%), followed by **breast** ($n=2,220$, 17.0%), **colon and rectum** ($n=1,432$, 11.0%), **bronchus and lung** ($n=806$, 6.2%), and **cervix uteri** ($n=736$, 5.6%). See *Figure 5.1*.




Figure 5.1: Top 5 Cancers Overall, 2003 to 2008

TOP 5 CANCERS BY AGE GROUP

There were 152 persons diagnosed with cancer within the age group 0 to 14 years; 138 persons in the age group 15 to 24 years; 4,914 persons in the age group 25 to 59 years; 4,571 persons in the age group 60 to 74 years; and 3,228 persons aged 75 years and over. Leukemia had the highest incidence among individuals under 15 years of age. In the 15 to 24 age group, lymphoma had the highest rate. For those aged 25 to 59 years, breast cancer had the highest incidence, while prostate cancer was highest among individuals 60 years and older. See *Table 5.1*.

AGE GROUP	TOPOGRAPHY CATEGORY	n	% WITHIN AGE GROUP
0 - 14	Leukemia	41	27.0
	CNS - Central Nervous System	32	21.1
	Kidney	11	7.2
	Bone & Articular Cartilage	9	5.9
	Ill-Defined	9	5.9
15-24	Lymphoma	38	27.5
	Leukemia	24	17.4
	Testis	16	11.6
	Bone & Articular Cartilage	12	8.7
	Ovary	11	8.0
25-59	Breast	1,323	26.9
	Colon & Rectum	536	10.9
	Cervix Uteri	453	9.2
	Prostate	318	6.5
	Bronchus & Lung	302	6.1

AGE GROUP	TOPOGRAPHY CATEGORY	<i>n</i>	% WITHIN AGE GROUP
60–74	Prostate	1,197	26.2
	Breast	610	13.3
	Colon & Rectum	537	11.7
	Bronchus & Lung	291	6.4
	Uterus	267	5.8
75+	Prostate	1,171	36.3
	Colon & Rectum	353	10.9
	Breast	283	8.8
	Bronchus & Lung	209	6.5
	Pancreas	155	4.8

Table 5.1: Top 5 Cancers by Age for the Period 2003 to 2008

Top 10 Leading Cancers, 2003–2008

Table 5.2 shows the top 10 leading cancers for the period 2003 to 2008.

With 2,688 registered cases and 1,319 deaths, **prostate cancer** was the leading cancer overall (20.6%) and among men (40.7%). Prostate cancer had an incidence rate of 69 cases and a mortality rate of 34 deaths per 100,000 men during the period 2003 to 2008 in Trinidad and Tobago. During their lifetimes, **1 in 14 men** could develop prostate cancer (*Figure 5.2*).

With 2,182 registered cases and 598 deaths, **breast cancer** was the second-leading cancer overall (17.0%) and leading cancer among women (33.9%). Breast cancer had an incidence rate of 56 cases and a mortality rate of 15 deaths per 100,000 individuals during the period 2003 to 2008 in Trinidad and Tobago. During their lifetimes, **1 in 18 women** could develop breast cancer (*Figure 5.2*).

There were 375 cancer cases with an unknown primary site, accounting for 2.9% of cancers among men and 2.8% of cancers among women.



Figure 5.2: Lifetime Risk of Leading Cancers, 2003 to 2008

TOPOGRAPHY CATEGORY	INCIDENCE (n)	%	CR	MORTALITY (n)	MORTALITY RATE
Male					
Prostate	2,688	40.7	69.0	1319	34
Colon & Rectum	806	12.2	20.7	430	11
Bronchus & Lung	635	9.6	16.3	493	13
Leukemia	290	4.4	7.4	196	5
Pancreas	242	3.7	6.2	215	6
Stomach	230	3.5	5.9	183	5
Lymphoma	192	2.9	4.9	126	3
Larynx	139	2.1	3.6	61	2
Oral Cavity & Salivary Gland	132	2.0	3.4	62	2
Bladder	116	1.8	3.0	56	1
Female					
Breast	2,182	33.9	56.4	598	15
Cervix Uteri	736	11.4	19.0	328	9
Colon & Rectum	626	9.7	16.2	340	9
Uterus	584	9.1	15.1	257	7
Ovary	411	6.4	10.6	242	6
Leukemia	255	4.0	6.6	175	5
Pancreas	192	3.0	5	162	4
Bronchus & Lung	171	2.7	4.4	125	3
Lymphoma	151	2.3	3.9	84	2
Stomach	148	2.3	3.8	118	3

Table 5.2: Incidence and Mortality of the Top 10 Leading Cancers for the Period 2003 to 2008

Age-Sex-Specific Incidence Rates of Top 5 Leading Cancers, 2003–2008

Topography Category	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
Prostate					0.5			0.8	1.7	13.2	43.1	99.3	243.6	424.9	650.0	1,142.4
Colon & Rectum				0.3	0.7	0.9	3.2	6.4	13.8	20.0	31.3	57.1	83.5	111.7	135.8	187.3
Bronchus & Lung				0.3	0.7	0.9	0.7	0.8	7.4	20.0	36.8	42.2	67.1	96.2	79.5	150.2
Leukemia	6.2	1.1	1.2	3.3	1.2	2.7	4.6	1.9	6.0	6.8	8.2	10.4	19.5	36.2	37.0	60.5
Pancreas							0.4	1.1	5.0	6.4	6.4	17.6	21.1	37.2	34.3	70.2

Table 5.3: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Males for the Period 2003 to 2008




Figure 5.3: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Males for the Period 2003 to 2008

OVERVIEW OF STATISTICS: 2003–2008

Topography Category	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
Breast					1.0	7.2	22.8	43.7	77.6	115.1	129.9	163.1	199.4	178.0	175.5	209.2
Cervix Uteri					1.2	8.1	14.1	22.6	30.4	32.2	35.4	42.2	59.6	69.3	47.4	66.7
Colon & Rectum				0.3	0.2	0.9	3.6	7.8	8.9	18.2	28.9	39.4	43.6	83.7	93.7	122.0
Uterus						0.9	1.8	5.2	7.9	12.5	25.1	41.6	82.5	93.3	73.5	84.1
Ovary	0.4		0.3	1.3	1.5	1.6	2.9	4.8	11.2	14.0	23.7	29.7	32.9	41.4	58.1	47.8

Table 5.4: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Females for the Period 2003 to 2008




Figure 5.4: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Females for the Period 2003 to 2008

Top 8 Leading Cancers by Ethnicity, 2003–2008

Figure 5.5 shows the top 8 leading cancers by ethnicity. The percentages indicate the proportion of ethnicity within a particular cancer.




Figure 5.5: Top 8 Leading Cancers by Ethnicity for the Period 2003 to 2008

Basis of Diagnosis of Top 8 Leading Cancers, 2003–2008

TOPOGRAPHY CATEGORY	BASIS OF DIAGNOSIS	<i>n</i>	%
Prostate	Autopsy/Histology	112	4.2
	Clinical Investigation/Ultrasound	78	2.9
	Clinical Only	31	1.2
	Death Certificate Only	486	18.1
	Histology of Metastases	4	0.1
	Histology of Primary	1,961	73.0
	Laboratory Test	8	0.3
	Surgery/Autopsy	2	0.1
	Unknown	6	0.2
Breast	Autopsy/Histology	38	1.7
	Clinical Investigation/Ultrasound	18	0.8
	Clinical Only	6	0.3
	Death Certificate Only	128	5.8
	Histology of Primary	2,027	91.3
	Surgery/Autopsy	1	0.0
	Unknown	2	0.1
Colon & Rectum	Autopsy/Histology	75	5.2
	Clinical Investigation/Ultrasound	25	1.7
	Clinical Only	4	0.3
	Cytology	1	0.1
	Death Certificate Only	182	12.7
	Histology of Metastases	3	0.2
	Histology of Primary	1,138	79.5
	Surgery/Autopsy	1	0.1
	Unknown	3	0.2
Bronchus & Lung	Autopsy/Histology	120	14.9
	Clinical Investigation/Ultrasound	48	6.0
	Clinical Only	8	1.0
	Cytology	3	0.4
	Death Certificate Only	107	13.3
	Histology of Metastases	5	0.6
	Histology of Primary	513	63.6
	Unknown	2	0.2

TOPOGRAPHY CATEGORY	BASIS OF DIAGNOSIS	<i>n</i>	%
Cervix Uteri	Autopsy/Histology	19	2.6
	Clinical Investigation/Ultrasound	1	0.1
	Clinical Only	2	0.3
	Cytology	3	0.4
	Death Certificate Only	63	8.6
	Histology of Metastases	2	0.3
	Histology of Primary	643	87.4
	Unknown	3	0.4
Uterus	Autopsy/Histology	24	4.1
	Clinical Investigation/Ultrasound	7	1.2
	Clinical Only	1	0.2
	Death Certificate Only	46	7.9
	Histology of Primary	500	85.6
	Surgery/Autopsy	2	0.3
	Unknown	4	0.7
Leukemia	Autopsy/Histology	51	9.4
	Clinical Investigation/Ultrasound	2	0.4
	Cytology	67	12.3
	Death Certificate Only	43	7.9
	Histology of Primary	378	69.4
	Laboratory Test	2	0.4
	Unknown	2	0.4
Pancreas	Autopsy/Histology	58	13.4
	Clinical Investigation/Ultrasound	46	10.6
	Clinical Only	1	0.2
	Cytology	2	0.5
	Death Certificate Only	102	23.5
	Histology of Metastases	3	0.7
	Histology of Primary	220	50.7
	Surgery/Autopsy	2	0.5

Table 5.5: Basis of Diagnosis of the Top 8 Leading Cancers for the Period 2003 to 2008

Grades of Top 8 Leading Cancers, 2003–2008

TOPOGRAPHY CATEGORY	GRADE	n	%
Prostate	Grade I; Well differentiated: Differentiated; NOS	297	11.0
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	466	17.3
	Grade III; Poorly differentiated	301	11.2
	Grade IV; Undifferentiated; Anaplastic	7	0.3
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,617	60.2
Breast	B-cell; Pre-B: B-precursor	2	0.1
	Grade I; Well differentiated: Differentiated; NOS	66	3.0
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	154	6.9
	Grade III; Poorly differentiated	359	16.2
	Grade IV; Undifferentiated; Anaplastic	14	0.6
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,625	73.2
Colon & Rectum	Grade I; Well differentiated: Differentiated; NOS	113	7.9
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	310	21.6
	Grade III; Poorly differentiated	95	6.6
	Grade IV; Undifferentiated; Anaplastic	2	0.1
	Grade, differentiation, or cell type not determined; not stated or not applicable	912	63.7
Bronchus & Lung	Grade I; Well differentiated: Differentiated; NOS	14	1.7
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	32	4.0
	Grade III; Poorly differentiated	66	8.2
	Grade IV; Undifferentiated; Anaplastic	11	1.4
	Grade, differentiation, or cell type not determined; not stated or not applicable	683	84.7
Cervix Uteri	Grade I; Well differentiated: Differentiated; NOS	42	5.7
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	134	18.2
	Grade III; Poorly differentiated	147	20.0
	Grade IV; Undifferentiated; Anaplastic	12	1.6
	Grade, differentiation, or cell type not determined; not stated or not applicable	401	54.5
Uterus	Grade I; Well differentiated: Differentiated; NOS	73	12.5
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	75	12.8
	Grade III; Poorly differentiated	84	14.4
	Grade IV; Undifferentiated; Anaplastic	6	1.0
	Grade, differentiation, or cell type not determined; not stated or not applicable	346	59.2
Leukemia	B-cell; Pre-B: B-precursor	26	4.8
	Grade IV; Undifferentiated; Anaplastic	1	0.2
	T-cell; T-precursor	22	4.0
	Grade, differentiation, or cell type not determined; not stated or not applicable	496	91.0

TOPOGRAPHY CATEGORY	GRADE	n	%
Pancreas	Grade I; Well differentiated: Differentiated; NOS	2	0.5
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	9	2.1
	Grade III; Poorly differentiated	11	2.5
	Grade, differentiation, or cell type not determined; not stated or not applicable	412	94.9

Table 5.6: Distribution of Grades of the Top 8 Leading Cancers for the Period 2003 to 2008

Stages of Top 8 Leading Cancers, 2003–2008

TOPOGRAPHY CATEGORY	STAGE	n	%	TOPOGRAPHY CATEGORY	STAGE	n	%
Prostate	Localised	977	36.3	Cervix Uteri	Localised	245	33.3
	Regional	118	4.4		Regional	190	25.8
	Distant	380	14.1		Distant	76	10.3
	Unknown	1213	45.1		Unknown	225	30.6
Breast	Localised	913	41.1	Uterus	Localised	265	45.4
	Regional	767	34.5		Regional	90	15.4
	Distant	217	9.8		Distant	87	14.9
	Unknown	323	14.5		Unknown	142	24.3
Colon & Rectum	Localised	417	29.1	Leukemia¹¹	Distant	366	67.2
	Regional	293	20.5		Unknown Primary Site	179	32.8
	Distant	262	18.3	Pancreas	Localised	34	7.8
	Unknown Primary Site	460	32.1		Regional	41	9.4
Bronchus & Lung	Localised	72	8.9		Distant	99	22.8
	Regional	40	5.0		Unknown	260	59.9
	Distant	213	26.4				
	Unknown	481	59.7				

¹¹ **Note:** Leukemia is staged as “Distant” in the Cancer Registries because its primary site is the Bone Marrow.

Table 5.7: Distribution of Stages of the Top 8 Leading Cancers for the Period 2003 to 2008

Details on cancer incidence, age-sex-specific rates, and cancer mortality for the period **2003 to 2008** can be found in **Appendix A**.




Photo: U.S. National Cancer Institute
(lung cancer desmoplasia)



Overview of Cancer Statistics

TRINIDAD AND TOBAGO

2009-2014

Top 5 Leading Cancers, 2009–2014

TOP 5 CANCERS OVERALL

Prostate cancer was the top cancer overall ($n=2,361$, 18.5%), followed by **breast** ($n=2,158$, 16.9%), **colon and rectum** ($n=1,371$, 10.7%), **bronchus and lung** ($n=995$, 7.8%), and **leukemia** ($n=660$, 5.2%). See *Figure 6.1*.




Figure 6.1: Top 5 Cancers Overall, 2009 to 2014

TOP 5 CANCERS BY AGE GROUP

There were 155 persons diagnosed with cancer within the age group 0 to 14 years; 129 persons in the age group 15 to 24 years; 4,566 persons in the age group 25 to 59 years; 4,863 persons in the age group 60 to 74 years; and 3,077 persons aged 75 years and over. Leukemia had the highest incidence among individuals under 15 years of age. In the 15 to 24 age group, lymphoma had the highest rate. For those aged 25 to 59 years, breast cancer had the highest incidence, while prostate cancer was highest among individuals 60 years and older. See *Table 6.1*.

AGE GROUP	TOPOGRAPHY CATEGORY	n	% WITHIN AGE GROUP
0 - 14	Leukemia	60	38.7
	CNS - Central Nervous System	19	12.3
	Ill-Defined	16	10.3
	Kidney	15	9.7
	Eye	8	5.2
15-24	Lymphoma	31	24.0
	Leukemia	23	17.8
	Bone & Articular Cartilage	12	9.3
	CNS - Central Nervous System	10	7.8
	Ovary	9	7.0
25-59	Breast	1,241	27.2
	Colon & Rectum	460	10.1
	Cervix Uteri	361	7.9
	Bronchus & Lung	342	7.5
	Leukemia	234	5.1

AGE GROUP	TOPOGRAPHY CATEGORY	<i>n</i>	% WITHIN AGE GROUP
60–74	Prostate	1,102	22.7
	Breast	623	12.8
	Colon & Rectum	548	11.3
	Bronchus & Lung	439	9.0
	Uterus	311	6.4
75+	Prostate	1,030	33.5
	Colon & Rectum	357	11.6
	Breast	290	9.4
	Bronchus & Lung	214	7.0
	Pancreas	146	4.7

Table 6.1: Top 5 Cancers by Age for the Period 2009 to 2014

Top 10 Leading Cancers, 2009–2014

Table 6.2 shows the top 10 leading cancers for the period 2009 to 2014.

With 2,361 registered cases and 1,625 deaths, **prostate cancer** was the leading cancer overall (18.5%) and among men (37.5%). Prostate cancer had an incidence rate of 59 cases and a mortality rate of 41 deaths per 100,000 men during the period 2009 to 2014 in Trinidad and Tobago. During their lifetimes, **1 in 20 men** could develop prostate cancer (*Figure 6.2*).

With 2,158 registered cases and 964 deaths, **breast cancer** was the second-leading cancer overall (16.9%) and leading cancer among women (32.7%). Breast cancer had an incidence rate of 53 cases and a mortality rate of 25 deaths per 100,000 individuals during the period 2009 to 2014 in Trinidad and Tobago. During their lifetimes, **1 in 22 women** could develop breast cancer (*Figure 6.2*).

There were 324 cancer cases with an unknown primary site, accounting for 2.7% of cancers among men and 2.4% of cancers among women.



Figure 6.2: Lifetime Risk of Leading Cancers, 2009 to 2014

TOPOGRAPHY CATEGORY	INCIDENCE (n)	%	CR	MORTALITY (n)	MORTALITY RATE
Male					
Prostate	2,361	37.5	59.1	1,625	41
Bronchus & Lung	732	11.6	18.3	656	16
Colon & Rectum	717	11.4	17.9	509	13
Leukemia	359	5.7	9.0	275	7
Pancreas	238	3.8	6.0	237	6
Lymphoma	198	3.1	5.0	147	4
Stomach	186	3.0	4.7	170	4
Bladder	173	2.7	4.3	123	3
Larynx	138	2.2	3.5	91	2
Liver	133	2.1	3.3	126	3
Female					
Breast	2,120	32.7	53.4	992	25
Colon & Rectum	654	10.1	16.5	452	11
Uterus	612	9.4	15.4	403	10
Cervix Uteri	610	9.4	15.4	409	10
Ovary	405	6.2	10.2	301	8
Leukemia	301	4.6	7.6	232	6
Bronchus & Lung	263	4.1	6.6	216	5
Pancreas	199	3.1	5.0	186	5
Lymphoma	169	2.6	4.3	122	3
Stomach	140	2.2	3.5	116	3

Table 6.2: Incidence and Mortality of the Top 10 Leading Cancers for the Period 2009 to 2014

Age-Sex-Specific Incidence Rates of Top 5 Leading Cancers, 2009–2014

Topography Category	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
Prostate						0.3			1.5	8.2	24.6	61.3	156.3	327.4	469.2	919.5
Bronchus & Lung						0.3	0.6	2.5	5.7	6.8	31.1	62.2	71.4	84.9	116.1	117.8
Colon & Rectum					0.6	0.8	2.5	2.8	9.6	12.3	18.2	41.3	61.3	91.1	116.1	151.8
Leukemia	4.5	3.6	2.2	1.7	3.2	3.2	3.4	4.6	4.6	7.5	9.5	15.0	29.2	25.5	39.9	59.8
Pancreas							0.6	0.4	1.1	2.7	8.0	12.3	16.3	25.5	52.8	61.6

Table 6.3: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Males for the Period 2009 to 2014




Figure 6.3: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Males for the Period 2009 to 2014

OVERVIEW OF STATISTICS: 2009–2014

Topography Category	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
Breast					1.2	5.7	17.7	39.0	68.4	93.1	119.6	132.9	148.8	149.6	151.3	183.5
Colon & Rectum					1.2	1.6	4.2	5.8	8.6	14.8	21.6	39.3	39.7	66.5	63.2	122.6
Uterus						0.8	0.3	2.9	7.4	10.9	17.4	37.4	75.3	78.1	74.6	73.4
Cervix Uteri					0.9	4.4	10.0	19.7	30.9	22.8	24.3	24.2	33.9	41.2	49.8	53.7
Ovary			1.2	1.7	1.2	3.0	3.2	4.4	9.0	14.4	17.4	26.9	28.2	34.7	43.5	34.7

Table 6.4: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Females for the Period 2009 to 2014




Figure 6.4: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Females for the Period 2009 to 2014

Top 8 Leading Cancers by Ethnicity, 2009–2014

Figure 6.5 shows the top 8 leading cancers by ethnicity. The percentages indicate the proportion of ethnicity within a particular cancer.




Figure 6.5: Top 8 Leading Cancers by Ethnicity for the Period 2009 to 2014

Basis of Diagnosis of Top 8 Leading Cancers, 2009–2014

TOPOGRAPHY CATEGORY	BASIS OF DIAGNOSIS	<i>n</i>	%
Prostate	Autopsy/Histology	12	0.5
	Clinical Investigation/Ultrasound	47	2.0
	Clinical Only	6	0.3
	Death Certificate Only	56	2.4
	Histology of Metastases	14	0.6
	Histology of Primary	2,209	93.6
	Laboratory Test	3	0.1
	Surgery/Autopsy	1	0.0
	Unknown	13	0.6
Breast	Autopsy/Histology	1	0.0
	Clinical Investigation/Ultrasound	14	0.6
	Clinical Only	2	0.1
	Cytology	2	0.1
	Death Certificate Only	17	0.8
	Histology of Metastases	8	0.4
	Histology of Primary	2,105	97.5
	Laboratory Test	1	0.0
	Unknown	8	0.4
Colon & Rectum	Autopsy/Histology	9	0.7
	Clinical Investigation/Ultrasound	21	1.5
	Clinical Only	3	0.2
	Death Certificate Only	29	2.1
	Histology of Metastases	17	1.2
	Histology of Primary	1,287	93.9
	Laboratory Test	2	0.1
	Surgery/Autopsy	1	0.1
	Unknown	2	0.1
Bronchus & Lung	Autopsy/Histology	5	0.5
	Clinical Investigation/Ultrasound	35	3.5
	Clinical Only	4	0.4
	Cytology	7	0.7
	Death Certificate Only	20	2.0
	Histology of Metastases	19	1.9
	Histology of Primary	895	89.9
	Laboratory Test	2	0.2
	Surgery/Autopsy	1	0.1
	Unknown	7	0.7

TOPOGRAPHY CATEGORY	BASIS OF DIAGNOSIS	<i>n</i>	%
Leukemia	Autopsy/Histology	4	0.6
	Clinical Investigation/Ultrasound	3	0.5
	Clinical Only	2	0.3
	Cytology	18	2.7
	Death Certificate Only	9	1.4
	Histology of Primary	623	94.4
	Laboratory Test	1	0.2
Uterus	Autopsy/Histology	5	0.8
	Clinical Investigation/Ultrasound	3	0.5
	Clinical Only	1	0.2
	Death Certificate Only	6	1.0
	Histology of Metastases	2	0.3
	Histology of Primary	593	96.9
	Unknown	2	0.3
Cervix Uteri	Clinical Investigation/Ultrasound	8	1.3
	Cytology	1	0.2
	Death Certificate Only	6	1.0
	Histology of Metastases	2	0.3
	Histology of Primary	591	96.9
	Unknown	2	0.3
Pancreas	Autopsy/Histology	13	3.0
	Clinical Investigation/Ultrasound	18	4.1
	Death Certificate Only	16	3.7
	Histology of Metastases	2	0.5
	Histology of Primary	386	88.3
	Laboratory Test	2	0.5

Table 6.5: Basis of Diagnosis of the Top 8 Leading Cancers for the Period 2009 to 2014

Grades of Top 8 Leading Cancers, 2009–2014

TOPOGRAPHY CATEGORY	GRADE	n	%
Prostate	Grade I; Well differentiated: Differentiated; NOS	58	2.5
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	481	20.4
	Grade III; Poorly differentiated	318	13.5
	Grade IV; Undifferentiated; Anaplastic	14	0.6
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,490	63.1
Breast	Grade I; Well differentiated: Differentiated; NOS	84	3.9
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	385	17.8
	Grade III; Poorly differentiated	371	17.2
	Grade IV; Undifferentiated; Anaplastic	18	0.8
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,300	60.2
Colon & Rectum	Grade I; Well differentiated: Differentiated; NOS	165	12.0
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	290	21.2
	Grade III; Poorly differentiated	95	6.9
	Grade IV; Undifferentiated; Anaplastic	5	0.4
	Grade, differentiation, or cell type not determined; not stated or not applicable	816	59.5
Bronchus & Lung	Grade I; Well differentiated: Differentiated; NOS	13	1.3
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	42	4.2
	Grade III; Poorly differentiated	87	8.7
	Grade IV; Undifferentiated; Anaplastic	13	1.3
	Grade, differentiation, or cell type not determined; not stated or not applicable	840	84.4
Leukemia	B-cell; Pre-B: B-precursor	46	7.0
	T-cell; T-precursor	33	5.0
	Grade, differentiation, or cell type not determined; not stated or not applicable	581	88.0
Uterus	Grade I; Well differentiated: Differentiated; NOS	79	12.9
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	93	15.2
	Grade III; Poorly differentiated	99	16.2
	Grade IV; Undifferentiated; Anaplastic	6	1.0
	Grade, differentiation, or cell type not determined; not stated or not applicable	335	54.7
Cervix Uteri	B-cell; Pre-B: B-precursor	1	0.2
	Grade I; Well differentiated: Differentiated; NOS	21	3.4
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	127	20.8
	Grade III; Poorly differentiated	106	17.4
	Grade IV; Undifferentiated; Anaplastic	4	0.7
	Grade, differentiation, or cell type not determined; not stated or not applicable	351	57.5

TOPOGRAPHY CATEGORY	GRADE	n	%
Pancreas	B-cell; Pre-B; B-precursor	1	0.2
	Grade I; Well differentiated: Differentiated; NOS	4	0.9
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	7	1.6
	Grade III; Poorly differentiated	12	2.7
	Grade, differentiation, or cell type not determined; not stated or not applicable	413	94.5

Table 6.6: Distribution of Grades of the Top 8 Leading Cancers for the Period 2009 to 2014

Stages of Top 8 Leading Cancers, 2009–2014

TOPOGRAPHY CATEGORY	STAGE	n	%	TOPOGRAPHY CATEGORY	STAGE	n	%
Prostate	Localised	566	24.0	Leukemia ¹¹	Localised	2	0.3
	Regional	171	7.2		Regional	5	0.8
	Distant	565	23.9		Distant	513	77.7
	Unknown	1,059	44.9		Unknown	140	21.2
Breast	Localised	702	32.5	Uterus	Localised	182	29.7
	Regional	636	29.5		Regional	112	18.3
	Distant	429	19.9		Distant	136	22.2
	Unknown	391	18.1		Unknown	182	29.7
Colon & Rectum	Localised	283	20.6	Cervix Uteri	Localised	170	27.9
	Regional	249	18.2		Regional	148	24.3
	Distant	370	27.0		Distant	129	21.1
	Unknown	469	34.2		Unknown	163	26.7
Bronchus & Lung	Localised	80	8.0	Pancreas	Localised	22	5.0
	Regional	67	6.7		Regional	26	5.9
	Distant	367	36.9		Distant	135	30.9
	Unknown	481	48.3		Unknown	254	58.1

¹¹ **Note:** Leukemia is staged as “Distant” in the Cancer Registries because its primary site is the Bone Marrow.

Table 6.7: Distribution of Stages of the Top 8 Leading Cancers for the Period 2009 to 2014

Details on cancer incidence, age-sex-specific rates, and cancer mortality for the period **2009 to 2014** can be found in **Appendix B**.

Overview of Cancer Statistics

TRINIDAD AND TOBAGO

2015-2020

Top 5 Leading Cancers, 2015–2020

TOP 5 CANCERS OVERALL

Breast cancer was the top cancer overall ($n=3,095$, 17.6%), followed by **prostate** ($n=3,072$, 17.5%), **colon and rectum** ($n=1,997$, 11.4%), **bronchus and lung** ($n=1,281$, 7.3%), and **uterus** ($n=1,150$, 6.6%). See *Figure 7.1*.




Figure 7.1: Top 5 Cancers Overall, 2015 to 2020

TOP 5 CANCERS BY AGE GROUP

There were 138 persons diagnosed with cancer within the age group 0 to 14 years; 152 persons in the age group 15 to 24 years; 5,709 persons in the age group 25 to 59 years; 7,464 persons in the age group 60 to 74 years; and 4,078 persons aged 75 years and over. Leukemia had the highest incidence among individuals under 15 years of age. In the 15 to 24 age group, lymphoma had the highest rate. For those aged 25 to 59 years, breast cancer had the highest incidence, while prostate cancer was highest among individuals 60 years and older. See *Table 7.1*.

AGE GROUP	TOPOGRAPHY CATEGORY	<i>n</i>	% WITHIN AGE GROUP
0 - 14	Leukemia	42	30.4
	CNS - Central Nervous System	30	21.7
	Kidney	15	10.9
	Eye	9	6.5
	Lymphoma	9	6.5
15-24	Lymphoma	27	17.8
	Leukemia	24	15.8
	Other Thoracic Organs	14	9.2
	Breast	10	6.6
	Bone & Articular Cartilage	10	6.6
25-59	Breast	1,570	27.5
	Colon & Rectum	617	10.8
	Cervix Uteri	423	7.4
	Uterus	335	5.9
	Bronchus & Lung	335	5.9

AGE GROUP	TOPOGRAPHY CATEGORY	<i>n</i>	% WITHIN AGE GROUP
60–74	Prostate	1,610	21.6
	Breast	1,033	13.8
	Colon & Rectum	888	11.9
	Bronchus & Lung	668	8.9
	Uterus	618	8.3
75+	Prostate	1,153	28.3
	Colon & Rectum	489	12.0
	Breast	482	11.8
	Bronchus & Lung	275	6.7
	Leukemia	209	5.1

Table 7.1: Top 5 Cancers by Age for the Period 2015 to 2020

Top 10 Leading Cancers, 2015–2020

Table 7.2 shows the top 10 leading cancers for the period 2009 to 2014.

With 3,095 registered cases and 1,473 deaths, **breast cancer** was the leading cancer overall (17.6%) and among women (33.1%). Breast cancer had an incidence rate of 75 cases and a mortality rate of 35 deaths per 100,000 individuals during the period 2015 to 2020 in Trinidad and Tobago. During their lifetimes, **1 in 15 women** could develop breast cancer (*Figure 7.2*).

With 3,072 registered cases and 2,019 deaths, **prostate cancer** was the second-leading cancer overall (17.5%) and leading cancer among men (36.8%). Prostate cancer had an incidence rate of 75 cases and a mortality rate of 49 deaths per 100,000 men during the period 2015 to 2020 in Trinidad and Tobago. During their lifetimes, **1 in 14 men** could develop prostate cancer (*Figure 7.2*).

There were 324 cancer cases with an unknown primary site, accounting for 2.7% of cancers among men and 2.4% of cancers among women.



Figure 7.2: Lifetime Risk of Leading Cancers, 2015 to 2020

TOPOGRAPHY CATEGORY	INCIDENCE (n)	%	CR	MORTALITY (n)	MORTALITY RATE
Male					
Prostate	3,072	36.8	75.2	2,019	49
Colon & Rectum	1,060	12.7	26.0	725	18
Bronchus & Lung	930	11.2	22.8	839	21
Leukemia	532	6.4	13.0	365	9
Pancreas	323	3.9	7.9	294	7
Bladder	226	2.7	5.5	154	4
Stomach	214	2.6	5.2	173	4
Lymphoma	214	2.6	5.2	142	4
Larynx	173	2.1	4.2	115	3
CNS - Central Nervous System	149	1.8	3.6	117	3
Female					
Breast	3,048	33.1	75.2	1,413	35
Uterus	1,150	12.5	28.4	611	15
Colon & Rectum	937	10.2	23.1	580	14
Cervix Uteri	706	7.7	17.4	433	11
Ovary	547	6.0	13.5	411	10
Leukemia	464	5.0	11.4	281	7
Bronchus & Lung	351	3.8	8.7	292	7
Pancreas	255	2.8	6.3	242	6
Lymphoma	174	1.9	4.3	110	3
Stomach	158	1.7	3.9	117	3

Table 7.2: Incidence and Mortality of the Top 10 Leading Cancers for the Period 2015 to 2020

Age-Sex-Specific Incidence Rates of Top 5 Leading Cancers, 2015–2020

Topography Category	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
Prostate		0.4					0.6	0.3	1.9	6.0	26.3	93.8	239.4	430.9	694.7	1007.6
Colon & Rectum					0.6	1.8	5.1	6.6	12.0	14.4	29.3	53.3	102.4	104.3	199.8	212.4
Bronchus & Lung		0.4		0.3		0.5	1.8	2.4	3.4	8.0	24.5	55.1	104.0	121.7	188.3	153.8
Leukemia	3.4	3.9	1.5	2.3	2.6	2.9	2.7	6.6	6.8	6.7	11.5	24.4	39.6	48.4	95.3	95.3
Pancreas							0.3	1.4	3.0	2.7	7.4	14.7	27.0	46.9	56.3	77.8

Table 7.3: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Males for the Period 2015 to 2020




Figure 7.3: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Males for the Period 2015 to 2020

OVERVIEW OF STATISTICS: 2015–2020

Topography Category	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
Breast				0.7	2.3	8.3	26.8	56.4	79.1	101.8	135.9	188.7	205.9	243.4	306.4	299.6
Uterus						0.5	3.2	8.9	9.9	14.4	30.6	66.6	128.8	157.1	169.5	126.4
Colon & Rectum				0.3		1.9	4.1	8.9	12.6	14.1	26.1	50.1	83.8	79.3	130.9	157.8
Cervix Uteri				0.3	0.9	2.4	12.0	23.9	31.4	23.0	30.2	35.8	34.9	53.1	60.9	52.6
Ovary		0.4		0.7	1.4	1.1	2.8	5.0	9.2	10.3	25.7	35.8	46.7	55.9	54.8	60.3

Table 7.4: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Females for the Period 2015 to 2020




Figure 7.4: Age-Specific Incidence Rates of the Top 5 Leading Cancers in Females for the Period 2015 to 2020

Top 8 Leading Cancers by Ethnicity, 2015–2020

Figure 7.5 shows the top 8 leading cancers by ethnicity. The percentages indicate the proportion of ethnicity within a particular cancer.




Figure 7.5: Top 8 Leading Cancers by Ethnicity for the Period 2015 to 2020

Basis of Diagnosis of Top 8 Leading Cancers, 2015–2020

TOPOGRAPHY CATEGORY	BASIS OF DIAGNOSIS	<i>n</i>	%
Breast	Autopsy/Histology	3	0.1
	Clinical Investigation/Ultrasound	162	5.2
	Cytology	10	0.3
	Death Certificate Only	138	4.5
	Histology of Metastases	27	0.9
	Histology of Primary	2,751	88.9
	Laboratory Test	1	0.0
	Surgery/Autopsy	1	0.0
	Unknown	2	0.1
Prostate	Autopsy/Histology	5	0.2
	Clinical Investigation/Ultrasound	397	12.9
	Clinical Only	4	0.1
	Cytology	4	0.1
	Death Certificate Only	443	14.4
	Histology of Metastases	19	0.6
	Histology of Primary	2,186	71.2
	Laboratory Test	1	0.0
	Surgery/Autopsy	5	0.2
	Unknown	8	0.3
Colon & Rectum	Autopsy/Histology	4	0.2
	Clinical Investigation/Ultrasound	199	10.0
	Cytology	6	0.3
	Death Certificate Only	169	8.5
	Histology of Metastases	40	2.0
	Histology of Primary	1,573	78.8
	Surgery/Autopsy	6	0.3
Bronchus & Lung	Autopsy/Histology	13	1.0
	Clinical Investigation/Ultrasound	167	13.0
	Clinical Only	1	0.1
	Cytology	49	3.8
	Death Certificate Only	106	8.3
	Histology of Metastases	89	6.9
	Histology of Primary	851	66.4
	Surgery/Autopsy	4	0.3
	Unknown	1	0.1

TOPOGRAPHY CATEGORY	BASIS OF DIAGNOSIS	<i>n</i>	%
Uterus	Autopsy/Histology	2	0.2
	Clinical Investigation/Ultrasound	87	7.6
	Cytology	6	0.5
	Death Certificate Only	63	5.5
	Histology of Metastases	26	2.3
	Histology of Primary	964	83.8
	Surgery/Autopsy	1	0.1
	Unknown	1	0.1
Leukemia	Autopsy/Histology	4	0.4
	Clinical Investigation/Ultrasound	9	0.9
	Cytology	85	8.5
	Death Certificate Only	13	1.3
	Histology of Metastases	1	0.1
	Histology of Primary	882	88.6
	Laboratory Test	2	0.2
Cervix Uteri	Clinical Investigation/Ultrasound	48	6.8
	Cytology	6	0.8
	Death Certificate Only	56	7.9
	Histology of Metastases	16	2.3
	Histology of Primary	578	81.9
	Surgery/Autopsy	1	0.1
	Unknown	1	0.1
Pancreas	Clinical Investigation/Ultrasound	137	23.7
	Cytology	8	1.4
	Death Certificate Only	94	16.3
	Histology of Metastases	41	7.1
	Histology of Primary	294	50.9
	Surgery/Autopsy	4	0.7

Table 7.5: Basis of Diagnosis of the Top 8 Leading Cancers for the Period 2015 to 2020

Grades of Top 8 Leading Cancers, 2015–2020

TOPOGRAPHY CATEGORY	GRADE	n	%
Breast	Grade I; Well differentiated: Differentiated; NOS	118	3.8
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	1,119	36.2
	Grade III; Poorly differentiated	679	21.9
	Grade IV; Undifferentiated; Anaplastic	15	0.5
	T-cell; T-precursor	1	0.0
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,163	37.6
Prostate	Grade I; Well differentiated: Differentiated; NOS	29	0.9
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	882	28.7
	Grade III; Poorly differentiated	566	18.4
	Grade IV; Undifferentiated; Anaplastic	10	0.3
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,585	51.6
Colon & Rectum	B-cell; Pre-B: B-precursor	1	0.1
	Grade I; Well differentiated: Differentiated; NOS	230	11.5
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	651	32.6
	Grade III; Poorly differentiated	102	5.1
	Grade IV; Undifferentiated; Anaplastic	4	0.2
	Grade, differentiation, or cell type not determined; not stated or not applicable	1,009	50.5
Bronchus & Lung	Grade I; Well differentiated: Differentiated; NOS	33	2.6
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	101	7.9
	Grade III; Poorly differentiated	185	14.4
	Grade IV; Undifferentiated; Anaplastic	19	1.5
	Grade, differentiation, or cell type not determined; not stated or not applicable	943	73.6
Uterus	Grade I; Well differentiated: Differentiated; NOS	170	14.8
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	218	19.0
	Grade III; Poorly differentiated	210	18.3
	Grade IV; Undifferentiated; Anaplastic	15	1.3
	Grade, differentiation, or cell type not determined; not stated or not applicable	537	46.7
Leukemia	B-cell; Pre-B: B-precursor	89	8.9
	Killer cell	1	0.1
	T-cell; T-precursor	45	4.5
	Grade, differentiation, or cell type not determined; not stated or not applicable	861	86.4
Cervix Uteri	Grade I; Well differentiated: Differentiated; NOS	43	6.1
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	217	30.7
	Grade III; Poorly differentiated	133	18.8
	Grade IV; Undifferentiated; Anaplastic	3	0.4

TOPOGRAPHY CATEGORY	GRADE	n	%
	Grade, differentiation, or cell type not determined; not stated or not applicable	310	43.9
Pancreas	Grade I; Well differentiated: Differentiated; NOS	11	1.9
	Grade II; Moderately differentiated; Moderately well differentiated; Intermediate differentiation	40	6.9
	Grade III; Poorly differentiated	13	2.2
	Grade IV; Undifferentiated; Anaplastic	3	0.5
	Grade, differentiation, or cell type not determined; not stated or not applicable	511	88.4

Table 7.6: Distribution of Grades of the Top 8 Leading Cancers for the Period 2015 to 2020

Stages of Top 8 Leading Cancers, 2015–2020

TOPOGRAPHY CATEGORY	STAGE	n	%	TOPOGRAPHY CATEGORY	STAGE	n	%
Breast	Localised	784	25.3	Uterus	Localised	303	26.3
	Regional	973	31.4		Regional	226	19.7
	Distant	608	19.6		Distant	298	25.9
	Unknown	730	23.6		Unknown	323	28.1
Prostate	Localised	541	17.6	Leukemia¹¹	Localised	3	0.3
	Regional	211	6.9		Regional	4	0.4
	Distant	833	27.1		Distant	946	95.0
	Unknown	1,487	48.4		Unknown	43	4.3
Colon & Rectum	Localised	269	13.5	Cervix Uteri	Localised	124	17.6
	Regional	490	24.5		Regional	175	24.8
	Distant	663	33.2		Distant	187	26.5
	Unknown	575	28.8		Unknown	220	31.2
Bronchus & Lung	Localised	42	3.3	Pancreas	Localised	16	2.8
	Regional	120	9.4		Regional	47	8.1
	Distant	728	56.8		Distant	240	41.5
	Unknown	391	30.5		Unknown	275	47.6


¹¹ **Note:** Leukemia is staged as “Distant” in the Cancer Registries because its primary site is the Bone Marrow.

Table 7.7: Distribution of Stages of the Top 8 Leading Cancers for the Period 2015 to 2020

Details on cancer incidence, age-sex-specific rates, and cancer mortality for the period **2015 to 2020** can be found in **Appendix C**.

References

1. Trinidad – **Geography**. Accessed July 11, 2024. <https://trinidad.us/geography>
2. **Population Statistics**. Central Statistical Office, Ministry of Planning and Development. Accessed July 11, 2024. <https://cso.gov.tt/subjects/population-and-vital-statistics/population/>
3. **2011 Census Data**. (2011). Accessed July 11, 2024. <https://cso.gov.tt/census/2011-census-data/>
4. Khan, N. (2022, August). **Profiles: Heroes, Role Models and Pioneers of Trinidad and Tobago**. First Citizens Bank. <https://epub.safaripublications.com/firstcitizenstt/profiles/130/>
5. Bray F, Parkin M. (2009). **Evaluation of Data Quality in the Cancer Registry: Principles and Methods. Part I: Comparability, Validity and Timeliness**. EJC 45(5): 747-755
6. Bray F, Parkin M. (2009). **Evaluation of Data Quality in the Cancer Registry: Principles and Methods. Part II: Completeness**. EJC 45(5): 759-764
7. Caribbean Public Health Agency. (2018, April). **Caribbean Registry Manual: Data Collection and Operating Procedures Module** – Version 1.0.
8. IACR - **CanReg (Version 5)**. (2023). [Computer software].
9. National Cancer Institute. (2022, August 1). **Tumor Grade**. <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-grade>
10. Pan American Health Organization. (2009, April). **Age Standardized Mortality Rates per 100,000 Population for Deaths < 70 years**. <https://www3.paho.org/hq/dmdocuments/2012/PAHO-Age-standardized-mortality-rates-2009.pdf>



APPENDIX A

2003–2008

**CANCER IN
TRINIDAD AND TOBAGO**
**2003
–2020**

Photo: U.S. National Cancer Institute
(lung cancer metastasis)

Appendix A

Summary of Cancer Incidence, 2003–2008

ICD-O-3	Topography Description	Male					Female					Total	
		<i>n</i>	%	CR	ASR	LR	<i>n</i>	%	CR	ASR	LR	<i>n</i>	%
	LIP												
C00	Lip	3	0.0	0.1	0.1	8,316	1	0.0	0.0	0.0		4	0.0
	ORAL CAVITY & SALIVARY GLAND												
C01	Base of Tongue	13	0.2	0.3	0.3	2,898	1	0.0	0.0	0.0	35,066	14	0.1
C02	Other and Unspecified Parts of the Tongue	45	0.7	1.2	1.3	747	15	0.2	0.4	0.4	2,515	60	0.5
C03	Gum	13	0.2	0.3	0.4	2,398	10	0.2	0.3	0.3	3,125	23	0.2
C04	Floor of Mouth	7	0.1	0.2	0.2	3,214	1	0.0	0.0	0.0	26,176	8	0.1
C05	Palate	12	0.2	0.3	0.3	4,052	2	0.0	0.1	0.1	19,309	14	0.1
C06	Other and Unspecified Parts of the Mouth	13	0.2	0.3	0.4	3,540	4	0.1	0.1	0.1	8,656	17	0.1
C07	Parotid Gland	22	0.3	0.6	0.6	1,382	13	0.2	0.3	0.3	4,062	35	0.3
C08	Other and Unspecified Major Salivary Glands	7	0.1	0.2	0.2	4,283	7	0.1	0.2	0.2	3,760	14	0.1
	PHARYNX												
C09	Tonsil	39	0.6	1.0	1.0	773	5	0.1	0.1	0.1	5,763	44	0.3
C10	Oropharynx	15	0.2	0.4	0.4	2,362	2	0.0	0.1	0.0	27,502	17	0.1
C11	Nasopharynx	20	0.3	0.5	0.5	2,228	17	0.3	0.4	0.4	2,332	37	0.3
C12	Pyriform Sinus	7	0.1	0.2	0.2	6,025	1	0.0	0.0	0.0	60,567	8	0.1
C13	Hypopharynx	4	0.1	0.1	0.1	5,138	5	0.1	0.1	0.1	12,504	9	0.1
	OTHER PHARYNX												
C14	Other Pharynx	13	0.2	0.3	0.4	2,269	5	0.1	0.1	0.1	6,522	18	0.1
	ESOPHAGUS												
C15	Esophagus	95	1.4	2.4	2.6	337	22	0.3	0.6	0.6	1,544	117	0.9
	STOMACH												
C16	Stomach	230	3.5	5.9	6.5	150	148	2.3	3.8	3.7	269	378	2.9
	SMALL INTESTINE												
C17	Small Intestine	34	0.5	0.9	0.9	1,029	16	0.2	0.4	0.4	2,865	50	0.4
	COLON & RECTUM												
C18	Colon	548	8.3	14.1	15.3	64	451	7.0	11.6	11.5	86	999	7.7
C19	Rectosigmoid Junction	55	0.8	1.4	1.5	655	40	0.6	1.0	1.0	991	95	0.7
C20	Rectum	181	2.7	4.6	5.0	178	109	1.7	2.8	2.8	329	290	2.2
C21	Anus and Anal Canal	22	0.3	0.6	0.6	2,292	26	0.4	0.7	0.7	1,403	48	0.4
	LIVER												
C22	Liver	100	1.5	2.6	2.8	356	75	1.2	1.9	1.9	567	175	1.3
	GALL BLADDER												
C23	Gallbladder	21	0.3	0.5	0.6	1,441	53	0.8	1.4	1.4	667	74	0.6
C24	Other and Unspecified Parts of the Biliary Tract	22	0.3	0.6	0.6	1,435	26	0.4	0.7	0.7	1,379	48	0.4
	PANCREAS												
C25	Pancreas	242	3.7	6.2	6.8	155	192	3.0	5.0	4.8	213	434	3.3

ICD-O-3	Topography Description	Male					Female					Total	
		n	%	CR	ASR	LR	n	%	CR	ASR	LR	n	%
	GASTROINTESTINAL												
C26	Other and Ill-Defined Digestive Organs	19	0.3	0.5	0.6	2,680	14	0.2	0.4	0.3	5,265	33	0.3
	NASAL CAVITY												
C30	Nasal Cavity and Middle Ear	4	0.1	0.1	0.1	10,204	6	0.1	0.2	0.1	6,773	10	0.1
C31	Accessory Sinuses	22	0.3	0.6	0.6	1,833	10	0.2	0.3	0.3	5,883	32	0.2
	LARYNX												
C32	Larynx	139	2.1	3.6	3.8	288	11	0.2	0.3	0.3	3,962	150	1.1
	BRONCHUS & LUNG												
C33	Trachea	1	0.0	0.0	0.0	14,585						1	0.0
C34	Bronchus and Lung	634	9.6	16.3	17.5	57	171	2.7	4.4	4.3	256	805	6.2
	OTHER THORACIC ORGANS												
C37	Thymus	12	0.2	0.3	0.3	3,337	12	0.2	0.3	0.3	4,060	24	0.2
C38	Heart, Mediastinum and Pleura	16	0.2	0.4	0.4	2,826	11	0.2	0.3	0.3	5,596	27	0.2
	BONE & ARTICULAR CARTILAGE												
C40	Bones, Joints and Articular Cartilage of Limbs	22	0.3	0.6	0.5	3,039	9	0.1	0.2	0.2	4,400	31	0.2
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	20	0.3	0.5	0.5	3,280	13	0.2	0.3	0.3	3,211	33	0.3
	LEUKEMIA												
C42	Hematopoietic and Reticuloendothelial Systems	290	4.4	7.4	8.0	137	255	4.0	6.6	6.6	148	545	4.2
	SKIN												
C44	Skin	30	0.5	0.8	0.9	812	20	0.3	0.5	0.5	2,886	50	0.4
	PERITONEUM												
C48	Peritoneum	14	0.2	0.4	0.4	2,440	12	0.2	0.3	0.3	3,149	26	0.2
	OTHER CONNECTIVE & SOFT TISSUE												
C47	Peripheral Nerves and Autonomic Nervous System	2	0.0	0.1	0.0	26,452	4	0.1	0.1	0.1	16,328	6	0.0
C49	Connective, Subcutaneous and Other Soft Tissues	55	0.8	1.4	1.5	767	42	0.7	1.1	1.0	1,153	97	0.7
	BREAST												
C50	Breast	38	0.6	1.0	1.0	851	2,182	33.9	56.4	54.9	18	2,220	17.0
	CERVIX UTERI												
C53	Cervix uteri						736	11.4	19.0	18.6	56	736	5.6
	UTERUS												
C54	Corpus Uteri						559	8.7	14.4	14.5	61	559	4.3
C55	Uterus, Not Otherwise Specified						25	0.4	0.6	0.6	1,552	25	0.2
	OVARY												
C56	Ovary						411	6.4	10.6	10.4	90	411	3.1
	OTHER FEMALE GENITAL ORGANS												
C51	Vulva						22	0.3	0.6	0.5	1,971	22	0.2
C52	Vagina						33	0.5	0.9	0.9	1,162	33	0.3
C57	Other and Unspecified Female Genital Organs						6	0.1	0.2	0.2	4,544	6	0.0
	PLACENTA												
C58	Placenta						5	0.1	0.1	0.1	12,670	5	0.0

CANCER INCIDENCE, 2003–2008

ICD-O-3	Topography Description	Male					Female					Total	
		n	%	CR	ASR	LR	n	%	CR	ASR	LR	n	%
	PENIS												
C60	Penis	30	0.5	0.8	0.8	1,625						30	0.2
	PROSTATE												
C61	Prostate	2,688	40.7	69.0	78.8	14						2,688	20.6
	TESTIS												
C62	Testis	40	0.6	1.0	0.9	1,606						40	0.3
	OTHER MALE GENITAL ORGANS												
C63	Other and Unspecified Male Genital Organs	1	0.0	0.0	0.0							1	0.0
	KIDNEY												
C64	Kidney	78	1.2	2.0	2.1	455	57	0.9	1.5	1.5	693	135	1.0
	RENAL PELVIS												
C66	Ureter	1	0.0	0.0	0.0	52,903	2	0.0	0.1	0.1	10,394	3	0.0
C68	Other and Unspecified Urinary Organs	3	0.0	0.1	0.1	8,041	1	0.0	0.0	0.0	26,176	4	0.0
	BLADDER												
C67	Bladder	116	1.8	3.0	3.3	317	38	0.6	1.0	0.9	1,567	154	1.2
	EYE												
C69	Eye and Adnexa	15	0.2	0.4	0.4	2,754	7	0.1	0.2	0.2	6,828	22	0.2
	CNS – CENTRAL NERVOUS SYSTEM												
C70	Meninges	2	0.0	0.1	0.1	12,638						2	0.0
C71	Brain	89	1.3	2.3	2.4	488	63	1.0	1.6	1.7	782	152	1.2
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	5	0.1	0.1	0.1	12,896	2	0.0	0.1	0.0	31,998	7	0.1
	THYROID												
C73	Thyroid Gland	21	0.3	0.5	0.6	1,778	62	1.0	1.6	1.5	752	83	0.6
	OTHER ENDOCRINE												
C74	Adrenal Gland	4	0.1	0.1	0.1	9,490	8	0.1	0.2	0.2	5,477	12	0.1
C75	Other Endocrine Glands and Related Structures	2	0.0	0.1	0.1	29,222	5	0.1	0.1	0.1	7,531	7	0.1
	ILL-DEFINED												
C76	Other and Ill-Defined Sites	26	0.4	0.7	0.7	1,840	47	0.7	1.2	1.2	1,421	73	0.6
	LYMPHOMA												
C77	Lymph Nodes	192	2.9	4.9	5.0	206	151	2.3	3.9	3.8	263	343	2.6
	UNKNOWN												
C80	Unknown Primary Site	193	2.9	5.0	5.4	189	182	2.8	4.7	4.6	223	375	2.9
Total		6,607	100.0	169.6	186.7		6,441	100.0	166.4	163.3		13,048	100.0

Table A-1: Summary of Cancer Incidence, 2003 to 2008

Cancer Incidence Rates by Age, Sex, and Site, 2003–2008

CANCER INCIDENCE RATES IN MALES BY AGE AND SITE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
LIP																					
C00	Lip														1	1	1	3	0.0	0.1	0.1
															1.0	1.4	1.0				
ORAL CAVITY & SALIVARY GLAND																					
C01	Base of Tongue	1									2	4	2	1	2		1	13	0.2	0.3	0.3
		0.4									0.8	1.8	1.1	0.8	2.1		1.0				
C02	Other and Unspecified Parts of the Tongue							1	2	3	4	2	3	7	8	5	10	45	0.7	1.2	1.3
								0.4	0.8	1.0	1.5	0.9	1.6	5.5	8.3	6.9	9.8				
C03	Gum								1		1	1	2	2	3	1	2	13	0.2	0.3	0.4
									0.4		0.4	0.5	1.1	1.6	3.1	1.4	2.0				
C04	Floor of Mouth												1	2		3	1	7	0.1	0.2	0.2
													0.5	1.6		4.1	1.0				
C05	Palate									1		2	2	2	1		4	12	0.2	0.3	0.3
										0.3		0.9	1.1	1.6	1.0		3.9				
C06	Other and Unspecified Parts of the Mouth								1		1	2	1		2	1	5	13	0.2	0.3	0.4
									0.4		0.4	0.9	0.5		2.1	1.4	4.9				
C07	Parotid Gland				1	1	1			1	1	3	2	2	6	2	2	22	0.3	0.6	0.6
					0.3	0.2	0.3			0.3	0.4	1.4	1.1	1.6	6.2	2.7	2.0				
C08	Other and Unspecified Major Salivary Glands									1	1	1	2		1	1		7	0.1	0.2	0.2
										0.3	0.4	0.5	1.1		1.0	1.4					
PHARYNX																					
C09	Tonsil									1	3	10	9	2	5	6	3	39	0.6	1.0	1.0
										0.3	1.1	4.5	4.9	1.6	5.2	8.2	2.9				
C10	Oropharynx										3	5	2	2	1	1	1	15	0.2	0.4	0.4
											1.1	2.3	1.1	1.6	1.0	1.4	1.0				

MALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C11	Nasopharynx			1						1	3	6	2	3	1		3	20	0.3	0.5	0.5
				0.3						0.3	1.1	2.7	1.1	2.3	1.0		2.9				
C12	Pyriform Sinus								1		1	1	1	2			1	7	0.1	0.2	0.2
									0.4		0.4	0.5	0.5	1.6			1.0				
C13	Hypopharynx											1			2	1		4	0.1	0.1	0.1
												0.5			2.1	1.4					
OTHER PHARYNX																					
C14	Other Pharynx										2		2	1	2	3	3	13	0.2	0.3	0.4
											0.8		1.1	0.8	2.1	4.1	2.9				
ESOPHAGUS																					
C15	Esophagus						1	1	2	1	9	6	14	17	7	17	20	95	1.4	2.4	2.6
							0.3	0.4	0.8	0.3	3.4	2.7	7.7	13.3	7.2	23.3	19.5				
STOMACH																					
C16	Stomach						1	1	3	9	14	18	13	27	33	39	72	230	3.5	5.9	6.5
							0.3	0.4	1.1	3.0	5.3	8.2	7.1	21.1	34.1	53.5	70.2				
SMALL INTESTINE																					
C17	Small Intestine					1	1	2				6	9	6	3	2	4	34	0.5	0.9	0.9
						0.2	0.3	0.7				2.7	4.9	4.7	3.1	2.7	3.9				
COLON & RECTUM																					
C18	Colon				1	3	1	5	10	27	32	44	64	69	81	67	144	548	8.3	14.1	15.3
					0.3	0.7	0.3	1.8	3.8	9.1	12.1	20.0	35.1	53.9	83.7	91.9	140.5				
C19	Rectosigmoid Junction								1	5	5	5	7	6	6	7	13	55	0.8	1.4	1.5
									0.4	1.7	1.9	2.3	3.8	4.7	6.2	9.6	12.7				
C20	Rectum						2	2	5	5	15	15	32	32	18	25	30	181	2.7	4.6	5.0
							0.6	0.7	1.9	1.7	5.7	6.8	17.6	25.0	18.6	34.3	29.3				
C21	Anus and Anal Canal							2	1	4	1	5	1		3		5	22	0.3	0.6	0.6
								0.7	0.4	1.3	0.4	2.3	0.5		3.1		4.9				
LIVER																					
C22	Liver	2						1	4	7	9	5	10	17	10	12	23	100	1.5	2.6	2.8
		0.8						0.4	1.5	2.3	3.4	2.3	5.5	13.3	10.3	16.5	22.4				

ICD-0-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
GALL BLADDER																					
C23	Gallbladder							1			1	2	3	3	4	3	4	21	0.3	0.5	0.6
								0.4			0.4	0.9	1.6	2.3	4.1	4.1	3.9				
C24	Other and Unspecified Parts of the Biliary Tract										1	2	2	6	4	2	5	22	0.3	0.6	0.6
											0.4	0.9	1.1	4.7	4.1	2.7	4.9				
PANCREAS																					
C25	Pancreas							1	3	15	17	14	32	27	36	25	72	242	3.7	6.2	6.8
								0.4	1.1	5.0	6.4	6.4	17.6	21.1	37.2	34.3	70.2				
GASTROINTESTINAL																					
C26	Other and Ill-Defined Digestive Organs								1		1			2	1	3	11	19	0.3	0.5	0.6
									0.4		0.4			1.6	1.0	4.1	10.7				
NASAL CAVITY																					
C30	Nasal Cavity and Middle Ear								1				1		1		1	4	0.1	0.1	0.1
									0.4				0.5		1.0		1.0				
C31	Accessory Sinuses					1					1	4	4	1	4	1	6	22	0.3	0.6	0.6
						0.2					0.4	1.8	2.2	0.8	4.1	1.4	5.9				
LARYNX																					
C32	Larynx						1	1		8	12	21	18	19	20	5	34	139	2.1	3.6	3.8
							0.3	0.4		2.7	4.5	9.5	9.9	14.8	20.7	6.9	33.2				
BRONCHUS & LUNG																					
C33	Trachea															1		1	0.0	0.0	0.0
																1.4					
C34	Bronchus and Lung				1	3	3	2	2	22	53	81	77	86	93	57	154	634	9.6	16.3	17.5
					0.3	0.7	0.9	0.7	0.8	7.4	20.0	36.8	42.2	67.1	96.2	78.2	150.2				
OTHER THORACIC ORGANS																					
C37	Thymus					2	1	1				2	2	1	2		1	12	0.2	0.3	0.3
						0.5	0.3	0.4				0.9	1.1	0.8	2.1		1.0				

MALE INCIDENCE, 2003–2008

ICD-0-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C38	Heart, Mediastinum and Pleura				2	1	2			1	1	1	5	1	1		1	16	0.2	0.4	0.4
					0.5	0.2	0.6			0.3	0.4	0.5	2.7	0.8	1.0		1.0				
BONE & ARTICULAR CARTILAGE																					
C40	Bones, Joints and Articular Cartilage of Limbs		2	2	6	1	4			5			1				1	22	0.3	0.6	0.5
			0.8	0.6	1.5	0.2	1.2			1.7			0.5				1.0				
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites		1		1			1	3	4	2		2	1			5	20	0.3	0.5	0.5
			0.4		0.3			0.4	1.1	1.3	0.8		1.1	0.8			4.9				
LEUKEMIA																					
C42	Hematopoietic and Reticuloendothelial Systems	16	3	4	13	5	9	13	5	18	18	18	19	25	35	27	62	290	4.4	7.4	8.0
		6.2	1.1	1.2	3.3	1.2	2.7	4.6	1.9	6.0	6.8	8.2	10.4	19.5	36.2	37.0	60.5				
SKIN																					
C44	Skin				1			1	1	1	2		1	8	2	10	3	30	0.5	0.8	0.9
					0.3			0.4	0.4	0.3	0.8		0.5	6.2	2.1	13.7	2.9				
PERITONEUM																					
C48	Peritoneum				1	1	1			1	1		2	1	2	2	2	14	0.2	0.4	0.4
					0.3	0.2	0.3			0.3	0.4		1.1	0.8	2.1	2.7	2.0				
OTHER CONNECTIVE & SOFT TISSUE																					
C47	Peripheral Nerves and Autonomic Nervous System										2							2	0.0	0.1	0.0
											0.8										
C49	Connective, Subcutaneous and Other Soft Tissues	5		1	3		3	3	4	5	7	2	2	6	3	4	7	55	0.8	1.4	1.5
		1.9		0.3	0.8		0.9	1.1	1.5	1.7	2.6	0.9	1.1	4.7	3.1	5.5	6.8				
BREAST																					
C50	Breast							1		3	1	8	2	6	4	6	7	38	0.6	1.0	1.0
								0.4		1.0	0.4	3.6	1.1	4.7	4.1	8.2	6.8				

ICD-0-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
PENIS																					
C60	Penis						1		2	6	6	3	3	2	1	1	5	30	0.5	0.8	0.8
							0.3		0.8	2.0	2.3	1.4	1.6	1.6	1.0	1.4	4.9				
PROSTATE																					
C61	Prostate					2			2	5	35	95	181	312	411	474	1171	2688	40.7	69.0	78.8
						0.5			0.8	1.7	13.2	43.1	99.3	243.6	424.9	650.0	1142.4				
TESTIS																					
C62	Testis				7	9	8	3	2	3	1	1	3	1			2	40	0.6	1.0	0.9
					1.8	2.2	2.4	1.1	0.8	1.0	0.4	0.5	1.6	0.8			2.0				
OTHER MALE GENITAL ORGANS																					
C63	Other and Unspecified Male Genital Organs																1	1	0.0	0.0	0.0
																	1.0				
KIDNEY																					
C64	Kidney	2	1	1	1	2	3		1	3	7	4	13	4	12	9	15	78	1.2	2.0	2.1
		0.8	0.4	0.3	0.3	0.5	0.9		0.4	1.0	2.6	1.8	7.1	3.1	12.4	12.3	14.6				
RENAL PELVIS																					
C66	Ureter										1							1	0.0	0.0	0.0
											0.4										
C68	Other and Unspecified Urinary Organs									1				1		1		3	0.0	0.1	0.1
										0.3				0.8		1.4					
BLADDER																					
C67	Bladder						1	1			7	11	15	17	11	16	37	116	1.8	3.0	3.3
							0.3	0.4			2.6	5.0	8.2	13.3	11.4	21.9	36.1				
EYE																					
C69	Eye and Adnexa	4			1				2	1		3	3			1		15	0.2	0.4	0.4
		1.5			0.3				0.8	0.3		1.4	1.6			1.4					
CNS – CENTRAL NERVOUS SYSTEM																					
C70	Meninges												1		1			2	0.0	0.1	0.1
													0.5		1.0						

MALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C71	Brain	7	7	6	2	1	5	4	11	6	7	5	13	6	3	3	3	89	1.3	2.3	2.4
		2.7	2.7	1.9	0.5	0.2	1.5	1.4	4.2	2.0	2.6	2.3	7.1	4.7	3.1	4.1	2.9				
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	1						2				1					1	5	0.1	0.1	0.1
		0.4						0.7				0.5					1.0				
THYROID																					
C73	Thyroid Gland						1	1		2	3	1	5	1	2	2	3	21	0.3	0.5	0.6
							0.3	0.4		0.7	1.1	0.5	2.7	0.8	2.1	2.7	2.9				
OTHER ENDOCRINE																					
C74	Adrenal Gland	1		1					1						1			4	0.1	0.1	0.1
		0.4		0.3					0.4						1.0						
C75	Other Endocrine Glands and Related Structures		1				1											2	0.0	0.1	0.1
			0.4				0.3														
ILL-DEFINED																					
C76	Other and Ill-Defined Sites	3	1				1	2		1		1	4	2	1	2	8	26	0.4	0.7	0.7
		1.2	0.4				0.3	0.7		0.3		0.5	2.2	1.6	1.0	2.7	7.8				
LYMPHOMA																					
C77	Lymph Nodes	1		6	7	11	12	5	11	16	12	25	17	23	9	17	20	192	2.9	4.9	5.0
		0.4		1.9	1.8	2.6	3.6	1.8	4.2	5.4	4.5	11.3	9.3	18.0	9.3	23.3	19.5				
UNKNOWN																					
C80	Unknown Primary Site		1			2	4	2	5	5	16	15	22	23	26	22	50	193	2.9	5.0	5.4
			0.4			0.5	1.2	0.7	1.9	1.7	6.0	6.8	12.1	18.0	26.9	30.2	48.8				
Total		43	17	22	48	46	68	60	88	198	322	462	634	785	886	888	2040	6607	100	169.6	186.7
		16.6	6.5	6.8	12.1	11.1	20.6	21.4	33.2	66.4	121.7	209.7	347.9	612.9	916.0	1217.7	1990.2				

Table A-2: Cancer Incidence Rates in Males by Age and Site, 2003 to 2008

CANCER INCIDENCE RATES IN FEMALES BY AGE AND SITE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
LIP																					
C00	Lip																1	1	0.0	0.0	0.0
																	0.8				
ORAL CAVITY & SALIVARY GLAND																					
C01	Base of Tongue												1					1	0.0	0.0	0.0
													0.6								
C02	Other and Unspecified Parts of the Tongue					2					1	1	1	2	1	3	4	15	0.2	0.4	0.4
						0.5					0.4	0.5	0.6	1.5	1.0	3.6	3.0				
C03	Gum										1			1	3	2	3	10	0.2	0.3	0.3
											0.4			0.8	2.9	2.4	2.3				
C04	Floor of Mouth													1				1	0.0	0.0	0.0
														0.8							
C05	Palate											1	1					2	0.0	0.1	0.1
												0.5	0.6								
C06	Other and Unspecified Parts of the Mouth						1					1	1		1			4	0.1	0.1	0.1
							0.3					0.5	0.6		1.0						
C07	Parotid Gland					1				1	3	2	4				2	13	0.2	0.3	0.3
						0.2				0.3	1.1	0.9	2.3				1.5				
C08	Other and Unspecified Major Salivary Glands										2	1		1	1	2		7	0.1	0.2	0.2
											0.8	0.5		0.8	1.0	2.4					
PHARYNX																					
C09	Tonsil										2			2		1		5	0.1	0.1	0.1
											0.8			1.5		1.2					
C10	Oropharynx				1							1						2	0.0	0.1	0.0
					0.3							0.5									
C11	Nasopharynx				2			2		1	2	3	3	1		2	1	17	0.3	0.4	0.4
					0.5			0.7		0.3	0.8	1.4	1.7	0.8		2.4	0.8				

FEMALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C12	Pyriform Sinus									1								1	0.0	0.0	0.0
										0.3											
C13	Hypopharynx								1			1		1			2	5	0.1	0.1	0.1
									0.4			0.5		0.8			1.5				
OTHER PHARYNX																					
C14	Other Pharynx										1			1	2		1	5	0.1	0.1	0.1
											0.4			0.8	1.9		0.8				
ESOPHAGUS																					
C15	Esophagus								1	1	2	1	2	2	5	3	5	22	0.3	0.6	0.6
									0.4	0.3	0.8	0.5	1.1	1.5	4.8	3.6	3.8				
STOMACH																					
C16	Stomach					1	1	2	2	5	5	10	8	21	17	23	53	148	2.3	3.8	3.7
						0.2	0.3	0.7	0.7	1.7	1.9	4.7	4.6	16.0	16.4	27.3	40.2				
SMALL INTESTINE																					
C17	Small Intestine									4	1	1	2	2	1	1	4	16	0.2	0.4	0.4
										1.3	0.4	0.5	1.1	1.5	1.0	1.2	3.0				
COLON & RECTUM																					
C18	Colon						1	7	20	18	30	41	57	38	64	54	121	451	7.0	11.6	11.5
							0.3	2.5	7.4	5.9	11.4	19.1	32.5	29.0	61.6	64.0	91.7				
C19	Rectosigmoid Junction				1			2		2	6	3	2	8	3	4	9	40	0.6	1.0	1.0
					0.3			0.7		0.7	2.3	1.4	1.1	6.1	2.9	4.7	6.8				
C20	Rectum					1	2		1	5	9	17	6	10	16	17	25	109	1.7	2.8	2.8
						0.2	0.6		0.4	1.7	3.4	7.9	3.4	7.6	15.4	20.2	18.9				
C21	Anus and Anal Canal							1		2	3	1	4	1	4	4	6	26	0.4	0.7	0.7
								0.4		0.7	1.1	0.5	2.3	0.8	3.8	4.7	4.5				
LIVER																					
C22	Liver	1		3				1	2	3	8	7	5	11	5	8	21	75	1.2	1.9	1.9
		0.4		1.0				0.4	0.7	1.0	3.0	3.3	2.9	8.4	4.8	9.5	15.9				
GALL BLADDER																					
C23	Gallbladder							1	1	3	3	4	6	7	11	5	12	53	0.8	1.4	1.4
								0.4	0.4	1.0	1.1	1.9	3.4	5.3	10.6	5.9	9.1				

FEMALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C24	Other and Unspecified Parts of the Biliary Tract										4	3	1	6	3	3	6	26	0.4	0.7	0.7
											1.5	1.4	0.6	4.6	2.9	3.6	4.5				
PANCREAS																					
C25	Pancreas					1			2	2	6	11	7	18	28	34	83	192	3.0	5.0	4.8
						0.2			0.7	0.7	2.3	5.1	4.0	13.8	26.9	40.3	62.9				
GASTROINTESTINAL																					
C26	Other and Ill-Defined Digestive Organs											1			1	2	10	14	0.2	0.4	0.3
												0.5			1.0	2.4	7.6				
NASAL CAVITY																					
C30	Nasal Cavity and Middle Ear					1				1	1	1	1		1			6	0.1	0.2	0.1
						0.2				0.3	0.4	0.5	0.6		1.0						
C31	Accessory Sinuses						1	2	1			1		2			3	10	0.2	0.3	0.3
							0.3	0.7	0.4			0.5		1.5			2.3				
LARYNX																					
C32	Larynx				1						1	2		3		1	3	11	0.2	0.3	0.3
					0.3						0.4	0.9		2.3		1.2	2.3				
BRONCHUS & LUNG																					
C34	Bronchus and Lung						1		7	5	13	20	16	22	19	13	55	171	2.7	4.4	4.3
							0.3		2.6	1.7	4.9	9.3	9.1	16.8	18.3	15.4	41.7				
OTHER THORACIC ORGANS																					
C37	Thymus		1	1				1	1	3	1		2		1		1	12	0.2	0.3	0.3
			0.4	0.3				0.4	0.4	1.0	0.4		1.1		1.0		0.8				
C38	Heart, Mediastinum and Pleura	1			1		2	1	2							1	3	11	0.2	0.3	0.3
		0.4			0.3		0.6	0.4	0.7							1.2	2.3				
BONE & ARTICULAR CARTILAGE																					
C40	Bones, Joints and Articular Cartilage of Limbs	1		1	1	1			1	1		1			1	1		9	0.1	0.2	0.2
		0.4		0.3	0.3	0.2			0.4	0.3		0.5			1.0	1.2					

FEMALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites			2	2		2				2			2	1	1	1	13	0.2	0.3	0.3
				0.6	0.5		0.6				0.8			1.5	1.0	1.2	0.8				
LEUKEMIA																					
C42	Hematopoietic and Reticuloendothelial Systems	7	7	4	3	3	5	2	4	16	7	23	23	29	32	33	57	255	4.0	6.6	6.6
		2.8	2.8	1.3	0.8	0.7	1.6	0.7	1.5	5.3	2.6	10.7	13.1	22.2	30.8	39.1	43.2				
SKIN																					
C44	Skin	1					1	1	4	1	3			1	1	1	6	20	0.3	0.5	0.5
		0.4					0.3	0.4	1.5	0.3	1.1			0.8	1.0	1.2	4.5				
PERITONEUM																					
C48	Peritoneum							1		4	1	1	1	3	1			12	0.2	0.3	0.3
								0.4		1.3	0.4	0.5	0.6	2.3	1.0						
OTHER CONNECTIVE & SOFT TISSUE																					
C47	Peripheral Nerves and Autonomic Nervous System			1						1			1				1	4	0.1	0.1	0.1
				0.3						0.3			0.6				0.8				
C49	Connective, Subcutaneous and Other Soft Tissues		1		4	4	3	2	5	1	4	6	3	1	2	2	4	42	0.7	1.1	1.0
			0.4		1.0	1.0	0.9	0.7	1.9	0.3	1.5	2.8	1.7	0.8	1.9	2.4	3.0				
BREAST																					
C50	Breast					4	23	63	118	235	304	279	286	261	185	148	276	2182	33.9	56.4	54.9
						1.0	7.2	22.8	43.7	77.6	115.1	129.9	163.1	199.4	178.0	175.5	209.2				
CERVIX UTERI																					
C53	Cervix Uteri					5	26	39	61	92	85	76	74	78	72	40	88	736	11.4	19.0	18.6
						1.2	8.1	14.1	22.6	30.4	32.2	35.4	42.2	59.6	69.3	47.4	66.7				
UTERUS																					
C54	Corpus Uteri						2	5	14	23	31	52	72	99	95	61	105	559	8.7	14.4	14.5
							0.6	1.8	5.2	7.6	11.7	24.2	41.1	75.6	91.4	72.3	79.6				

FEMALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C55	Uterus, Not Otherwise Specified						1			1	2	2	1	9	2	1	6	25	0.4	0.6	0.6
							0.3			0.3	0.8	0.9	0.6	6.9	1.9	1.2	4.5				
OVARY																					
C56	Ovary	1		1	5	6	5	8	13	34	37	51	52	43	43	49	63	411	6.4	10.6	10.4
		0.4		0.3	1.3	1.5	1.6	2.9	4.8	11.2	14.0	23.7	29.7	32.9	41.4	58.1	47.8				
OTHER FEMALE GENITAL ORGANS																					
C51	Vulva					1		1	1	2		2	1	2	2	3	7	22	0.3	0.6	0.5
						0.2		0.4	0.4	0.7		0.9	0.6	1.5	1.9	3.6	5.3				
C52	Vagina	1					1		1	1	1	2	5	4	4	4	9	33	0.5	0.9	0.9
		0.4					0.3		0.4	0.3	0.4	0.9	2.9	3.1	3.8	4.7	6.8				
C57	Other and Unspecified Female Genital Organs									1					3	1	1	6	0.1	0.2	0.2
										0.3					2.9	1.2	0.8				
PLACENTA																					
C58	Placenta				1	1			2	1								5	0.1	0.1	0.1
					0.3	0.2			0.7	0.3											
KIDNEY																					
C64	Kidney	7				1	2	2		2	6	4	5	8	5	5	10	57	0.9	1.5	1.5
		2.8				0.2	0.6	0.7		0.7	2.3	1.9	2.9	6.1	4.8	5.9	7.6				
RENAL PELVIS																					
C66	Ureter														2			2	0.0	0.1	0.1
															1.9						
C68	Other and Unspecified Urinary Organs													1				1	0.0	0.0	0.0
														0.8							
BLADDER																					
C67	Bladder	1									4	3	2	4	3	2	19	38	0.6	1.0	0.9
		0.4									1.5	1.4	1.1	3.1	2.9	2.4	14.4				
EYE																					
C69	Eye and Adnexa	3	1						1						1		1	7	0.1	0.2	0.2
		1.2	0.4						0.4						1.0		0.8				

FEMALE INCIDENCE, 2003–2008

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
CNS – CENTRAL NERVOUS SYSTEM																					
C71	Brain	6	4	1	5		3	6	3	6	8	7	4	4	1	1	4	63	1.0	1.6	1.7
		2.4	1.6	0.3	1.3		0.9	2.2	1.1	2.0	3.0	3.3	2.3	3.1	1.0	1.2	3.0				
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System					1					1							2	0.0	0.1	0.0
						0.2					0.4										
THYROID																					
C73	Thyroid Gland				2	2	3	3	5	11	5	5	8	5	2	3	8	62	1.0	1.6	1.5
					0.5	0.5	0.9	1.1	1.9	3.6	1.9	2.3	4.6	3.8	1.9	3.6	6.1				
OTHER ENDOCRINE																					
C74	Adrenal Gland	3						1			2		1	1				8	0.1	0.2	0.2
		1.2						0.4			0.8		0.6	0.8							
C75	Other Endocrine Glands and Related Structures						1	1		1		1				1		5	0.1	0.1	0.1
							0.3	0.4		0.3		0.5				1.2					
ILL-DEFINED																					
C76	Other and Ill-Defined Sites	5				2	1	1		3	4	4	2	3	2	1	19	47	0.7	1.2	1.2
		2.0				0.5	0.3	0.4		1.0	1.5	1.9	1.1	2.3	1.9	1.2	14.4				
LYMPHOMA																					
C77	Lymph Nodes			2	10	10	12	7	15	6	14	13	12	17	14	10	9	151	2.3	3.9	3.8
				0.6	2.6	2.5	3.8	2.5	5.6	2.0	5.3	6.1	6.8	13.0	13.5	11.9	6.8				
UNKNOWN																					
C80	Unknown Primary Site		2			2	1	4	4	3	14	6	22	17	22	25	60	182	2.8	4.7	4.6
			0.8			0.5	0.3	1.4	1.5	1.0	5.3	2.8	12.5	13.0	21.2	29.6	45.5				
Total		38	16	16	39	50	101	167	293	503	640	673	705	753	683	576	1,188	6,441	100	166.4	163.3
		15.2	6.4	5.2	10.2	12.3	31.6	60.4	108.4	166.1	242.2	313.2	402.1	575.3	657.1	683.0	900.5				

Table A-3: Cancer Incidence Rates in Females by Age and Site, 2003 to 2008

Cancer Mortality, 2003–2008

ICD-O-3 Code	Topography Description	Male			Female			Total		
		n	%	MR	n	%	MR	n	%	MR
	LIP									
C00	Lip	1	0.0	0.0				1	0.0	0.0
	ORAL CAVITY & SALIVARY GLAND									
C01	Base of Tongue	7	0.2	0.2				7	0.1	0.1
C02	Other and Unspecified Parts of the Tongue	23	0.6	0.6	7	0.2	0.2	30	0.4	0.4
C03	Gum	5	0.1	0.1	4	0.1	0.1	9	0.1	0.1
C04	Floor of Mouth	4	0.1	0.1				4	0.1	0.1
C05	Palate	6	0.2	0.2	1	0.0	0.0	7	0.1	0.1
C06	Other and Unspecified Parts of the Mouth	9	0.2	0.2	3	0.1	0.1	12	0.2	0.2
C07	Parotid Gland	6	0.2	0.2	1	0.0	0.0	7	0.1	0.1
C08	Other and Unspecified Major Salivary Glands	2	0.1	0.1	3	0.1	0.1	5	0.1	0.1
	PHARYNX									
C09	Tonsil	21	0.5	0.5	1	0.0	0.0	22	0.3	0.3
C10	Oropharynx	9	0.2	0.2	1	0.0	0.0	10	0.1	0.1
C11	Nasopharynx	10	0.3	0.3	8	0.3	0.2	18	0.3	0.2
C12	Pyriform Sinus	3	0.1	0.1				3	0.0	0.0
C13	Hypopharynx	2	0.1	0.1	4	0.1	0.1	6	0.1	0.1
	OTHER PHARYNX									
C14	Other Pharynx	9	0.2	0.2	5	0.2	0.1	14	0.2	0.2
	ESOPHAGUS									
C15	Esophagus	73	1.9	1.9	16	0.5	0.4	89	1.3	1.1
	STOMACH									
C16	Stomach	183	4.8	4.7	118	3.9	3.0	301	4.4	3.9
	SMALL INTESTINE									
C17	Small Intestine	24	0.6	0.6	11	0.4	0.3	35	0.5	0.5
	COLON & RECTUM									
C18	Colon	324	8.4	8.3	257	8.5	6.6	581	8.5	7.5
C19	Rectosigmoid Junction	23	0.6	0.6	23	0.8	0.6	46	0.7	0.6
C20	Rectum	76	2.0	2.0	45	1.5	1.2	121	1.8	1.6
C21	Anus and Anal Canal	7	0.2	0.2	15	0.5	0.4	22	0.3	0.3
	LIVER									
C22	Liver	88	2.3	2.3	59	2.0	1.5	147	2.1	1.9
	GALL BLADDER									
C23	Gallbladder	19	0.5	0.5	42	1.4	1.1	61	0.9	0.8
C24	Other and Unspecified Parts of the Biliary Tract	17	0.4	0.4	20	0.7	0.5	37	0.5	0.5
	PANCREAS									
C25	Pancreas	215	5.6	5.5	162	5.4	4.2	377	5.5	4.9
	GASTROINTESTINAL									
C26	Other and Ill-Defined Digestive Organs	17	0.4	0.4	14	0.5	0.4	31	0.5	0.4

CANCER MORTALITY, 2003–2008

ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	NASAL CAVITY									
C30	Nasal Cavity and Middle Ear	1	0.0	0.0	5	0.2	0.1	6	0.1	0.1
C31	Accessory Sinuses	13	0.3	0.3	3	0.1	0.1	16	0.2	0.2
	LARYNX									
C32	Larynx	61	1.6	1.6	2	0.1	0.1	63	0.9	0.8
	BRONCHUS & LUNG									
C34	Bronchus and Lung	493	12.9	12.7	125	4.1	3.2	618	9.0	8.0
	OTHER THORACIC ORGANS									
C37	Thymus	7	0.2	0.2	4	0.1	0.1	11	0.2	0.1
C38	Heart, Mediastinum and Pleura	8	0.2	0.2	6	0.2	0.2	14	0.2	0.2
	BONE & ARTICULAR CARTILAGE									
C40	Bones, Joints and Articular Cartilage of Limbs	8	0.2	0.2	3	0.1	0.1	11	0.2	0.1
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	10	0.3	0.3	7	0.2	0.2	17	0.2	0.2
	LEUKEMIA									
C42	Hematopoietic and Reticuloendothelial Systems	196	5.1	5.0	175	5.8	4.5	371	5.4	4.8
	SKIN									
C44	Skin	10	0.3	0.3	9	0.3	0.2	19	0.3	0.2
	PERITONEUM									
C48	Peritoneum	10	0.3	0.3	5	0.2	0.1	15	0.2	0.2
	OTHER CONNECTIVE & SOFT TISSUE									
C47	Peripheral Nerves and Autonomic Nervous System	2	0.1	0.1	1	0.0	0.0	3	0.0	0.0
C49	Connective, Subcutaneous and Other Soft Tissues	17	0.4	0.4	15	0.5	0.4	32	0.5	0.4
	BREAST									
C50	Breast	17	0.4	0.4	598	19.8	15.4	615	9.0	7.9
	CERVIX UTERI									
C53	Cervix uteri				328	10.9	8.5	328	4.8	4.2
	UTERUS									
C54	Corpus Uteri				237	7.9	6.1	237	3.5	3.1
C55	Uterus, Not Otherwise Specified				20	0.7	0.5	20	0.3	0.3
	OVARY									
C56	Ovary				242	8.0	6.3	242	3.5	3.1
	OTHER FEMALE GENITAL ORGANS									
C51	Vulva				11	0.4	0.3	11	0.2	0.1
C52	Vagina				13	0.4	0.3	13	0.2	0.2
C57	Other and Unspecified Female Genital Organs				5	0.2	0.1	5	0.1	0.1
	PLACENTA									
C58	Placenta				4	0.1	0.1	4	0.1	0.1
	PENIS									
C60	Penis	14	0.4	0.4				14	0.2	0.2
	PROSTATE									
C61	Prostate	1319	34.4	33.9				1319	19.3	17.0

ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	TESTIS									
C62	Testis	9	0.2	0.2				9	0.1	0.1
	OTHER MALE GENITAL ORGANS									
C63	Other and Unspecified Male Genital Organs	1	0.0	0.0				1	0.0	0.0
	KIDNEY									
C64	Kidney	52	1.4	1.3	31	1.0	0.8	83	1.2	1.1
	RENAL PELVIS									
C66	Ureter	1	0.0	0.0	1	0.0	0.0	2	0.0	0.0
C68	Other and Unspecified Urinary Organs	2	0.1	0.1				2	0.0	0.0
	BLADDER									
C67	Bladder	56	1.5	1.4	26	0.9	0.7	82	1.2	1.1
	EYE									
C69	Eye and Adnexa	2	0.1	0.1	2	0.1	0.1	4	0.1	0.1
	CNS – CENTRAL NERVOUS SYSTEM									
C70	Meninges	1	0.0	0.0				1	0.0	0.0
C71	Brain	37	1.0	0.9	32	1.1	0.8	69	1.0	0.9
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	2	0.1	0.1				2	0.0	0.0
	THYROID									
C73	Thyroid Gland	6	0.2	0.2	21	0.7	0.5	27	0.4	0.3
	OTHER ENDOCRINE									
C74	Adrenal Gland	4	0.1	0.1	2	0.1	0.1	6	0.1	0.1
C75	Other Endocrine Glands and Related Structures				2	0.1	0.1	2	0.0	0.0
	ILL-DEFINED									
C76	Other and Ill-Defined Sites	14	0.4	0.4	34	1.1	0.9	48	0.7	0.6
	LYMPHOMA									
C77	Lymph Nodes	126	3.3	3.2	84	2.8	2.2	210	3.1	2.7
	UNKNOWN									
C80	Unknown Primary Site	154	4.0	4.0	142	4.7	3.7	296	4.3	3.8
Total		3,836	100.0	98.5	3,015	100.0	77.9	6,851	100.0	88.2

Table A-4: Cancer Mortality, 2003 to 2008



APPENDIX B

2009–2014

CANCER IN
TRINIDAD AND TOBAGO
2003
–2020

Appendix B

Summary of Cancer Incidence, 2009–2014

ICD-O-3	Topography Description	Male					Female					Total	
		<i>n</i>	%	CR	ASR	LR	<i>n</i>	%	CR	ASR	LR	<i>n</i>	%
	LIP												
C00	Lip	3	0.0	0.1	0.1	27,565	1	0.0	0.0	0.0	56,915	4	0.0
	ORAL CAVITY & SALIVARY GLAND												
C01	Base of Tongue	8	0.1	0.2	0.2	3,632	2	0.0	0.1	0.0	16,956	10	0.1
C02	Other and Unspecified Parts of the Tongue	38	0.6	1.0	0.9	1,048	26	0.4	0.7	0.6	1,745	64	0.5
C03	Gum	5	0.1	0.1	0.1	11,786	3	0.0	0.1	0.1	16,956	8	0.1
C04	Floor of Mouth	5	0.1	0.1	0.1	6,390						5	0.0
C05	Palate	6	0.1	0.2	0.1	4,974	6	0.1	0.2	0.1	7,651	12	0.1
C06	Other and Unspecified Parts of the Mouth	10	0.2	0.3	0.2	5,104	13	0.2	0.3	0.3	3,546	23	0.2
C07	Parotid Gland	12	0.2	0.3	0.3	3,197	8	0.1	0.2	0.2	5,303	20	0.2
C08	Other and Unspecified Major Salivary Glands	8	0.1	0.2	0.2	4,257	1	0.0	0.0	0.0	62,020	9	0.1
	PHARYNX												
C09	Tonsil	27	0.4	0.7	0.6	1,576	2	0.0	0.1	0.0	1,4062	29	0.2
C10	Oropharynx	7	0.1	0.2	0.2	6,283	1	0.0	0.0	0.0	51,844	8	0.1
C11	Nasopharynx	30	0.5	0.8	0.7	1,620	12	0.2	0.3	0.3	4,306	42	0.3
C12	Pyriform Sinus	3	0.0	0.1	0.1	17,374	1	0.0	0.0	0.0	51,844	4	0.0
C13	Hypopharynx	6	0.1	0.2	0.1	4,864	1	0.0	0.0	0.0	68,200	7	0.1
	OTHER PHARYNX												
C14	Other Pharynx	14	0.2	0.4	0.3	3,421	1	0.0	0.0	0.0	43,796	15	0.1
	ESOPHAGUS												
C15	Esophagus	99	1.6	2.5	2.3	358	25	0.4	0.6	0.5	1,897	124	1.0
	STOMACH												
C16	Stomach	186	3.0	4.7	4.4	236	140	2.2	3.5	3.0	330	326	2.5
	SMALL INTESTINE												
C17	Small Intestine	9	0.1	0.2	0.2	3,886	12	0.2	0.3	0.3	3,991	21	0.2
	COLON & RECTUM												
C18	Colon	445	7.1	11.1	10.6	91	444	6.8	11.2	9.4	119	889	7.0
C19	Rectosigmoid Junction	80	1.3	2.0	1.9	531	65	1.0	1.6	1.4	749	145	1.1
C20	Rectum	173	2.7	4.3	4.0	227	116	1.8	2.9	2.5	364	289	2.3
C21	Anus and Anal Canal	19	0.3	0.5	0.4	2,146	29	0.4	0.7	0.6	1,254	48	0.4
	LIVER												
C22	Liver	133	2.1	3.3	3.1	334	115	1.8	2.9	2.5	407	248	1.9
	GALL BLADDER												
C23	Gallbladder	18	0.3	0.5	0.4	2,765	36	0.6	0.9	0.8	1,584	54	0.4
C24	Other and Unspecified Parts of the Biliary Tract	19	0.3	0.5	0.4	2,228	18	0.3	0.5	0.4	1,917	37	0.3
	PANCREAS												
C25	Pancreas	238	3.8	6.0	5.7	168	199	3.1	5.0	4.2	260	437	3.4

CANCER INCIDENCE, 2009–2014

ICD-O-3	Topography Description	Male					Female					Total	
		n	%	CR	ASR	LR	n	%	CR	ASR	LR	n	%
	GASTROINTESTINAL												
C26	Other and Ill-Defined Digestive Organs	26	0.4	0.7	0.6	2,355	20	0.3	0.5	0.4	4,587	46	0.4
	NASAL CAVITY												
C30	Nasal Cavity and Middle Ear	4	0.1	0.1	0.1	9,890	1	0.0	0.0	0.0	34,803	5	0.0
C31	Accessory Sinuses	23	0.4	0.6	0.5	1,908	7	0.1	0.2	0.2	6,765	30	0.2
	LARYNX												
C32	Larynx	138	2.2	3.5	3.2	292	11	0.2	0.3	0.2	3,801	149	1.2
	BRONCHUS & LUNG												
C33	Trachea						1	0.0	0.0	0.0	43,796	1	0.0
C34	Bronchus and Lung	732	11.6	18.3	16.9	53	262	4.0	6.6	5.6	179	994	7.8
	OTHER THORACIC ORGANS												
C37	Thymus	9	0.1	0.2	0.2	3,976	13	0.2	0.3	0.3	4,712	22	0.2
C38	Heart, Mediastinum and Pleura	13	0.2	0.3	0.3	3,373	8	0.1	0.2	0.2	4,431	21	0.2
	BONE & ARTICULAR CARTILAGE												
C40	Bones, Joints and Articular Cartilage of Limbs	15	0.2	0.4	0.4	3,319	11	0.2	0.3	0.3	4,503	26	0.2
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	18	0.3	0.5	0.4	2,302	13	0.2	0.3	0.3	3,205	31	0.2
	LEUKEMIA												
C42	Hematopoietic and Reticuloendothelial Systems	359	5.7	9.0	8.7	127	301	4.6	7.6	6.8	156	660	5.2
	SKIN												
C44	Skin	22	0.3	0.6	0.5	1,611	19	0.3	0.5	0.4	2,231	41	0.3
	PERITONEUM												
C48	Peritoneum	4	0.1	0.1	0.1	17,593	12	0.2	0.3	0.3	5,012	16	0.1
	OTHER CONNECTIVE & SOFT TISSUE												
C47	Peripheral Nerves and Autonomic Nervous System	6	0.1	0.2	0.2	7,636	4	0.1	0.1	0.1	12,433	10	0.1
C49	Connective, Subcutaneous and Other Soft Tissues	33	0.5	0.8	0.8	1,439	30	0.5	0.8	0.7	1,426	63	0.5
	BREAST												
C50	Breast	38	0.6	1.0	0.9	1,283	2,120	32.7	53.4	46.2	22	2,158	16.9
	CERVIX UTERI												
C53	Cervix uteri						610	9.4	15.4	13.6	77	610	4.8
	UTERUS												
C54	Corpus Uteri						548	8.4	13.8	11.7	72	548	4.3
C55	Uterus, Not Otherwise Specified						64	1.0	1.6	1.3	821	64	0.5
	OVARY												
C56	Ovary						405	6.2	10.2	8.9	106	405	3.2
	OTHER FEMALE GENITAL ORGANS												
C51	Vulva						15	0.2	0.4	0.3	2,670	15	0.1
C52	Vagina						27	0.4	0.7	0.6	1,328	27	0.2
C57	Other and Unspecified Female Genital Organs						18	0.3	0.5	0.4	2,936	18	0.1
	PLACENTA												
C58	Placenta						1	0.0	0.0	0.0	58,405	1	0.0

ICD-O-3	Topography Description	Male					Female					Total	
		n	%	CR	ASR	LR	n	%	CR	ASR	LR	n	%
	PENIS												
C60	Penis	22	0.3	0.6	0.5	2,085						22	0.2
	PROSTATE												
C61	Prostate	2,361	37.5	59.1	58.7	20						2,361	18.5
	TESTIS												
C62	Testis	28	0.4	0.7	0.7	1,846						28	0.2
	OTHER MALE GENITAL ORGANS												
C63	Other and Unspecified Male Genital Organs	2	0.0	0.1	0.1	25,900						2	0.0
	KIDNEY												
C64	Kidney	98	1.6	2.5	2.3	344	83	1.3	2.1	1.9	451	181	1.4
	RENAL PELVIS												
C65	Renal Pelvis	1	0.0	0.0	0.0	25,900						1	0.0
C66	Ureter	1	0.0	0.0	0.0		1	0.0	0.0	0.0	43,796	2	0.0
C68	Other and Unspecified Urinary Organs	2	0.0	0.1	0.0	17,788						2	0.0
	BLADDER												
C67	Bladder	173	2.7	4.3	4.2	250	53	0.8	1.3	1.1	1,134	226	1.8
	EYE												
C69	Eye and Adnexa	12	0.2	0.3	0.3	3,138	5	0.1	0.1	0.1	6,548	17	0.1
	CNS – CENTRAL NERVOUS SYSTEM												
C70	Meninges	3	0.0	0.1	0.1	17,470	1	0.0	0.0	0.0	62,020	4	0.0
C71	Brain	109	1.7	2.7	2.6	403	93	1.4	2.3	2.1	525	202	1.6
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	4	0.1	0.1	0.1	14,541	5	0.1	0.1	0.1	6,968	9	0.1
	THYROID												
C73	Thyroid Gland	27	0.4	0.7	0.6	1,696	77	1.2	1.9	1.7	597	104	0.8
	OTHER ENDOCRINE												
C74	Adrenal Gland	4	0.1	0.1	0.1	8,398	5	0.1	0.1	0.1	13,080	9	0.1
C75	Other Endocrine Glands and Related Structures	3	0.0	0.1	0.1	21,438	3	0.0	0.1	0.1	15,040	6	0.0
	ILL-DEFINED												
C76	Other and Ill-Defined Sites	43	0.7	1.1	1.0	1,146	41	0.6	1.0	1.0	1,256	84	0.7
	LYMPHOMA												
C77	Lymph Nodes	198	3.1	5.0	4.6	243	169	2.6	4.3	3.8	285	367	2.9
	UNKNOWN												
C80	Unknown Primary Site	168	2.7	4.2	4.0	256	156	2.4	3.9	3.3	337	324	2.5
Total		6,300	100.0	157.6	151.4		6,490	100.0	163.5	141.7		12,790	100.0

Table B-1: Summary of Cancer Incidence, 2009 to 2014

Cancer Incidence Rates by Age, Sex, and Site, 2009–2014

CANCER INCIDENCE RATES IN MALES BY AGE AND SITE, 2009–2014

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
LIP																					
C00	Lip									1	1						1	3	0.0	0.1	0.1
										0.4	0.3						0.9				
ORAL CAVITY & SALIVARY GLAND																					
C01	Base of Tongue									1		1	1		1	3	1	8	0.1	0.2	0.2
										0.4		0.4	0.5		0.8	3.5	0.9				
C02	Other and Unspecified Parts of the Tongue						1	1	2	1	1	5	3	8	6	4	6	38	0.6	1.0	0.9
							0.3	0.3	0.7	0.4	0.3	1.9	1.4	4.5	4.6	4.7	5.4				
C03	Gum				1								3				1	5	0.1	0.1	0.1
					0.3								1.4				0.9				
C04	Floor of Mouth											1	1	2		1		5	0.1	0.1	0.1
												0.4	0.5	1.1		1.2					
C05	Palate								1			2		1		2		6	0.1	0.2	0.1
									0.4			0.8		0.6		2.3					
C06	Other and Unspecified Parts of the Mouth									1		1	2	4			2	10	0.2	0.3	0.2
										0.4		0.4	0.9	2.2			1.8				
C07	Parotid Gland									1		2	1		3	2	3	12	0.2	0.3	0.3
										0.4		0.8	0.5		2.3	2.3	2.7				
C08	Other and Unspecified Major Salivary Glands										1	1	2	2	1	1		8	0.1	0.2	0.2
											0.3	0.4	0.9	1.1	0.8	1.2					
PHARYNX																					
C09	Tonsil								1		4	4	4	6	4	1	3	27	0.4	0.7	0.6
									0.4		1.4	1.5	1.8	3.4	3.1	1.2	2.7				
C10	Oropharynx								1		1	1		1	2		1	7	0.1	0.2	0.2
									0.4		0.3	0.4		0.6	1.5		0.9				

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C11	Nasopharynx			1		1		1	1	3	6	5	2	2	2	2	4	30	0.5	0.8	0.7
				0.4		0.3		0.3	0.4	1.1	2.1	1.9	0.9	1.1	1.5	2.3	3.6				
C12	Pyriform Sinus											1			1		1	3	0.0	0.1	0.1
												0.4			0.8		0.9				
C13	Hypopharynx											1	1	1	2	1		6	0.1	0.2	0.1
												0.4	0.5	0.6	1.5	1.2					
OTHER PHARYNX																					
C14	Other Pharynx										2	1	3	4		1	3	14	0.2	0.4	0.3
											0.7	0.4	1.4	2.2		1.2	2.7				
ESOPHAGUS																					
C15	Esophagus						1	3			2	10	12	16	22	16	17	99	1.6	2.5	2.3
							0.3	0.9			0.7	3.8	5.4	9.0	17.0	18.8	15.2				
STOMACH																					
C16	Stomach						3		3	9	9	18	22	23	24	24	51	186	3.0	4.7	4.4
							0.8		1.1	3.4	3.1	6.8	10.0	12.9	18.5	28.2	45.5				
SMALL INTESTINE																					
C17	Small Intestine									1	2		3		2	1		9	0.1	0.2	0.2
										0.4	0.7		1.4		1.5	1.2					
COLON & RECTUM																					
C18	Colon						1	2	3	14	14	28	54	60	83	65	121	445	7.1	11.1	10.6
							0.3	0.6	1.1	5.4	4.8	10.6	24.5	33.7	64.1	76.2	108.0				
C19	Rectosigmoid Junction					1		2	1	3	5	7	10	13	11	9	18	80	1.3	2.0	1.9
						0.3		0.6	0.4	1.1	1.7	2.7	4.5	7.3	8.5	10.6	16.1				
C20	Rectum					1	2	4	1	7	15	12	25	31	20	25	30	173	2.7	4.3	4.0
						0.3	0.5	1.2	0.4	2.7	5.1	4.5	11.3	17.4	15.4	29.3	26.8				
C21	Anus and Anal Canal								3	1	2	1	2	5	4		1	19	0.3	0.5	0.4
									1.1	0.4	0.7	0.4	0.9	2.8	3.1		0.9				
LIVER																					
C22	Liver	3				1		2	2	2	11	10	19	22	18	12	31	133	2.1	3.3	3.1
		1.0				0.3		0.6	0.7	0.8	3.8	3.8	8.6	12.4	13.9	14.1	27.7				

MALE INCIDENCE, 2009–2014

ICD-0-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
GALL BLADDER																					
C23	Gallbladder											1	2	3	4	1	7	18	0.3	0.5	0.4
												0.4	0.9	1.7	3.1	1.2	6.2				
C24	Other and Unspecified Parts of the Biliary Tract									1		1	5	3	4	1	4	19	0.3	0.5	0.4
										0.4		0.4	2.3	1.7	3.1	1.2	3.6				
PANCREAS																					
C25	Pancreas							2	1	3	8	21	27	29	33	45	69	238	3.8	6.0	5.7
								0.6	0.4	1.1	2.7	8.0	12.3	16.3	25.5	52.8	61.6				
GASTROINTESTINAL																					
C26	Other and Ill-Defined Digestive Organs											1	4	5	3	1	12	26	0.4	0.7	0.6
												0.4	1.8	2.8	2.3	1.2	10.7				
NASAL CAVITY																					
C30	Nasal Cavity and Middle Ear										1		2		1			4	0.1	0.1	0.1
											0.3		0.9		0.8						
C31	Accessory Sinuses						1		1		1	3	2	5	3	2	5	23	0.4	0.6	0.5
							0.3		0.4		0.3	1.1	0.9	2.8	2.3	2.3	4.5				
LARYNX																					
C32	Larynx								1	5	4	11	21	34	22	13	27	138	2.2	3.5	3.2
									0.4	1.9	1.4	4.2	9.5	19.1	17.0	15.2	24.1				
BRONCHUS & LUNG																					
C34	Bronchus and Lung						1	2	7	15	20	82	137	127	110	99	132	732	11.6	18.3	16.9
							0.3	0.6	2.5	5.7	6.8	31.1	62.2	71.4	84.9	116.1	117.8				
OTHER THORACIC ORGANS																					
C37	Thymus					1	2		1			1		2		2		9	0.1	0.2	0.2
						0.3	0.5		0.4			0.4		1.1		2.3					
C38	Heart, Mediastinum and Pleura			1		1				1			4	2	1	1	2	13	0.2	0.3	0.3
				0.4		0.3				0.4			1.8	1.1	0.8	1.2	1.8				

ICD-0-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
BONE & ARTICULAR CARTILAGE																					
C40	Bones, Joints and Articular Cartilage of Limbs		1	1	4	3	1	1						1	1	1	1	15	0.2	0.4	0.4
			0.4	0.4	1.3	0.9	0.3	0.3						0.6	0.8	1.2	0.9				
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites					1		2			3	1	3	2	2	2	2	18	0.3	0.5	0.4
						0.3		0.6			1.0	0.4	1.4	1.1	1.5	2.3	1.8				
LEUKEMIA																					
C42	Hematopoietic and Reticuloendothelial Systems	13	10	6	5	11	12	11	13	12	22	25	33	52	33	34	67	359	5.7	9.0	8.7
		4.5	3.6	2.2	1.7	3.2	3.2	3.4	4.6	4.6	7.5	9.5	15.0	29.2	25.5	39.9	59.8				
SKIN																					
C44	Skin					1		1			1	2	4	2	4	4	3	22	0.3	0.6	0.5
						0.3		0.3			0.3	0.8	1.8	1.1	3.1	4.7	2.7				
PERITONEUM																					
C48	Peritoneum											3					1	4	0.1	0.1	0.1
												1.1					0.9				
OTHER CONNECTIVE & SOFT TISSUE																					
C47	Peripheral Nerves and Autonomic Nervous System			2				1			1		1		1			6	0.1	0.2	0.2
				0.7				0.3			0.3		0.5		0.8						
C49	Connective, Subcutaneous and Other Soft Tissues			2			1	1	3	2	5	3	6	3	3	1	3	33	0.5	0.8	0.8
				0.7			0.3	0.3	1.1	0.8	1.7	1.1	2.7	1.7	2.3	1.2	2.7				
BREAST																					
C50	Breast						1	3	2	1	1	5	4	4	3	4	10	38	0.6	1.0	0.9
							0.3	0.9	0.7	0.4	0.3	1.9	1.8	2.2	2.3	4.7	8.9				
PENIS																					
C60	Penis									1	3	3	2	4	2	2	5	22	0.3	0.6	0.5
										0.4	1.0	1.1	0.9	2.2	1.5	2.3	4.5				

MALE INCIDENCE, 2009–2014

ICD-0-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
PROSTATE																					
C61	Prostate						1			4	24	65	135	278	424	400	1030	2361	37.5	59.1	58.7
							0.3			1.5	8.2	24.6	61.3	156.3	327.4	469.2	919.5				
TESTIS																					
C62	Testis	1			2		4	5	1	5	3	1	1	2	1	1	1	28	0.4	0.7	0.7
		0.3			0.7		1.1	1.5	0.4	1.9	1.0	0.4	0.5	1.1	0.8	1.2	0.9				
OTHER MALE GENITAL ORGANS																					
C63	Other and Unspecified Male Genital Organs														1		1	2	0.0	0.1	0.1
															0.8		0.9				
KIDNEY																					
C64	Kidney	3					1	1	1		3	10	16	12	12	24	15	98	1.6	2.5	2.3
		1.0					0.3	0.3	0.4		1.0	3.8	7.3	6.7	9.3	28.2	13.4				
RENAL PELVIS																					
C65	Renal Pelvis														1			1	0.0	0.0	0.0
															0.8						
C66	Ureter																1	1	0.0	0.0	0.0
																	0.9				
C68	Other and Unspecified Urinary Organs													2				2	0.0	0.1	0.0
														1.1							
BLADDER																					
C67	Bladder					1			1	1	10	11	12	26	30	24	57	173	2.7	4.3	4.2
						0.3			0.4	0.4	3.4	4.2	5.4	14.6	23.2	28.2	50.9				
EYE																					
C69	Eye and Adnexa	4	1	1						1		1			3	1		12	0.2	0.3	0.3
		1.4	0.4	0.4						0.4		0.4			2.3	1.2					
CNS – CENTRAL NERVOUS SYSTEM																					
C70	Meninges				1				1				1					3	0.0	0.1	0.1
					0.3				0.4				0.5								
C71	Brain	6	3		2	1	6	5	8	7	10	11	8	11	13	8	10	109	1.7	2.7	2.6
		2.1	1.1		0.7	0.3	1.6	1.5	2.8	2.7	3.4	4.2	3.6	6.2	10.0	9.4	8.9				

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System		1										1	1			1	4	0.1	0.1	0.1
			0.4										0.5	0.6			0.9				
THYROID																					
C73	Thyroid Gland				1		3	2			1	2	4	3	4	2	5	27	0.4	0.7	0.6
					0.3		0.8	0.6			0.3	0.8	1.8	1.7	3.1	2.3	4.5				
OTHER ENDOCRINE																					
C74	Adrenal Gland									1			1		2			4	0.1	0.1	0.1
										0.4			0.5		1.5						
C75	Other Endocrine Glands and Related Structures			1										1			1	3	0.0	0.1	0.1
				0.4										0.6			0.9				
ILL-DEFINED																					
C76	Other and Ill-Defined Sites	5		2			2	4	1	2	2	5	4	4	4	2	6	43	0.7	1.1	1.0
		1.7		0.7			0.5	1.2	0.4	0.8	0.7	1.9	1.8	2.2	3.1	2.3	5.4				
LYMPHOMA																					
C77	Lymph Nodes	1	1	4	9	11	18	9	6	7	20	15	29	19	22	7	20	198	3.1	5.0	4.6
		0.3	0.4	1.5	3.0	3.2	4.8	2.8	2.1	2.7	6.8	5.7	13.2	10.7	17.0	8.2	17.9				
UNKNOWN																					
C80	Unknown Primary Site		1		1		1	3	3	3	12	10	18	21	28	21	46	168	2.7	4.2	4.0
			0.4		0.3		0.3	0.9	1.1	1.1	4.1	3.8	8.2	11.8	21.6	24.6	41.1				
Total		36	18	21	26	35	63	68	70	117	231	406	657	859	981	873	1839	6300	100	157.6	151.4
		12.5	6.5	7.8	8.7	10.2	16.9	21.0	24.9	44.8	79.1	153.9	298.2	482.9	757.5	1024	1641.7				

Table B-2: Cancer Incidence Rates in Males by Age and Site, 2009 to 2014

CANCER INCIDENCE RATES IN FEMALES BY AGE AND SITE, 2009–2014

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
LIP																					
C00	Lip										1							1	0.0	0.0	0.0
											0.4										
ORAL CAVITY & SALIVARY GLAND																					
C01	Base of Tongue												1		1			2	0.0	0.1	0.0
													0.5		0.7						
C02	Other and Unspecified Parts of the Tongue								2	1	2	1	4	5	2	3	6	26	0.4	0.7	0.6
									0.7	0.4	0.7	0.4	1.8	2.9	1.4	3.1	3.9				
C03	Gum												1		1		1	3	0.0	0.1	0.1
													0.5		0.7		0.7				
C05	Palate									1	1			2	1		1	6	0.1	0.2	0.1
										0.4	0.4			1.1	0.7		0.7				
C06	Other and Unspecified Parts of the Mouth								1			3	2		3	1	3	13	0.2	0.3	0.3
									0.4			1.2	0.9		2.2	1.0	2.0				
C07	Parotid Gland							1	2			1		1	1	1	1	8	0.1	0.2	0.2
								0.3	0.7			0.4		0.6	0.7	1.0	0.7				
C08	Other and Unspecified Major Salivary Glands							1										1	0.0	0.0	0.0
								0.3													
PHARYNX																					
C09	Tonsil											1				1		2	0.0	0.1	0.0
												0.4				1.0					
C10	Oropharynx											1						1	0.0	0.0	0.0
												0.4									
C11	Nasopharynx				2	1	2		1		1	1		1	2		1	12	0.2	0.3	0.3
					0.7	0.3	0.5		0.4		0.4	0.4		0.6	1.4		0.7				
C12	Pyriiform Sinus											1						1	0.0	0.0	0.0
												0.4									

FEMALE INCIDENCE, 2009–2014

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C13	Hypopharynx					1												1	0.0	0.0	0.0
						0.3															
OTHER PHARYNX																					
C14	Other Pharynx												1					1	0.0	0.0	0.0
													0.5								
ESOPHAGUS																					
C15	Esophagus							1	1		1	5		4	3	3	7	25	0.4	0.6	0.5
								0.3	0.4		0.4	1.9		2.3	2.2	3.1	4.6				
STOMACH																					
C16	Stomach					1	2	1	6	3	7	10	19	12	23	17	39	140	2.2	3.5	3.0
						0.3	0.5	0.3	2.2	1.2	2.5	3.9	8.7	6.9	16.6	17.6	25.6				
SMALL INTESTINE																					
C17	Small Intestine										2	1	1	1	4		3	12	0.2	0.3	0.3
											0.7	0.4	0.5	0.6	2.9		2.0				
COLON & RECTUM																					
C18	Colon					1	2	11	10	11	31	41	56	47	45	43	146	444	6.8	11.2	9.4
						0.3	0.5	3.5	3.6	4.3	10.9	15.8	25.6	27.0	32.5	44.6	95.7				
C19	Rectosigmoid Junction					1	2		3	2	2	3	6	7	17	3	19	65	1.0	1.6	1.4
						0.3	0.5		1.1	0.8	0.7	1.2	2.7	4.0	12.3	3.1	12.5				
C20	Rectum					2	1	2	3	8	7	10	17	12	22	12	20	116	1.8	2.9	2.5
						0.6	0.3	0.6	1.1	3.1	2.5	3.9	7.8	6.9	15.9	12.4	13.1				
C21	Anus and Anal Canal						1			1	2	2	7	3	8	3	2	29	0.4	0.7	0.6
							0.3			0.4	0.7	0.8	3.2	1.7	5.8	3.1	1.3				
LIVER																					
C22	Liver						1	2	3	4	8	6	8	14	14	18	37	115	1.8	2.9	2.5
							0.3	0.6	1.1	1.6	2.8	2.3	3.7	8.0	10.1	18.7	24.3				
GALL BLADDER																					
C23	Gallbladder									2		3	2	1	7	4	17	36	0.6	0.9	0.8
										0.8		1.2	0.9	0.6	5.1	4.1	11.1				

FEMALE INCIDENCE, 2009–2014

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C24	Other and Unspecified Parts of the Biliary Tract											3		1	2	7	5	18	0.3	0.5	0.4
												1.2		0.6	1.4	7.3	3.3				
PANCREAS																					
C25	Pancreas						1	2	1	4	8	7	21	28	28	22	77	199	3.1	5.0	4.2
							0.3	0.6	0.4	1.6	2.8	2.7	9.6	16.1	20.2	22.8	50.5				
GASTROINTESTINAL																					
C26	Other and Ill-Defined Digestive Organs						1						1	2	2	1	13	20	0.3	0.5	0.4
							0.3						0.5	1.1	1.4	1.0	8.5				
NASAL CAVITY																					
C30	Nasal Cavity and Middle Ear													1				1	0.0	0.0	0.0
														0.6							
C31	Accessory Sinuses					1				2	2		1		1			7	0.1	0.2	0.2
						0.3				0.8	0.7		0.5		0.7						
LARYNX																					
C32	Larynx									3		3	2	1	2			11	0.2	0.3	0.2
										1.2		1.2	0.9	0.6	1.4						
BRONCHUS & LUNG																					
C33	Trachea												1					1	0.0	0.0	0.0
													0.5								
C34	Bronchus and Lung						1		6	7	12	30	21	28	40	35	82	262	4.0	6.6	5.6
							0.3		2.2	2.7	4.2	11.6	9.6	16.1	28.9	36.3	53.7				
OTHER THORACIC ORGANS																					
C37	Thymus							1	1			2	2	2	1		4	13	0.2	0.3	0.3
								0.3	0.4			0.8	0.9	1.1	0.7		2.6				
C38	Heart, Mediastinum and Pleura	2								1	1			1	2	1		8	0.1	0.2	0.2
		0.7								0.4	0.4			0.6	1.4	1.0					

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
BONE & ARTICULAR CARTILAGE																					
C40	Bones, Joints and Articular Cartilage of Limbs		2	2	1	2	1	1	1							1		11	0.2	0.3	0.3
			0.7	0.8	0.3	0.6	0.3	0.3	0.4							1.0					
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites			1	1							1	1	2	2	2	3	13	0.2	0.3	0.3
				0.4	0.3							0.4	0.5	1.1	1.4	2.1	2.0				
LEUKEMIA																					
C42	Hematopoietic and Reticuloendothelial Systems	15	12	4	5	2	10	6	11	7	11	22	39	35	32	29	61	301	4.6	7.6	6.8
		5.4	4.4	1.6	1.7	0.6	2.7	1.9	4.0	2.7	3.9	8.5	17.8	20.1	23.1	30.1	40.0				
SKIN																					
C44	Skin								1	2		2	1	3	1	4	5	19	0.3	0.5	0.4
									0.4	0.8		0.8	0.5	1.7	0.7	4.1	3.3				
PERITONEUM																					
C48	Peritoneum						1				1	1	3	1		1	4	12	0.2	0.3	0.3
							0.3				0.4	0.4	1.4	0.6		1.0	2.6				
OTHER CONNECTIVE & SOFT TISSUE																					
C47	Peripheral Nerves and Autonomic Nervous System	1						1			1			1				4	0.1	0.1	0.1
		0.4						0.3			0.4			0.6							
C49	Connective, Subcutaneous and Other Soft Tissues			1	2	3	1	1	2	1	1	2	3	2	5	3	3	30	0.5	0.8	0.7
				0.4	0.7	0.9	0.3	0.3	0.7	0.4	0.4	0.8	1.4	1.1	3.6	3.1	2.0				
BREAST																					
C50	Breast					4	21	55	107	175	265	310	291	259	207	146	280	2120	32.7	53.4	46.2
						1.2	5.7	17.7	39.0	68.4	93.1	119.6	132.9	148.8	149.6	151.3	183.5				
CERVIX UTERI																					
C53	Cervix Uteri					3	16	31	54	79	65	63	53	59	57	48	82	610	9.4	15.4	13.6
						0.9	4.4	10.0	19.7	30.9	22.8	24.3	24.2	33.9	41.2	49.8	53.7				

FEMALE INCIDENCE, 2009–2014

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
UTERUS																					
C54	Corpus Uteri						3	1	8	17	24	39	72	124	101	67	92	548	8.4	13.8	11.7
							0.8	0.3	2.9	6.6	8.4	15.0	32.9	71.3	73.0	69.4	60.3				
C55	Uterus, Not Otherwise Specified									2	7	6	10	7	7	5	20	64	1.0	1.6	1.3
										0.8	2.5	2.3	4.6	4.0	5.1	5.2	13.1				
OVARY																					
C56	Ovary			3	5	4	11	10	12	23	41	45	59	49	48	42	53	405	6.2	10.2	8.9
				1.2	1.7	1.2	3.0	3.2	4.4	9.0	14.4	17.4	26.9	28.2	34.7	43.5	34.7				
OTHER FEMALE GENITAL ORGANS																					
C51	Vulva								1	1		1	3	2	1	3	3	15	0.2	0.4	0.3
									0.4	0.4		0.4	1.4	1.1	0.7	3.1	2.0				
C52	Vagina	1						1	1	1	3		1	2	8	5	4	27	0.4	0.7	0.6
		0.4						0.3	0.4	0.4	1.1		0.5	1.1	5.8	5.2	2.6				
C57	Other and Unspecified Female Genital Organs		1			1				1	2	2	2	1	1	2	5	18	0.3	0.5	0.4
			0.4			0.3				0.4	0.7	0.8	0.9	0.6	0.7	2.1	3.3				
PLACENTA																					
C58	Placenta				1													1	0.0	0.0	0.0
					0.3																
KIDNEY																					
C64	Kidney	7	5							2	5	6	14	8	9	17	10	83	1.3	2.1	1.9
		2.5	1.9							0.8	1.8	2.3	6.4	4.6	6.5	17.6	6.6				
RENAL PELVIS																					
C66	Ureter												1					1	0.0	0.0	0.0
													0.5								
BLADDER																					
C67	Bladder									3	2	3	6	3	4	7	25	53	0.8	1.3	1.1
										1.2	0.7	1.2	2.7	1.7	2.9	7.3	16.4				
EYE																					
C69	Eye and Adnexa	2												1	1	1		5	0.1	0.1	0.1
		0.7												0.6	0.7	1.0					

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
CNS – CENTRAL NERVOUS SYSTEM																					
C70	Meninges							1										1	0.0	0.0	0.0
								0.3													
C71	Brain	3	3	1	2	4	4	2	10	4	8	7	10	5	9	7	14	93	1.4	2.3	2.1
		1.1	1.1	0.4	0.7	1.2	1.1	0.6	3.6	1.6	2.8	2.7	4.6	2.9	6.5	7.3	9.2				
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	2								1					1	1		5	0.1	0.1	0.1
		0.7								0.4					0.7	1.0					
THYROID																					
C73	Thyroid Gland				2		3	6	6	7	8	10	10	10	7	3	5	77	1.2	1.9	1.7
					0.7		0.8	1.9	2.2	2.7	2.8	3.9	4.6	5.7	5.1	3.1	3.3				
OTHER ENDOCRINE																					
C74	Adrenal Gland					1		1					2				1	5	0.1	0.1	0.1
						0.3		0.3					0.9				0.7				
C75	Other Endocrine Glands and Related Structures					1										1	1	3	0.0	0.1	0.1
						0.3										1.0	0.7				
ILL-DEFINED																					
C76	Other and Ill-Defined Sites	6	1	2		1	1		1	1	3	2	2	5	5	2	9	41	0.6	1.0	1.0
		2.2	0.4	0.8		0.3	0.3		0.4	0.4	1.1	0.8	0.9	2.9	3.6	2.1	5.9				
LYMPHOMA																					
C77	Lymph Nodes		1	1	2	9	10	13	12	8	20	15	15	12	15	14	22	169	2.6	4.3	3.8
			0.4	0.4	0.7	2.6	2.7	4.2	4.4	3.1	7.0	5.8	6.9	6.9	10.8	14.5	14.4				
UNKNOWN																					
C80	Unknown Primary Site			1		2	4	2	5	6	6	15	17	13	15	18	52	156	2.4	3.9	3.3
				0.4		0.6	1.1	0.6	1.8	2.3	2.1	5.8	7.8	7.5	10.8	18.7	34.1				
Total		39	25	16	23	45	100	154	272	390	561	688	789	778	768	604	1,238	6,490	100	163.5	141.7
		14.0	9.3	6.2	7.9	13.2	27.2	49.7	99.2	152.3	197.1	265.4	360.3	447.1	555.2	626.1	811.4				

Table B-3: Cancer Incidence Rates in Females by Age and Site, 2009 to 2014

Cancer Mortality, 2009–2014


ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	LIP									
C00	Lip	1	0.0	0.0	1	0.0	0.0	2	0.0	0.0
	ORAL CAVITY & SALIVARY GLAND									
C01	Base of Tongue	8	0.2	0.2				8	0.1	0.1
C02	Other and Unspecified Parts of the Tongue	34	0.7	0.9	17	0.4	0.4	51	0.6	0.6
C03	Gum	4	0.1	0.1				4	0.0	0.1
C04	Floor of Mouth	4	0.1	0.1				4	0.0	0.1
C05	Palate	4	0.1	0.1	4	0.1	0.1	8	0.1	0.1
C06	Other and Unspecified Parts of the Mouth	10	0.2	0.3	11	0.3	0.3	21	0.2	0.3
C07	Parotid Gland	6	0.1	0.2	3	0.1	0.1	9	0.1	0.1
C08	Other and Unspecified Major Salivary Glands	5	0.1	0.1				5	0.1	0.1
	PHARYNX									
C09	Tonsil	19	0.4	0.5	2	0.0	0.1	21	0.2	0.3
C10	Oropharynx	6	0.1	0.2	1	0.0	0.0	7	0.1	0.1
C11	Nasopharynx	16	0.3	0.4	11	0.3	0.3	27	0.3	0.3
C12	Pyriform Sinus	4	0.1	0.1	1	0.0	0.0	5	0.1	0.1
C13	Hypopharynx	5	0.1	0.1	1	0.0	0.0	6	0.1	0.1
	OTHER PHARYNX									
C14	Other Pharynx	12	0.2	0.3				12	0.1	0.2
	ESOPHAGUS									
C15	Esophagus	87	1.8	2.2	19	0.5	0.5	106	1.2	1.3
	STOMACH									
C16	Stomach	170	3.5	4.3	116	2.8	2.9	286	3.2	3.6
	SMALL INTESTINE									
C17	Small Intestine	7	0.1	0.2	8	0.2	0.2	15	0.2	0.2
	COLON & RECTUM									
C18	Colon	321	6.7	8.0	318	7.6	8.0	639	7.1	8.0
C19	Rectosigmoid Junction	61	1.3	1.5	42	1.0	1.1	103	1.1	1.3
C20	Rectum	110	2.3	2.8	80	1.9	2.0	190	2.1	2.4
C21	Anus and Anal Canal	17	0.4	0.4	12	0.3	0.3	29	0.3	0.4
	LIVER									
C22	Liver	126	2.6	3.2	121	2.9	3.0	247	2.7	3.1
	GALL BLADDER									
C23	Gallbladder	18	0.4	0.5	31	0.7	0.8	49	0.5	0.6
C24	Other and Unspecified Parts of the Biliary Tract	17	0.4	0.4	16	0.4	0.4	33	0.4	0.4
	PANCREAS									
C25	Pancreas	237	4.9	5.9	186	4.4	4.7	423	4.7	5.3
	GASTROINTESTINAL									
C26	Other and Ill-Defined Digestive Organs	25	0.5	0.6	19	0.5	0.5	44	0.5	0.6

ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	NASAL CAVITY									
C31	Accessory Sinuses	19	0.4	0.5	3	0.1	0.1	22	0.2	0.3
	LARYNX									
C32	Larynx	91	1.9	2.3	8	0.2	0.2	99	1.1	1.2
	BRONCHUS & LUNG									
C34	Bronchus and Lung	656	13.7	16.4	216	5.1	5.4	872	9.7	10.9
	OTHER THORACIC ORGANS									
C37	Thymus	7	0.1	0.2	7	0.2	0.2	14	0.2	0.2
C38	Heart, Mediastinum and Pleura	8	0.2	0.2	6	0.1	0.2	14	0.2	0.2
	BONE & ARTICULAR CARTILAGE									
C40	Bones, Joints and Articular Cartilage of Limbs	10	0.2	0.3	5	0.1	0.1	15	0.2	0.2
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	19	0.4	0.5	14	0.3	0.4	33	0.4	0.4
	LEUKEMIA									
C42	Hematopoietic and Reticuloendothelial Systems	275	5.7	6.9	232	5.5	5.8	507	5.6	6.4
	SKIN									
C44	Skin	15	0.3	0.4	11	0.3	0.3	26	0.3	0.3
	PERITONEUM									
C48	Peritoneum	3	0.1	0.1	11	0.3	0.3	14	0.2	0.2
	OTHER CONNECTIVE & SOFT TISSUE									
C47	Peripheral Nerves and Autonomic Nervous System	5	0.1	0.1	4	0.1	0.1	9	0.1	0.1
C49	Connective, Subcutaneous and Other Soft Tissues	26	0.5	0.7	15	0.4	0.4	41	0.5	0.5
	BREAST									
C50	Breast	19	0.4	0.5	992	23.6	25.0	1,011	11.2	12.7
	CERVIX UTERI									
C53	Cervix uteri				409	9.7	10.3	409	4.5	5.1
	UTERUS									
C54	Corpus Uteri				347	8.3	8.7	347	3.9	4.4
C55	Uterus, Not Otherwise Specified				56	1.3	1.4	56	0.6	0.7
	OVARY									
C56	Ovary				301	7.2	7.6	301	3.3	3.8
	OTHER FEMALE GENITAL ORGANS									
C51	Vulva				7	0.2	0.2	7	0.1	0.1
C52	Vagina				18	0.4	0.5	18	0.2	0.2
C57	Other and Unspecified Female Genital Organs				14	0.3	0.4	14	0.2	0.2
	PLACENTA									
C58	Placenta				1	0.0	0.0	1	0.0	0.0
	PENIS									
C60	Penis	16	0.3	0.4				16	0.2	0.2
	PROSTATE									
C61	Prostate	1,625	33.8	40.6				1,625	18.0	20.4

CANCER MORTALITY, 2009–2014

ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	TESTIS									
C62	Testis	15	0.3	0.4				15	0.2	0.2
	OTHER MALE GENITAL ORGANS									
C63	Other and Unspecified Male Genital Organs	1	0.0	0.0				1	0.0	0.0
	KIDNEY									
C64	Kidney	76	1.6	1.9	51	1.2	1.3	127	1.4	1.6
	RENAL PELVIS									
C65	Renal Pelvis	1	0.0	0.0				1	0.0	0.0
C66	Ureter	1	0.0	0.0				1	0.0	0.0
C68	Other and Unspecified Urinary Organs	2	0.0	0.1				2	0.0	0.0
	BLADDER									
C67	Bladder	123	2.6	3.1	41	1.0	1.0	164	1.8	2.1
	EYE									
C69	Eye and Adnexa	5	0.1	0.1	3	0.1	0.1	8	0.1	0.1
	CNS – CENTRAL NERVOUS SYSTEM									
C70	Meninges	2	0.0	0.1				2	0.0	0.0
C71	Brain	88	1.8	2.2	74	1.8	1.9	162	1.8	2.0
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	4	0.1	0.1	3	0.1	0.1	7	0.1	0.1
	THYROID									
C73	Thyroid Gland	14	0.3	0.4	29	0.7	0.7	43	0.5	0.5
	OTHER ENDOCRINE									
C74	Adrenal Gland	4	0.1	0.1	6	0.1	0.2	10	0.1	0.1
C75	Other Endocrine Glands and Related Structures	3	0.1	0.1	3	0.1	0.1	6	0.1	0.1
	ILL-DEFINED									
C76	Other and Ill-Defined Sites	29	0.6	0.7	29	0.7	0.7	58	0.6	0.7
	LYMPHOMA									
C77	Lymph Nodes	147	3.1	3.7	122	2.9	3.1	269	3.0	3.4
	UNKNOWN									
C80	Unknown Primary Site	159	3.3	4.0	147	3.5	3.7	306	3.4	3.8
Total		4,802	100.0	120.1	4,205	100.0	105.9	9,007	100.0	113.0

Table B-4: Cancer Mortality, 2009 to 2014



APPENDIX C

2015–2020

**CANCER IN
TRINIDAD AND TOBAGO**
**2003
–2020**

Appendix C

Summary of Cancer Incidence, 2015–2020

ICD-O-3	Topography Description	Male					Female					Total	
		<i>n</i>	%	CR	ASR	LR	<i>n</i>	%	CR	ASR	LR	<i>n</i>	%
	LIP												
C00	Lip	3	0.0	0.1	0.1	10,762	1	0.0	0.0	0.0	44,739	4	0.0
	ORAL CAVITY & SALIVARY GLAND												
C01	Base of Tongue	9	0.1	0.2	0.2	4,047						9	0.1
C02	Other and Unspecified Parts of the Tongue	45	0.5	1.1	1.0	879	33	0.4	0.8	0.7	1,252	78	0.4
C03	Gum	5	0.1	0.1	0.1	8,693	5	0.1	0.1	0.1	9,642	10	0.1
C04	Floor of Mouth	9	0.1	0.2	0.2	6,818	3	0.0	0.1	0.1	24,869	12	0.1
C05	Palate	14	0.2	0.3	0.3	2,267	4	0.0	0.1	0.1	8,754	18	0.1
C06	Other and Unspecified Parts of the Mouth	22	0.3	0.5	0.5	1,899	17	0.2	0.4	0.4	3,199	39	0.2
C07	Parotid Gland	18	0.2	0.4	0.4	2,440	12	0.1	0.3	0.3	3,997	30	0.2
C08	Other and Unspecified Major Salivary Glands	18	0.2	0.4	0.4	2,645	9	0.1	0.2	0.2	5,226	27	0.2
	PHARYNX												
C09	Tonsil	39	0.5	1.0	0.9	925	8	0.1	0.2	0.2	5,126	47	0.3
C10	Oropharynx	12	0.1	0.3	0.3	2,577						12	0.1
C11	Nasopharynx	27	0.3	0.7	0.6	1,388	17	0.2	0.4	0.4	2,426	44	0.3
C12	Pyriform Sinus	3	0.0	0.1	0.1	6,553	2	0.0	0.0	0.0	21,273	5	0.0
C13	Hypopharynx	13	0.2	0.3	0.3	3,376	3	0.0	0.1	0.1	18,513	16	0.1
	OTHER PHARYNX												
C14	Other Pharynx	19	0.2	0.5	0.4	2,285	3	0.0	0.1	0.1	28,263	22	0.1
	ESOPHAGUS												
C15	Esophagus	138	1.7	3.4	3.1	267	29	0.3	0.7	0.6	1,438	167	1.0
	STOMACH												
C16	Stomach	214	2.6	5.2	5.0	197	158	1.7	3.9	3.3	348	372	2.1
	SMALL INTESTINE												
C17	Small Intestine	38	0.5	0.9	0.8	1,008	33	0.4	0.8	0.7	1,516	71	0.4
	COLON & RECTUM												
C18	Colon	645	7.7	15.8	15.0	63	666	7.2	16.4	14.0	69	1,311	7.5
C19	Rectosigmoid Junction	120	1.4	2.9	2.8	348	87	0.9	2.1	1.8	579	207	1.2
C20	Rectum	271	3.2	6.6	6.2	142	152	1.7	3.7	3.2	284	423	2.4
C21	Anus and Anal Canal	24	0.3	0.6	0.5	1,770	32	0.3	0.8	0.7	1,383	56	0.3
	LIVER												
C22	Liver	126	1.5	3.1	2.9	327	62	0.7	1.5	1.3	800	188	1.1
	GALL BLADDER												
C23	Gallbladder	17	0.2	0.4	0.4	2,536	50	0.5	1.2	1.0	1,069	67	0.4
C24	Other and Unspecified Parts of the Biliary Tract	42	0.5	1.0	1.0	1,077	61	0.7	1.5	1.3	635	103	0.6
	PANCREAS												
C25	Pancreas	323	3.9	7.9	7.6	126	255	2.8	6.3	5.3	198	578	3.3

ICD-O-3	Topography Description	Male					Female					Total	
		n	%	CR	ASR	LR	n	%	CR	ASR	LR	n	%
	GASTROINTESTINAL												
C26	Other and Ill-Defined Digestive Organs	13	0.2	0.3	0.3	3,119	14	0.2	0.3	0.3	2,791	27	0.2
	NASAL CAVITY												
C30	Nasal Cavity and Middle Ear	3	0.0	0.1	0.1	12,559	5	0.1	0.1	0.1	10,671	8	0.0
C31	Accessory Sinuses	15	0.2	0.4	0.3	2,326	12	0.1	0.3	0.3	4,056	27	0.2
	LARYNX												
C32	Larynx	173	2.1	4.2	3.9	222	14	0.2	0.3	0.3	2,777	187	1.1
	BRONCHUS & LUNG												
C34	Bronchus and Lung	930	11.2	22.8	21.3	40	351	3.8	8.7	7.4	131	1,281	7.3
	OTHER THORACIC ORGANS												
C37	Thymus	14	0.2	0.3	0.3	3,665	27	0.3	0.7	0.6	1,671	41	0.2
C38	Heart, Mediastinum and Pleura	19	0.2	0.5	0.5	3,025	17	0.2	0.4	0.4	2,927	36	0.2
	BONE & ARTICULAR CARTILAGE												
C40	Bones, Joints and Articular Cartilage of Limbs	18	0.2	0.4	0.4	3,186	15	0.2	0.4	0.4	3,622	33	0.2
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	24	0.3	0.6	0.6	1,941	31	0.3	0.8	0.7	1,804	55	0.3
	LEUKEMIA												
C42	Hematopoietic and Reticuloendothelial Systems	532	6.4	13.0	12.6	78	464	5.0	11.4	10.1	95	996	5.7
	SKIN												
C44	Skin	39	0.5	1.0	0.9	1,220	28	0.3	0.7	0.6	2,045	67	0.4
	PERITONEUM												
C48	Peritoneum	8	0.1	0.2	0.2	8,888	17	0.2	0.4	0.4	2,277	25	0.1
	OTHER CONNECTIVE & SOFT TISSUE												
C47	Peripheral Nerves and Autonomic Nervous System	1	0.0	0.0	0.0	36,341	4	0.0	0.1	0.1	11,888	5	0.0
C49	Connective, Subcutaneous and Other Soft Tissues	38	0.5	0.9	0.9	1,418	41	0.4	1.0	0.9	1,333	79	0.5
	BREAST												
C50	Breast	47	0.6	1.2	1.0	898	3,048	33.1	75.2	65.0	15	3,095	17.6
	CERVIX UTERI												
C53	Cervix uteri						706	7.7	17.4	15.4	65	706	4.0
	UTERUS												
C54	Corpus Uteri						1,096	11.9	27.0	23.1	36	1,096	6.2
C55	Uterus, Not Otherwise Specified						54	0.6	1.3	1.1	840	54	0.3
	OVARY												
C56	Ovary						547	5.9	13.5	11.5	81	547	3.1
	OTHER FEMALE GENITAL ORGANS												
C51	Vulva						25	0.3	0.6	0.5	1,841	25	0.1
C52	Vagina						28	0.3	0.7	0.6	1,664	28	0.2
C57	Other and Unspecified Female Genital Organs						29	0.3	0.7	0.6	1,268	29	0.2
	PLACENTA												
C58	Placenta						1	0.0	0.0	0.0	55,994	1	0.0
	PENIS												
C60	Penis	40	0.5	1.0	0.9	971						40	0.2

CANCER INCIDENCE, 2015–2020

ICD-O-3	Topography Description	Male					Female					Total	
		n	%	CR	ASR	LR	n	%	CR	ASR	LR	n	%
	PROSTATE												
C61	Prostate	3,072	36.8	75.2	74.1	14						3,072	17.5
	TESTIS												
C62	Testis	43	0.5	1.1	1.0	1,349						43	0.2
	OTHER MALE GENITAL ORGANS												
C63	Other and Unspecified Male Genital Organs	5	0.1	0.1	0.1	14,422						5	0.0
	KIDNEY												
C64	Kidney	141	1.7	3.5	3.3	294	86	0.9	2.1	1.9	583	227	1.3
	RENAL PELVIS												
C66	Ureter	2	0.0	0.0	0.0	10,504						2	0.0
C68	Other and Unspecified Urinary Organs	1	0.0	0.0	0.0							1	0.0
	BLADDER												
C67	Bladder	226	2.7	5.5	5.3	190	88	1.0	2.2	1.8	661	314	1.8
	EYE												
C69	Eye and Adnexa	9	0.1	0.2	0.2	4,439	12	0.1	0.3	0.3	3,428	21	0.1
	CNS – CENTRAL NERVOUS SYSTEM												
C70	Meninges	5	0.1	0.1	0.1	8,517	11	0.1	0.3	0.2	4,555	16	0.1
C71	Brain	141	1.7	3.5	3.3	306	96	1.0	2.4	2.1	441	237	1.4
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	3	0.0	0.1	0.1	19,148	7	0.1	0.2	0.2	7,007	10	0.1
	THYROID												
C73	Thyroid Gland	49	0.6	1.2	1.1	1,017	146	1.6	3.6	3.1	321	195	1.1
	OTHER ENDOCRINE												
C74	Adrenal Gland	6	0.1	0.1	0.1	6,430	3	0.0	0.1	0.1	10,231	9	0.1
C75	Other Endocrine Glands and Related Structures	2	0.0	0.0	0.0	11,775	3	0.0	0.1	0.1	16,570	5	0.0
	ILL-DEFINED												
C76	Other and Ill-Defined Sites	45	0.5	1.1	1.0	686	53	0.6	1.3	1.1	872	98	0.6
	LYMPHOMA												
C77	Lymph Nodes	214	2.6	5.2	4.9	206	174	1.9	4.3	3.9	288	388	2.2
	UNKNOWN												
C80	Unknown Primary Site	248	3.0	6.1	5.8	167	246	2.7	6.1	5.1	232	494	2.8
Total		8,340	100.0	204.2	196.2		9,201	100.0	226.9	196.0		17,541	100.0

Table C-1: Summary of Cancer Incidence, 2015 to 2020

Cancer Incidence Rates by Age, Sex, and Site, 2015–2020

CANCER INCIDENCE RATES IN MALES BY AGE AND SITE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
LIP																					
C00	Lip									1	1					1		3	0.0	0.1	0.1
										0.4	0.3					1.1					
ORAL CAVITY & SALIVARY GLAND																					
C01	Base of Tongue											2			1	3	3	9	0.1	0.2	0.2
												0.7			0.8	3.4	2.6				
C02	Other and Unspecified Parts of the Tongue							1	2	1	3	4	9	7	4	7	7	45	0.5	1.1	1.0
								0.3	0.7	0.4	1.0	1.5	4.0	3.9	3.0	8.0	6.1				
C03	Gum												1	2	1		1	5	0.1	0.1	0.1
													0.4	1.1	0.8		0.9				
C04	Floor of Mouth										1	2		2	1		3	9	0.1	0.2	0.2
											0.3	0.7		1.1	0.8		2.6				
C05	Palate	1									1		3	2	3	3	1	14	0.2	0.3	0.3
		0.3									0.3		1.3	1.1	2.3	3.4	0.9				
C06	Other and Unspecified Parts of the Mouth										2	3	1	4	2	4	6	22	0.3	0.5	0.5
											0.7	1.1	0.4	2.2	1.5	4.6	5.2				
C07	Parotid Gland							2	1			2	1	2	2	3	5	18	0.2	0.4	0.4
								0.6	0.3			0.7	0.4	1.1	1.5	3.4	4.4				
C08	Other and Unspecified Major Salivary Glands	1	1			1				1	1	1	3		4	1	4	18	0.2	0.4	0.4
		0.3	0.4			0.3				0.4	0.3	0.4	1.3		3.0	1.1	3.5				
PHARYNX																					
C09	Tonsil									1	3	3	6	5	6	8	7	39	0.5	1.0	0.9
										0.4	1.0	1.1	2.7	2.8	4.5	9.2	6.1				
C10	Oropharynx											1	3	2	2	3	1	12	0.1	0.3	0.3
												0.4	1.3	1.1	1.5	3.4	0.9				

MALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C11	Nasopharynx				1	1		2		2	1	4	6	2	3	4	1	27	0.3	0.7	0.6
					0.3	0.3		0.6		0.8	0.3	1.5	2.7	1.1	2.3	4.6	0.9				
C12	Pyriform Sinus														1	2		3	0.0	0.1	0.1
															0.8	2.3					
C13	Hypopharynx										1	1	2	1	5		3	13	0.2	0.3	0.3
											0.3	0.4	0.9	0.6	3.8		2.6				
OTHER PHARYNX																					
C14	Other Pharynx											1	4	3	2	3	6	19	0.2	0.5	0.4
												0.4	1.8	1.7	1.5	3.4	5.2				
ESOPHAGUS																					
C15	Esophagus							2	1	1	5	16	19	25	26	21	22	138	1.7	3.4	3.1
								0.6	0.3	0.4	1.7	5.9	8.4	13.8	19.7	24.1	19.2				
STOMACH																					
C16	Stomach					1	1	2	4	7	8	15	26	40	21	34	55	214	2.6	5.2	5.0
						0.3	0.3	0.6	1.4	2.6	2.7	5.6	11.6	22.0	15.9	39.0	48.1				
SMALL INTESTINE																					
C17	Small Intestine					2		1	2	1	2	7	7	3	7	4	2	38	0.5	0.9	0.8
						0.6		0.3	0.7	0.4	0.7	2.6	3.1	1.7	5.3	4.6	1.7				
COLON & RECTUM																					
C18	Colon					1	5	11	7	19	24	47	61	112	78	115	165	645	7.7	15.8	15.0
						0.3	1.3	3.3	2.4	7.1	8.0	17.4	27.1	61.6	59.0	132.0	144.2				
C19	Rectosigmoid Junction							3	2	2	6	9	13	20	18	17	30	120	1.4	2.9	2.8
								0.9	0.7	0.8	2.0	3.3	5.8	11.0	13.6	19.5	26.2				
C20	Rectum					1	2	2	10	8	10	20	43	52	38	40	45	271	3.2	6.6	6.2
						0.3	0.5	0.6	3.5	3.0	3.4	7.4	19.1	28.6	28.7	45.9	39.3				
C21	Anus and Anal Canal							1		3	3	3	3	2	4	2	3	24	0.3	0.6	0.5
								0.3		1.1	1.0	1.1	1.3	1.1	3.0	2.3	2.6				
LIVER																					
C22	Liver		1					1	4	7	3	15	15	20	20	15	25	126	1.5	3.1	2.9
			0.4					0.3	1.4	2.6	1.0	5.6	6.7	11.0	15.1	17.2	21.8				

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
GALL BLADDER																					
C23	Gallbladder												2	3	1	4	7	17	0.2	0.4	0.4
													0.9	1.7	0.8	4.6	6.1				
C24	Other and Unspecified Parts of the Biliary Tract										1	5	2	4	10	5	15	42	0.5	1.0	1.0
											0.3	1.9	0.9	2.2	7.6	5.7	13.1				
PANCREAS																					
C25	Pancreas							1	4	8	8	20	33	49	62	49	89	323	3.9	7.9	7.6
								0.3	1.4	3.0	2.7	7.4	14.7	27.0	46.9	56.3	77.8				
GASTROINTESTINAL																					
C26	Other and Ill-Defined Digestive Organs						1			1		1	2	2	3	1	2	13	0.2	0.3	0.3
							0.3			0.4		0.4	0.9	1.1	2.3	1.1	1.7				
NASAL CAVITY																					
C30	Nasal Cavity and Middle Ear												1			1	1	3	0.0	0.1	0.1
													0.4			1.1	0.9				
C31	Accessory Sinuses								1			5	2	1	2	3	1	15	0.2	0.4	0.3
									0.3			1.9	0.9	0.6	1.5	3.4	0.9				
LARYNX																					
C32	Larynx								1	4	4	11	30	32	37	21	33	173	2.1	4.2	3.9
									0.3	1.5	1.3	4.1	13.3	17.6	28.0	24.1	28.8				
BRONCHUS & LUNG																					
C34	Bronchus and Lung		1		1		2	6	7	9	24	66	124	189	161	164	176	930	11.2	22.8	21.3
			0.4		0.3		0.5	1.8	2.4	3.4	8.0	24.5	55.1	104.0	121.7	188.3	153.8				
OTHER THORACIC ORGANS																					
C37	Thymus				1	1			1	1	3	1	2	2	1		1	14	0.2	0.3	0.3
					0.3	0.3			0.3	0.4	1.0	0.4	0.9	1.1	0.8		0.9				
C38	Heart, Mediastinum and Pleura			1	2	2		1	2	3	1	1	2	1	1		2	19	0.2	0.5	0.5
				0.4	0.7	0.6		0.3	0.7	1.1	0.3	0.4	0.9	0.6	0.8		1.7				

MALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
BONE & ARTICULAR CARTILAGE																					
C40	Bones, Joints and Articular Cartilage of Limbs		2	1	3	2	2	1	1	1	2		2	1				18	0.2	0.4	0.4
			0.7	0.4	1.0	0.6	0.5	0.3	0.3	0.4	0.7		0.9	0.6							
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	1			1		1	1	1	1	1		1	2	4	3	7	24	0.3	0.6	0.6
		0.3			0.3		0.3	0.3	0.3	0.4	0.3		0.4	1.1	3.0	3.4	6.1				
LEUKEMIA																					
C42	Hematopoietic and Reticuloendothelial Systems	10	11	4	7	9	11	9	19	18	20	31	55	72	64	83	109	532	6.4	13.0	12.6
		3.4	3.9	1.5	2.3	2.6	2.9	2.7	6.6	6.8	6.7	11.5	24.4	39.6	48.4	95.3	95.3				
SKIN																					
C44	Skin				1				4	1	3	1	7	4	4	4	10	39	0.5	1.0	0.9
					0.3				1.4	0.4	1.0	0.4	3.1	2.2	3.0	4.6	8.7				
PERITONEUM																					
C48	Peritoneum	2		1		1						1		1			2	8	0.1	0.2	0.2
		0.7		0.4		0.3						0.4		0.6			1.7				
OTHER CONNECTIVE & SOFT TISSUE																					
C47	Peripheral Nerves and Autonomic Nervous System													1				1	0.0	0.0	0.0
														0.6							
C49	Connective, Subcutaneous and Other Soft Tissues	2		1	3	2	3	2	2	2	3	1	3	6	2	1	5	38	0.5	0.9	0.9
		0.7		0.4	1.0	0.6	0.8	0.6	0.7	0.8	1.0	0.4	1.3	3.3	1.5	1.1	4.4				
BREAST																					
C50	Breast								2	2	1	2	4	5	8	8	15	47	0.6	1.2	1.1
									0.7	0.8	0.3	0.7	1.8	2.8	6.0	9.2	13.1				
PENIS																					
C60	Penis								1	1	1	5	5	6	7	6	8	40	0.5	1.0	0.9
									0.3	0.4	0.3	1.9	2.2	3.3	5.3	6.9	7.0				

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
PROSTATE																					
C61	Prostate		1					2	1	5	18	71	211	435	570	605	1153	3072	36.8	75.2	74.1
			0.4					0.6	0.3	1.9	6.0	26.3	93.8	239.4	430.9	694.7	1007.6				
TESTIS																					
C62	Testis				2	6	4	10	8	1	1	3	3	1	1	1	2	43	0.5	1.1	1.0
					0.7	1.7	1.0	3.0	2.8	0.4	0.3	1.1	1.3	0.6	0.8	1.1	1.7				
OTHER MALE GENITAL ORGANS																					
C63	Other and Unspecified Male Genital Organs				1			1							1		2	5	0.1	0.1	0.1
					0.3			0.3							0.8		1.7				
KIDNEY																					
C64	Kidney	5	1			1	1	2	1	4	10	10	17	17	29	15	28	141	1.7	3.5	3.3
		1.7	0.4			0.3	0.3	0.6	0.3	1.5	3.4	3.7	7.6	9.4	21.9	17.2	24.5				
RENAL PELVIS																					
C66	Ureter														1	1		2	0.0	0.0	0.0
															0.8	1.1					
C68	Other and Unspecified Urinary Organs																1	1	0.0	0.0	0.0
																	0.9				
BLADDER																					
C67	Bladder	1							3	6	3	15	21	42	39	29	67	226	2.7	5.5	5.3
		0.3							1.0	2.3	1.0	5.6	9.3	23.1	29.5	33.3	58.6				
EYE																					
C69	Eye and Adnexa	3										2	1			2	1	9	0.1	0.2	0.2
		1.0										0.7	0.4			2.3	0.9				
CNS – CENTRAL NERVOUS SYSTEM																					
C70	Meninges												1		1	1	2	5	0.1	0.1	0.1
													0.4		0.8	1.1	1.7				
C71	Brain	6	6	3	1	4	4	6	6	10	10	17	10	22	18	9	9	141	1.7	3.5	3.3
		2.0	2.1	1.1	0.3	1.1	1.0	1.8	2.1	3.8	3.4	6.3	4.4	12.1	13.6	10.3	7.9				

MALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	1	2															3	0.0	0.1	0.1
		0.3	0.7																		
THYROID																					
C73	Thyroid Gland				1		1	3	3	2	7	3	8	8	2	3	8	49	0.6	1.2	1.1
					0.3		0.3	0.9	1.0	0.8	2.3	1.1	3.6	4.4	1.5	3.4	7.0				
OTHER ENDOCRINE																					
C74	Adrenal Gland										2	2		1		1		6	0.1	0.1	0.1
											0.7	0.7		0.6		1.1					
C75	Other Endocrine Glands and Related Structures													1		1		2	0.0	0.0	0.0
														0.6		1.1					
ILL-DEFINED																					
C76	Other and Ill-Defined Sites			1				1		3	2	4	1	9	8	12	4	45	0.5	1.1	1.0
				0.4				0.3		1.1	0.7	1.5	0.4	5.0	6.0	13.8	3.5				
LYMPHOMA																					
C77	Lymph Nodes	2	2	3	7	8	10	5	9	9	12	19	27	27	20	23	31	214	2.6	5.2	4.9
		0.7	0.7	1.1	2.3	2.3	2.6	1.5	3.1	3.4	4.0	7.0	12.0	14.9	15.1	26.4	27.1				
UNKNOWN																					
C80	Unknown Primary Site						2	1	6	7	6	14	26	36	52	32	66	248	3.0	6.1	5.8
							0.5	0.3	2.1	2.6	2.0	5.2	11.6	19.8	39.3	36.7	57.7				
Total		35	28	15	32	43	50	80	116	153	218	467	829	1,286	1,358	1,378	2,252	8,340	100.0	204.2	196.2
		11.9	9.8	5.4	10.5	12.2	13.1	24.2	40.4	57.4	73.1	173.2	368.3	707.7	1,026.5	1,582.3	1,968.0				

Table C-2: Cancer Incidence Rates in Males by Age and Site, 2015 to 2020

CANCER INCIDENCE RATES IN FEMALES BY AGE AND SITE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
LIP																					
C00	Lip												1					1	0.0	0.0	0.0
													0.4								
ORAL CAVITY & SALIVARY GLAND																					
C02	Other and Unspecified Parts of the Tongue						2	1	1	1	2	4	7	3	9	1	2	33	0.4	0.8	0.7
							0.5	0.3	0.4	0.4	0.7	1.5	3.1	1.7	6.4	1.0	1.3				
C03	Gum								1				1	1	1		1	5	0.1	0.1	0.1
									0.4				0.4	0.6	0.7		0.6				
C04	Floor of Mouth								1				1				1	3	0.0	0.1	0.1
									0.4				0.4				0.6				
C05	Palate													1	1	1	1	4	0.0	0.1	0.1
														0.6	0.7	1.0	0.6				
C06	Other and Unspecified Parts of the Mouth				1				1		2		1	3	1	2	6	17	0.2	0.4	0.4
					0.3				0.4		0.7		0.4	1.7	0.7	2.0	3.8				
C07	Parotid Gland								1	1		1	2	1	2	1	3	12	0.1	0.3	0.3
									0.4	0.4		0.4	0.9	0.6	1.4	1.0	1.9				
C08	Other and Unspecified Major Salivary Glands										1	3	4	1				9	0.1	0.2	0.2
											0.3	1.1	1.8	0.6							
PHARYNX																					
C09	Tonsil						1				2	1	1		3			8	0.1	0.2	0.2
							0.3				0.7	0.4	0.4		2.1						
C11	Nasopharynx				1	1	1			4	2	1	1	1	1	3	1	17	0.2	0.4	0.4
					0.3	0.3	0.3			1.5	0.7	0.4	0.4	0.6	0.7	3.0	0.6				
C12	Pyriform Sinus											1		1				2	0.0	0.0	0.0
												0.4		0.6							
C13	Hypopharynx							1		2								3	0.0	0.1	0.1
								0.3		0.8											

FEMALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
OTHER PHARYNX																					
C14	Other Pharynx														1		2	3	0.0	0.1	0.1
															0.7		1.3				
ESOPHAGUS																					
C15	Esophagus							1		1	1	3	3	3	8	3	6	29	0.3	0.7	0.6
								0.3		0.4	0.3	1.1	1.3	1.7	5.7	3.0	3.8				
STOMACH																					
C16	Stomach							3	2	5	2	12	21	18	14	19	62	158	1.7	3.9	3.3
								0.9	0.7	1.9	0.7	4.5	9.4	10.1	9.9	19.3	39.8				
SMALL INTESTINE																					
C17	Small Intestine								1	4	4	5	4	5	2	2	6	33	0.4	0.8	0.7
									0.4	1.5	1.4	1.9	1.8	2.8	1.4	2.0	3.8				
COLON & RECTUM																					
C18	Colon				1		6	10	18	23	32	48	86	112	71	90	169	666	7.2	16.4	14.0
					0.3		1.6	3.2	6.4	8.8	11.0	18.1	38.4	63.0	50.2	91.3	108.4				
C19	Rectosigmoid Junction								1	3	2	7	9	12	11	11	31	87	0.9	2.1	1.8
									0.4	1.1	0.7	2.6	4.0	6.8	7.8	11.2	19.9				
C20	Rectum						1	2	6	7	5	8	16	23	25	22	37	152	1.7	3.7	3.2
							0.3	0.6	2.1	2.7	1.7	3.0	7.2	12.9	17.7	22.3	23.7				
C21	Anus and Anal Canal							1			2	6	1	2	5	6	9	32	0.3	0.8	0.7
								0.3			0.7	2.3	0.4	1.1	3.5	6.1	5.8				
LIVER																					
C22	Liver				1			2		2	3	2	2	6	10	10	24	62	0.7	1.5	1.3
					0.3			0.6		0.8	1.0	0.8	0.9	3.4	7.1	10.1	15.4				
GALL BLADDER																					
C23	Gallbladder											3	5	10	8	4	20	50	0.5	1.2	1.0
												1.1	2.2	5.6	5.7	4.1	12.8				
C24	Other and Unspecified Parts of the Biliary Tract							1	1	1	2	6	10	8	9	12	11	61	0.7	1.5	1.3
								0.3	0.4	0.4	0.7	2.3	4.5	4.5	6.4	12.2	7.1				

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
PANCREAS																					
C25	Pancreas							2	2	1	6	14	19	28	30	46	107	255	2.8	6.3	5.3
								0.6	0.7	0.4	2.1	5.3	8.5	15.8	21.2	46.7	68.7				
GASTROINTESTINAL																					
C26	Other and Ill-Defined Digestive Organs								1				4	1	2	3	3	14	0.2	0.3	0.3
									0.4				1.8	0.6	1.4	3.0	1.9				
NASAL CAVITY																					
C30	Nasal Cavity and Middle Ear				1				2			1	1					5	0.1	0.1	0.1
					0.3				0.7			0.4	0.4								
C31	Accessory Sinuses				1			1		1		1		5	1		2	12	0.1	0.3	0.3
					0.3			0.3		0.4		0.4		2.8	0.7		1.3				
LARYNX																					
C32	Larynx											2	1	4	1	3	3	14	0.2	0.3	0.3
												0.8	0.4	2.3	0.7	3.0	1.9				
BRONCHUS & LUNG																					
C34	Bronchus and Lung		1					4	5	13	21	18	36	55	54	45	99	351	3.8	8.7	7.4
			0.4					1.3	1.8	5.0	7.2	6.8	16.1	30.9	38.2	45.7	63.5				
OTHER THORACIC ORGANS																					
C37	Thymus				1	1	1	1	2	4	3	2	1	2	3	3	3	27	0.3	0.7	0.6
					0.3	0.3	0.3	0.3	0.7	1.5	1.0	0.8	0.4	1.1	2.1	3.0	1.9				
C38	Heart, Mediastinum and Pleura		1		2	4	2	1	1	1			3		1	1		17	0.2	0.4	0.4
			0.4		0.7	1.1	0.5	0.3	0.4	0.4			1.3		0.7	1.0					
BONE & ARTICULAR CARTILAGE																					
C40	Bones, Joints and Articular Cartilage of Limbs			4	3	1					2		1	1		1	2	15	0.2	0.4	0.4
				1.5	1.0	0.3					0.7		0.4	0.6		1.0	1.3				

FEMALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites			1			1	1	3	1	3	2	4	6	1	1	7	31	0.3	0.8	0.7
				0.4			0.3	0.3	1.1	0.4	1.0	0.8	1.8	3.4	0.7	1.0	4.5				
LEUKEMIA																					
C42	Hematopoietic and Reticuloendothelial Systems	8	5	4	5	3	11	15	18	19	18	27	47	48	68	68	100	464	5.0	11.4	10.1
		2.8	1.8	1.5	1.7	0.9	2.9	4.7	6.4	7.3	6.2	10.2	21.0	27.0	48.1	69.0	64.2				
SKIN																					
C44	Skin	1				1		1	2		4	3	3	2	3	1	7	28	0.3	0.7	0.6
		0.4				0.3		0.3	0.7		1.4	1.1	1.3	1.1	2.1	1.0	4.5				
PERITONEUM																					
C48	Peritoneum					2				2		2		2	5	2	2	17	0.2	0.4	0.4
						0.6				0.8		0.8		1.1	3.5	2.0	1.3				
OTHER CONNECTIVE & SOFT TISSUE																					
C47	Peripheral Nerves and Autonomic Nervous System							1	1				1	1				4	0.0	0.1	0.1
								0.3	0.4				0.4	0.6							
C49	Connective, Subcutaneous and Other Soft Tissues		1	1	3	1	3	3	2	3		7	3	4	3	1	6	41	0.4	1.0	0.9
			0.4	0.4	1.0	0.3	0.8	0.9	0.7	1.1		2.6	1.3	2.3	2.1	1.0	3.8				
BREAST																					
C50	Breast				2	8	31	85	158	207	296	360	422	366	344	302	467	3048	33.1	75.2	65.0
					0.7	2.3	8.3	26.8	56.4	79.1	101.8	135.9	188.7	205.9	243.4	306.4	299.6				
CERVIX UTERI																					
C53	Cervix Uteri				1	3	9	38	67	82	67	80	80	62	75	60	82	706	7.7	17.4	15.4
					0.3	0.9	2.4	12.0	23.9	31.4	23.0	30.2	35.8	34.9	53.1	60.9	52.6				
UTERUS																					
C54	Corpus Uteri						2	9	24	26	41	77	143	224	214	157	179	1096	11.9	27.0	23.1
							0.5	2.8	8.6	9.9	14.1	29.1	63.9	126.0	151.4	159.3	114.8				

FEMALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C55	Uterus, Not Otherwise Specified							1	1		1	4	6	5	8	10	18	54	0.6	1.3	1.1
								0.3	0.4		0.3	1.5	2.7	2.8	5.7	10.1	11.5				
OVARY																					
C56	Ovary		1		2	5	4	9	14	24	30	68	80	83	79	54	94	547	5.9	13.5	11.5
			0.4		0.7	1.4	1.1	2.8	5.0	9.2	10.3	25.7	35.8	46.7	55.9	54.8	60.3				
OTHER FEMALE GENITAL ORGANS																					
C51	Vulva								1	2	1	2	3	2	3	4	7	25	0.3	0.6	0.5
									0.4	0.8	0.3	0.8	1.3	1.1	2.1	4.1	4.5				
C52	Vagina								2	2	3	3	5	3	2	3	5	28	0.3	0.7	0.6
									0.7	0.8	1.0	1.1	2.2	1.7	1.4	3.0	3.2				
C57	Other and Unspecified Female Genital Organs											4	3	1	6	8	7	29	0.3	0.7	0.6
												1.5	1.3	0.6	4.2	8.1	4.5				
PLACENTA																					
C58	Placenta								1									1	0.0	0.0	0.0
									0.4												
KIDNEY																					
C64	Kidney	6	2	1		1	1	2	3	3	4	6	9	9	4	12	23	86	0.9	2.1	1.9
		2.1	0.7	0.4		0.3	0.3	0.6	1.1	1.1	1.4	2.3	4.0	5.1	2.8	12.2	14.8				
BLADDER																					
C67	Bladder		1				1	1	1	2	2	6	6	7	12	10	39	88	1.0	2.2	1.8
			0.4				0.3	0.3	0.4	0.8	0.7	2.3	2.7	3.9	8.5	10.1	25.0				
EYE																					
C69	Eye and Adnexa	6								1	1			1	2	1		12	0.1	0.3	0.3
		2.1								0.4	0.3			0.6	1.4	1.0					
CNS – CENTRAL NERVOUS SYSTEM																					
C70	Meninges									1		1	2		1	2	4	11	0.1	0.3	0.2
										0.4		0.4	0.9		0.7	2.0	2.6				
C71	Brain	3	4	2	1		4	2	3	2	5	7	9	11	12	15	16	96	1.0	2.4	2.1
		1.1	1.5	0.8	0.3		1.1	0.6	1.1	0.8	1.7	2.6	4.0	6.2	8.5	15.2	10.3				

FEMALE INCIDENCE, 2015–2020

ICD-O-3 Code	Topography Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	n	%	CR	ASR World
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	2	1						1		1	1			1			7	0.1	0.2	0.2
		0.7	0.4						0.4		0.3	0.4			0.7						
THYROID																					
C73	Thyroid Gland					5	7	7	8	8	20	18	16	15	12	13	17	146	1.6	3.6	3.1
						1.4	1.9	2.2	2.9	3.1	6.9	6.8	7.2	8.4	8.5	13.2	10.9				
OTHER ENDOCRINE																					
C74	Adrenal Gland											1		1		1		3	0.0	0.1	0.1
												0.4		0.6		1.0					
C75	Other Endocrine Glands and Related Structures									1		1	1					3	0.0	0.1	0.1
										0.4		0.4	0.4								
ILL-DEFINED																					
C76	Other and Ill-Defined Sites	2					1	2		3	3	5	3	8	9	5	12	53	0.6	1.3	1.1
		0.7					0.3	0.6		1.1	1.0	1.9	1.3	4.5	6.4	5.1	7.7				
LYMPHOMA																					
C77	Lymph Nodes		1	1	6	6	9	11	16	17	11	17	13	18	11	13	24	174	1.9	4.3	3.9
			0.4	0.4	2.0	1.7	2.4	3.5	5.7	6.5	3.8	6.4	5.8	10.1	7.8	13.2	15.4				
UNKNOWN																					
C80	Unknown Primary Site				2	1	2	2	11	4	10	17	23	23	23	29	99	246	2.7	6.1	5.1
					0.7	0.3	0.5	0.6	3.9	1.5	3.4	6.4	10.3	12.9	16.3	29.4	63.5				
Total		28	18	14	34	43	100	221	384	484	615	868	1,124	1,209	1,172	1,061	1,826	9,201	100	226.9	196.0
		9.9	6.5	5.3	11.4	12.3	26.6	69.8	137.2	185.1	211.6	327.8	502.5	680.1	829.4	1076.6	1171.5				

Table C-3: Cancer Incidence Rates in Females by Age and Site, 2015 to 2020

Cancer Mortality, 2015–2020

ICD-O-3 Code	Topography Description	Male			Female			Total		
		n	%	MR	n	%	MR	n	%	MR
	LIP									
C00	Lip	2	0.0	0.0				2	0.0	0.0
	ORAL CAVITY & SALIVARY GLAND									
C01	Base of Tongue	6	0.1	0.1				6	0.1	0.1
C02	Other and Unspecified Parts of the Tongue	30	0.5	0.7	17	0.3	0.4	47	0.4	0.6
C03	Gum	2	0.0	0.0	4	0.1	0.1	6	0.1	0.1
C04	Floor of Mouth	6	0.1	0.1	1	0.0	0.0	7	0.1	0.1
C05	Palate	9	0.1	0.2	4	0.1	0.1	13	0.1	0.2
C06	Other and Unspecified Parts of the Mouth	19	0.3	0.5	14	0.3	0.3	33	0.3	0.4
C07	Parotid Gland	12	0.2	0.3	9	0.2	0.2	21	0.2	0.3
C08	Other and Unspecified Major Salivary Glands	14	0.2	0.3	3	0.1	0.1	17	0.1	0.2
	PHARYNX									
C09	Tonsil	20	0.3	0.5	3	0.1	0.1	23	0.2	0.3
C10	Oropharynx	8	0.1	0.2				8	0.1	0.1
C11	Nasopharynx	24	0.4	0.6	8	0.1	0.2	32	0.3	0.4
C12	Pyriform Sinus	3	0.0	0.1	1	0.0	0.0	4	0.0	0.0
C13	Hypopharynx	10	0.2	0.2	3	0.1	0.1	13	0.1	0.2
	OTHER PHARYNX									
C14	Other Pharynx	16	0.3	0.4	3	0.1	0.1	19	0.2	0.2
	ESOPHAGUS									
C15	Esophagus	113	1.9	2.8	26	0.5	0.6	139	1.2	1.7
	STOMACH									
C16	Stomach	173	2.9	4.2	117	2.1	2.9	290	2.5	3.6
	SMALL INTESTINE									
C17	Small Intestine	15	0.2	0.4	14	0.3	0.3	29	0.3	0.4
	COLON & RECTUM									
C18	Colon	430	7.2	10.5	405	7.4	10.0	835	7.3	10.3
C19	Rectosigmoid Junction	98	1.6	2.4	67	1.2	1.7	165	1.4	2.0
C20	Rectum	176	2.9	4.3	89	1.6	2.2	265	2.3	3.3
C21	Anus and Anal Canal	21	0.3	0.5	19	0.3	0.5	40	0.3	0.5
	LIVER									
C22	Liver	121	2.0	3.0	56	1.0	1.4	177	1.5	2.2
	GALL BLADDER									
C23	Gallbladder	15	0.2	0.4	43	0.8	1.1	58	0.5	0.7
C24	Other and Unspecified Parts of the Biliary Tract	35	0.6	0.9	55	1.0	1.4	90	0.8	1.1
	PANCREAS									
C25	Pancreas	294	4.9	7.2	242	4.4	6.0	536	4.7	6.6
	GASTROINTESTINAL									
C26	Other and Ill-Defined Digestive Organs	11	0.2	0.3	12	0.2	0.3	23	0.2	0.3

CANCER MORTALITY, 2015–2020

ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	NASAL CAVITY									
C30	Nasal Cavity and Middle Ear	1	0.0	0.0	2	0.0	0.0	3	0.0	0.0
C31	Accessory Sinuses	11	0.2	0.3	8	0.1	0.2	19	0.2	0.2
	LARYNX									
C32	Larynx	115	1.9	2.8	11	0.2	0.3	126	1.1	1.5
	BRONCHUS & LUNG									
C34	Bronchus and Lung	839	14.0	20.5	292	5.4	7.2	1,131	9.9	13.9
	OTHER THORACIC ORGANS									
C37	Thymus	5	0.1	0.1	11	0.2	0.3	16	0.1	0.2
C38	Heart, Mediastinum and Pleura	11	0.2	0.3	6	0.1	0.1	17	0.1	0.2
	BONE & ARTICULAR CARTILAGE									
C40	Bones, Joints and Articular Cartilage of Limbs	10	0.2	0.2	3	0.1	0.1	13	0.1	0.2
C41	Bones, Joints and Articular Cartilage of Other and Unspecified Sites	18	0.3	0.4	18	0.3	0.4	36	0.3	0.4
	LEUKEMIA									
C42	Hematopoietic and Reticuloendothelial Systems	365	6.1	8.9	281	5.2	6.9	646	5.6	7.9
	SKIN									
C44	Skin	30	0.5	0.7	16	0.3	0.4	46	0.4	0.6
	PERITONEUM									
C48	Peritoneum	5	0.1	0.1	11	0.2	0.3	16	0.1	0.2
	OTHER CONNECTIVE & SOFT TISSUE									
C47	Peripheral Nerves and Autonomic Nervous System	1	0.0	0.0	2	0.0	0.0	3	0.0	0.0
C49	Connective, Subcutaneous and Other Soft Tissues	21	0.3	0.5	25	0.5	0.6	46	0.4	0.6
	BREAST									
C50	Breast	30	0.5	0.7	1,413	26.0	34.8	1,443	12.6	17.7
	CERVIX UTERI									
C53	Cervix uteri				433	8.0	10.7	433	3.8	5.3
	UTERUS									
C54	Corpus Uteri				558	10.2	13.8	558	4.9	6.9
C55	Uterus, Not Otherwise Specified				53	1.0	1.3	53	0.5	0.7
	OVARY									
C56	Ovary				411	7.5	10.1	411	3.6	5.0
	OTHER FEMALE GENITAL ORGANS									
C51	Vulva				11	0.2	0.3	11	0.1	0.1
C52	Vagina				17	0.3	0.4	17	0.1	0.2
C57	Other and Unspecified Female Genital Organs				20	0.4	0.5	20	0.2	0.2
	PENIS									
C60	Penis	23	0.4	0.6				23	0.2	0.3
	PROSTATE									
C61	Prostate	2,019	33.6	49.4				2,019	17.6	24.8
	TESTIS									
C62	Testis	12	0.2	0.3				12	0.1	0.1

ICD-O-3 Code	Topography Description	Male			Female			Total		
		<i>n</i>	%	MR	<i>n</i>	%	MR	<i>n</i>	%	MR
	OTHER MALE GENITAL ORGANS									
C63	Other and Unspecified Male Genital Organs	2	0.0	0.0				2	0.0	0.0
	KIDNEY									
C64	Kidney	103	1.7	2.5	55	1.0	1.4	158	1.4	1.9
	RENAL PELVIS									
C66	Ureter	2	0.0	0.0				2	0.0	0.0
C68	Other and Unspecified Urinary Organs	2	0.0	0.0				2	0.0	0.0
	BLADDER									
C67	Bladder	154	2.6	3.8	63	1.2	1.6	217	1.9	2.7
	EYE									
C69	Eye and Adnexa	4	0.1	0.1	5	0.1	0.1	9	0.1	0.1
	CNS – CENTRAL NERVOUS SYSTEM									
C70	Meninges	4	0.1	0.1	9	0.2	0.2	13	0.1	0.2
C71	Brain	112	1.9	2.7	88	1.6	2.2	200	1.7	2.5
C72	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System	1	0.0	0.0	5	0.1	0.1	6	0.1	0.1
	THYROID									
C73	Thyroid Gland	26	0.4	0.6	41	0.8	1.0	67	0.6	0.8
	OTHER ENDOCRINE									
C74	Adrenal Gland	5	0.1	0.1	2	0.0	0.0	7	0.1	0.1
C75	Other Endocrine Glands and Related Structures	1	0.0	0.0	2	0.0	0.0	3	0.0	0.0
	ILL-DEFINED									
C76	Other and Ill-Defined Sites	33	0.5	0.8	36	0.7	0.9	69	0.6	0.8
	LYMPHOMA									
C77	Lymph Nodes	142	2.4	3.5	110	2.0	2.7	252	2.2	3.1
	UNKNOWN									
C80	Unknown Primary Site	218	3.6	5.3	212	3.9	5.2	430	3.8	5.3
Total		6,008	100	147.1	5,445	100	134.3	11,453	100	140.7

Table C-4: Cancer Mortality, 2015 to 2020

APPENDIX D

Data Entry Form

DATA ENTRY FORM

CONFIDENTIAL

SECTION A			
REGISTRY NO.: _____		MEDICAL RECORD NO.: _____	
PERSONAL ID.: _____			
NAME: _____			
SURNAME		FIRST	
MIDDLE		MAIDEN	
ADDRESS: _____			CSO:
GENDER: 1 ☐ MALE 2 ☐ FEMALE 9 ☐ UNSPECIFIED			
DATE OF BIRTH: / /		COUNTRY OF BIRTH: _____	
DAY MONTH YEAR		01 ☐ T&T 02 ☐ OTHER CARIBBEAN 03 ☐ OTHER	
ETHNIC ORIGIN: 1 ☐ African 2 ☐ Indian 3 ☐ Chinese 4 ☐ Mixed 5 ☐ White/Caucasian			
6 ☐ Syrian/Lebanese 7 ☐ Other 9 ☐ Unspecified			
UNION STATUS: 1 ☐ Single 2 ☐ Married 3 ☐ Separated 4 ☐ Divorced			
5 ☐ Widowed 6 ☐ Common Law 9 ☐ Unspecified			
OCCUPATION: _____		INDUSTRY: _____	
SECTION B			
DATE OF INCIDENCE: / /		AGE AT INCIDENCE:	
DAY MONTH YEAR			
SITE AT PRIMARY: _____		C _____ / _____ (ICDO)	
HISTOLOGY: _____		M _____ / _____ (ICDO)	
STAGING: 1 ☐ In Situ 2 ☐ Localised 3 ☐ Regional 4 ☐ Distant 9 ☐ Unknown			
METHOD OF DETECTION: 1 ☐ Screening exam. – Type _____			
2 ☐ Incident Finding – Test/procedure _____			
3 ☐ Clinical presentation (with symptoms) 4 ☐ Incidental finding at autopsy			
5 ☐ Other (specify) _____ 9 ☐ Unknown			
BASIS OF DIAGNOSIS:			
Non-microscopic 0 ☐ Death Certificate Only 1 ☐ Clinical only* 2 ☐ Clinical Investigation*			
3 ☐ Sugery/Autopsy only 4 ☐ Laboratory Tests			
Microscopic other 5 ☐ Cystology/Haematology 6 ☐ Histology of Metastasis 7 ☐ Histology of Primary			
8 ☐ Autopsy/Histology 9 ☐ Unknown			
TREATMENT: 1 ☐ Surgery 2 ☐ Radiotherapy 3 ☐ Chemotherapy 4 ☐ Immunotherapy			
5 ☐ Hormonal 6 ☐ Other (specify) _____ 9 ☐ Unknown			
SECTION C			
REFERRED TO CANCER CENTRE T&T? 1 ☐ Yes 2 ☐ No			
DATE OF LAST CONTACT: / /		STATUS AT THAT DATE: 1 ☐ ALIVE 2 ☐ DEAD	
DAY MONTH YEAR			
CAUSE OF DEATH: 1 ☐ _____ (ICD 10) 2 ☐ _____ (ICD 10) 3 ☐ _____ (ICD 10)			
SECTION D			
SOURCE OF INFORMATION:			
01 ☐ Arima Dist. Hosp. 02 ☐ Caura Hosp. 04 ☐ EWMSC Mt. Hope 06 ☐ Mt. Hope Mty. Hosp.			
07 ☐ P.O.S Gen. Hosp. 11 ☐ St. James Med. Complex 12 ☐ San Fernando Gen. Hosp.			
13 ☐ Tobago Hosp. 14 ☐ Cancer Centre T&T 15 ☐ Sangre Grande Hosp.			
20 ☐ Private Inst. (specify) _____ 24 ☐ West Shore Medical			
27 ☐ Southern Medical Clinic Hospital 30 ☐ Private Practitioner(specify) _____			
31 ☐ Brian Lara 32 ☐ Vitas House 35 ☐ Medical Associates			
40 ☐ Other (specify) _____			
CLERK (SIGN & DATE) _____		REGISTRY OFFICER (SIGN & DATE) _____	
		REGISTRAR (SIGN & DATE) _____	

CONFIDENTIAL

Death

REGISTRY NO.: _____		PERSONAL ID. NO.: _____	
NAME: _____			
SURNAME		FIRST	
OTHER			
USUAL RESIDENCE: _____			
DATE DEATH OCCURRED: / /		AGE AT DEATH:	
DAY		MONTH	
YEAR			
GENDER: 1 ☐ MALE 2 ☐ FEMALE 9 ☐ UNSPECIFIED			
ETHNIC ORIGIN: 1 ☐ African 2 ☐ Indian 3 ☐ Chinese 4 ☐ Mixed			
5 ☐ White/Caucasian 6 ☐ Syrian/Lebanese 7 ☐ Other			
CAUSE OF DEATH			
Disease or condition directly leading to death		(ICD 10)	
Antecedent Cause		(ICD 10)	
Morbid condition if any giving rise to the above cause stating the underlying condition last		(ICD 10)	
Other significant condition contribution to the death, but not related to the disease or condition causing it		(ICD 10)	
		C _____ / _____ (ICD 10)	
		M _____ / _____ (ICD 10)	
SOURCE OF INFORMATION:			
01 ☐ Arima Dist. Hosp.	02 ☐ Caura Hosp.	03 ☐ Couva District Hosp.	
04 ☐ EWMSC Mt. Hope	05 ☐ Mayaro District Hosp.	06 ☐ Mt. Hope Mty. Hosp.	
07 ☐ P.O.S Gen. Hosp.	08 ☐ Point Fortin Hosp.	09 ☐ Princess Town Hosp.	
10 ☐ St. Ann's Hosp.	11 ☐ St. James Med. Complex	12 ☐ San Fernando Gen. Hosp.	
13 ☐ Tobago Hosp.	14 ☐ Cancer Centre T&T	15 ☐ Sangre Grande Hosp.	
20 ☐ Private Inst.	21 ☐ Augustus Long Hosp.	24 ☐ West Shore Medical	
31 ☐ Brian Lara	32 ☐ Vitas House	35 ☐ Medical Associates	
NAME OF DOCTOR CERTIFYING DEATH/ISSUING DEATH CERTIFICATE: _____			
ADDRESS OF DOCTOR: _____			
CLERK (SIGN & DATE) _____		REGISTRY OFFICER (SIGN & DATE) _____	
		REGISTRAR (SIGN & DATE) _____	

CANCER IN TRINIDAD AND TOBAGO

**2003
–2020**

2025

